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Zusammenfassung 
Als Hauptfunktion der differenzierten Skelettmuskulatur gilt die Kontraktion, welche den Lebewesen 
die aktive Bewegung ermöglicht. Die Kontraktion spielt jedoch auch eine wichtige Rolle in der 
Myogenese und ist daher unerlässlich für die korrekte Ausbildung und Organisation des 
muskuloskeletalen Systems. Auf molekularer Ebene erfordert die Initiierung der 
Skelettmuskelkontraktion das Zusammenspiel zweier mechanisch gekoppelter Ca
2+ 
Kanäle, der 
Hauptuntereinheit des 1,4-Dihydropyridin-Rezeptors (Cav1.1) und des Typ 1 Ryanodin-Rezeptors 
(RYR1), im Rahmen der sogennanten elektromechanischen Kopplung (ECC). Obwohl mehrere 
funktionelle und strukturelle Studien im Laufe letzten Jahrzehnten ein tieferes Verständnis der Rolle 
von Cav1.1 und RYR1 beim ECC ermöglicht haben, bleibt die genaue Rolle, die sie bei der 
Regulation der Genexpression während der Muskelentwicklung spielen unklar. 
Die vorliegende Arbeit untersucht die morphologischen und globalen Veränderungen im 
Transkriptom der Extremitätenmuskulatur von RYR1- und Cav1.1-defizienten (RYR1
-/-
 und 
Cav1.1
-/ -
) Mäusen zu Beginn (E14.5) und am Ende (E18.5) der sekundären Myogenese. In beiden 
Modellen sind bereits zum Zeitpunkt E14.5 erste Veränderungen der Muskelstruktur feststellbar. In 
diesem Stadium wird in Cav1.1
-/-
 Skelettmuskeln auch eine erhöhte Apoptoserate beobachtet. 
Microarray-Analysen zeigen diskrete Veränderungen des Transkriptoms beider Mutanten zum 
Zeitpunkt E14.5, mit einer Herunterregulation von Genen, die hauptsächlich mit Innervation und 
Neuronenentwicklung in RYR1
-/-
- und mit Muskelkontraktion in Cav1.1
-/-
-Skelettmuskeln assoziiert 
sind. Zum Zeitpunkt E18.5 weist sowohl die RYR1
-/-
- als auch die Cav1.1
-/-
-Skelettmuskulatur 
schwerere strukturelle Anomalien, Fibrose sowie Anzeichen einer Entwicklungsverzögerung auf. 
Dieses späte Stadium ist durch einen hohen Überlappungsgrad der identifizierten differentiell 
exprimierten Gene (DEGs) zwischen RYR1
-/-
 und Cav1.1
-/-
 gekennzeichnet: Beide Mutanten zeigen 
eine fehlerhafte Regulation zahlreicher Gene, die am Aufbau der kontraktilen Maschinerie beteiligt 
sind, Veränderungen in der Expression von Transkripten globaler Signalwege sowie von multiplen 
microRNAs. Mutantenspezifische Transkriptomveränderungen zu E18.5 deuten auf Veränderungen 
in der Zusammensetzung der extrazellulären Matrix in RYR1
-/-
-Muskeln und im Lipidstoffwechsel in 
Cav1.1
-/-
-Muskeln hin. Zudem beeinträchtigt das Fehlen von RYR1 im Muskel das normale 
Verhältnis von Cav1.1 Spleißvarianten zum Zeitpunkt E14.5 sowie den Gesamt-Expressionslevel von 
Cav1.1 mRNA zum Zeitpunkt E18.5. 
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Zusammenfassend heben die Ergebnisse dieser Arbeit die Bedeutung von Cav1.1 und RYR1 für die 
korrekte Durchführung des Genexpressionsprogramms während der sekundären Myogenese in 
Skelettmuskeln der Maus hervor. Darüber hinaus ergeben sich Einblicke in die Synergie, aber auch in 
die spezifischen Rollen der beiden Ca
2+
-Kanäle während der Skelettmuskelentwicklung. 
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Abstract 
The main function of differentiated skeletal muscle is contraction, allowing for movement. However, 
contraction also has important developmental roles and thus is indispensable for proper muscle 
formation and organization. On a molecular level, the initiation of skeletal muscle contraction relies 
on the interplay of two mechanically coupled Ca
2+
 channels - the principal subunit of the 
1,4-dihydropyridine receptor (Cav1.1) and the type 1 ryanodine receptor (RYR1), the key event in the 
process of excitation-contraction coupling (ECC). While multiple functional and structural studies 
over the last decades have led to a deeper understanding of the roles of Cav1.1 and RYR1 in ECC, 
their specific involvement in muscle development and in gene expression remains obscure. 
The present work analyzes the morphological and global transcriptomic changes occurring in limb 
skeletal muscle from RYR1- and Cav1.1-deficient (RYR1
-/-
 and Cav1.1
-/-
, respectively) mice at the 
beginning (E14.5) and at the end (E18.5) of secondary myogenesis. In both models initial muscle 
structure alterations are already observable E14.5. At this stage, increased apoptosis is observed only 
in Cav1.1
-/-
 limb skeletal muscle. Microarray analyses reveal discrete transcriptomic changes in both 
mutants at E14.5, with downregulation of genes primarily associated with innervation and neuron 
development in RYR1
-/-
, and with muscle contraction in Cav1.1
-/-
 skeletal muscle. At E18.5, both 
RYR1
-/-
 and Cav1.1
-/-
 skeletal muscles are characterized by more severe structural malformation, 
fibrosis, and signs of developmental retardation. At this stage a high number of the detected 
differentially expressed genes (DEGs) overlap i RYR1
-/-
 and Cav1.1
-/-
. Both mutants display a failure 
to upregulate the expression of many genes involved in the buildup of the contractile machinery and 
exhibit changes in the expression of global signaling pathways and multiple microRNAs. Mutant-
specific transcriptomic changes point to changes in the composition of the extracellular matrix in 
RYR1
-/-
 muscle and in the lipid metabolism in Cav1.1
-/-
 muscle. Finally, the absence of RYR1 in 
RYR1
-/-
 mice alters the ratio of Cav1.1 splice variants at E14.5, and the total Cav1.1 mRNA levels at 
E18.5. 
Taken together, the results of this work highlight the importance of Cav1.1 and RYR1 for the proper 
execution of the developmental gene expression program during secondary myogenesis in mouse 
limb skeletal muscle. Furthermore, it provides insights into mutual but also specific roles of each 
Ca
2+
 channel during skeletal muscle development.
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1 Introduction 
1.1 The skeletal muscle organ 
In humans skeletal muscle is the largest organ by mass, accounting for approximately 40% of the 
total body weight, 50-75% of all body proteins and up to 50% of the entire protein turnover (Frontera 
& Ochala, 2015; Janssen, Heymsfield, Wang, & Ross, 2000). Together with the cardiac muscle, the 
skeletal muscle is composed of striated muscle tissue, named after its characteristic pattern of 
alternating light and dark regions, when observed under a microscope. Out of the three muscle tissue 
types – skeletal, cardiac and smooth – the skeletal muscle is the only one that is under a conscious, 
voluntary control (Klinke, 2005). Skeletal muscle is a part of the musculoskeletal system that also 
includes bones, cartilage, tendons, connective tissue, blood vessels and nerves (Deries & 
Thorsteinsdottir, 2016). As a part of the musculoskeletal system different groups of skeletal muscles 
are involved in the execution of various movements, mimics and maintenance of postures and 
breathing. From a metabolic point of view, skeletal muscle is one of the major organs participating in 
energy metabolism, glucose uptake and storage and is an essential reservoir for carbohydrates and 
amino acids (Wolfe, 2006). 
The skeletal muscle organ is described by a high degree of complexity and plasticity in both 
structural and functional aspect. Therefore, substantial changes in skeletal muscle mass and 
composition can be caused by exercise, diet and other physiological conditions, as well as by various 
diseases and ageing (Hoppeler, 2016). 
1.1.2 Skeletal muscle structure 
Muscle, connective and nervous tissue, as well as parts of the circulatory system are all entangled in 
the buildup of the skeletal muscle organ and contribute to its elaborate characteristics and functions. 
In healthy adults the predominant part of the organ consists of muscle tissue, although adipose tissue 
can also constitute a substantial part, especially in some pathological conditions (Frontera & Ochala, 
2015; Javan et al., 2013). Depending on the developmental stage, species and (patho-)physiological 
condition, the skeletal muscle tissue comprises various cell types of the myogenic lineage 
(Buckingham et al., 2003). Fully developed muscle tissue is mostly composed of long, cylindrical, 
Introduction 
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multinucleated cells called muscle fibers or myofibers (Lang, Thews, & Schmidt, 2000). The muscle 
fibers are terminally differentiated post-mitotic cells with a diameter between 10 and 100 µm and a 
length up to several cm that are situated in parallel relative to each other in bundles called fascicles 
(Fig. 1) (Lang et al., 2000). Branches of motor-neurons’ axons form complex chemical synapses with 
each myofiber, called neuromuscular junctions (NMJs). Three layers of connective tissue contribute 
to the myofiber organization in skeletal muscle – epimysium, covering the whole outer surface of a 
muscle; perimysium – covering each of the fascicles; and endomysium – covering each of the muscle 
fibers. (Fig. 1) (Lang et al., 2000). Furthermore, a mesh of extracellular matrix, called basal lamina, 
lies between the endomysium and the fiber membrane – the sarcolemma, ensheathing multiple 
quiescent muscle stem cells – satellite cells (SCs) – located along the periphery of each fiber. These 
are quiescent mononucleated muscle stem cells that are activated upon muscle injury or disease and 
differentiate into mature myofibers. 
Each muscle fiber contains hundreds of myofibrils – rod-shaped structures, composed of parallel 
thick and thin myofilaments that contain the muscle active contractile proteins (Huxley & Hanson, 
1954), as well as of titin filaments, responsible for passive force development and elasticity (Linke & 
Kruger, 2010). Microscopically, the myofilaments in the myofibrils are arranged in regularly 
alternating darker and lighter regions, aligned across the myofibrils and myofibers, giving rise to the 
typical striation pattern of skeletal muscle (Huxley, 1961). The microscopically denser (darker) 
regions constitute the anisotropic bands – A-bands, and the less dense (lighter) regions – the isotropic 
bands – I-bands (Fig. 1). The A-bands are divided in half by a lighter H-zone, and in the middle of 
the I-bands darker, narrower regions – the Z-discs – mark the borders of the smallest morphological 
units of striated muscle – the sarcomeres (Fig. 1) (Huxley, 1961). Thin filaments are directly attached 
to the Z-discs and protrude in the I- and A-bands but at rest do not reach the center of the sarcomere, 
forming the less dense H-zone, whereas thick filaments occupy only the A-band regions and are 
indirectly attached to the Z-discs via titin filaments. At rest, the length of each sarcomere from one 
Z-disc to another is approximately 2.2 to 2.4 µm. When contraction is initiated, cross-bridges are 
formed between the thick and the thin myofilaments, causing the thin filaments to slide towards the 
M-line, leading to a disappearance of the H-zone and a shortening of the I-bands and consequently – 
of the sarcomere to approximately 2.0 µm (Klinke, 2005). Thus, the simultaneous shortening of the 
sarcomeres along the myofibrils of a muscle fiber leads to the shortening of the whole fiber and 
consequently – of the whole muscle. 
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Fig. 1: Skeletal muscle and associated structures. 
(A) A scheme of the skeletal muscle structure, showing the hierarchical organization of skeletal muscle starting from the 
whole organ down to the intracellular architecture of individual muscle fibers. Deep tubular invaginations of the 
sarcolemma called the T-tubuli form an intracellular network with the terminal cisternae of the myofibers’ endoplasmic 
reticulum – the sarcoplasmic reticulum (SR). Most of the intracellular space of the myofibers is taken up by numerous 
myofibrils, consisting of thick (myosin) and thin (actin) myofilaments that are perfectly aligned and build up the skeletal 
muscle’s contractile machinery. The smallest functional units of this machinery are the sarcomeres. Each sarcomere 
contains a microscopically denser A-band, thick filaments and two halves of a brighter I-band, containing the thin 
filaments. In the middle of the A-band is a narrow lighter region – the H-zone, and in the middle of it there is a denser 
line – the M-line, anchoring the thick and thin filaments. Two darker vertical regions – the Z-discs – mark the borders of 
each sarcomere. Beside the myofibrils, the myofibers possess a high mitochondrial content due to the muscle’s high 
energy demands. Other organs like blood vessels (veins and arteries) and cell types like nerves and fibroblast contribute 
to the functions and structure of skeletal muscle. (B) An electron micrograph of a sarcomere. Modified from (Lang et al., 
2000) and (Tajbakhsh, 2009). 
1.1.3 Proteins of the contractile machinery 
Multiple diverse proteins are involved in the sarcomeric structure and regulate skeletal muscle 
contractile properties (Fig. 2). The main two proteins in the execution of muscle contraction and in 
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the composition of the thick and thin myofilaments are myosin and actin, respectively  (Huxley, 
1961). 
 
Fig. 2: A molecular model of the sarcomeric structure between two Z-discs. 
The I-band, A-band and M-line regions are schematically represented. Multiple diverse proteins bind to and contribute 
for the functions of the myofilaments. Components whose binding sites are unknown are shown with question marks. 
Abbreviations stand for: CARP, cardiac ankyrin repeat protein; MM-creatin kinase, M-line creatin kinase; MyBP-C, 
myosin binding protein C; MURF-1, muscle-specific ring-finger 1. Modified from (Clark, McElhinny, Beckerle, & 
Gregorio, 2002). 
Approximately 300 myosin molecules polymerize to form the thick myosin filaments (Fig. 2). Each 
myosin protein is composed of two heavy chains (MyHCs) and four light chains – 2 regulatory and 2 
essential light chains. Each MyHC is composed of an α-helical domain, called a “tail” and a globular 
domain, called a “head” (Klinke, 2005). The two MyHC tails are coiled around each other and are 
connected to the myosin heads via an elastic transition, called a “hinge” or “neck”. The myosin heads 
distal ends contain catalytical domains that are able to bind actin and hydrolyze adenosine 
triphosphate (ATP). The two regulatory and essential myosin light chains bind to the hinges and the 
proximal ends of the myosin heads and together with the hinges act as molecular levers, facilitating 
the cross-bridges between the myosin heads and the actin filaments. Each half of the myosin 
filaments is bound to 3 – 6 titin molecules that bind the free myosin filaments termini and form 
elastic filaments, anchored at the Z-discs. Throughout the A-bands the titin filaments align with the 
myosin filaments, whereas in the I-bands the titin filaments continue freely and in these regions they 
exhibit substantial stretch capabilities (Klinke, 2005).  
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Actin is the most abundant protein in striated muscle and is found either in a monomeric state 
(G-actin), or as a homopolymer, forming long actin filaments (F-actin) (Pollard, 1990). In mammals 
six actin isoforms exist and are usually characterized by their isoelectric points as α, β and γ actin, 
where α actin isoforms are specific for skeletal and cardiac muscle (Clark et al., 2002). Around 400 
globular G-actin monomers polymerize into filamentous F-actin to form the actin filaments (Fig. 2). 
The actin filaments have a double helical structure with 2x7 actin monomers in each turn (Klinke, 
2005). Muscle contraction is initiated in the cross-bridge cycle that involves several steps, including 
actin binding to the myosin heads, that in turn release ADP and inorganic phosphate, Pi, generating a 
power stroke, pulling the actin filaments towards the M-line and resulting in sarcomere shortening 
(Huxley, 2000). Binding of ATP to the myosin heads allows their detachment from the actin 
filaments, and its hydrolysis to ADP and Pi by the myosin ATPase returns the myosin heads to their 
pre-stroke (“cocked”) position, thus closing the cross-bridge cycle. Regulatory proteins like the 
filamentous tropomyosin and the globular troponin complex bind to actin filaments’ double helical 
grooves at regular intervals and are vital for proper regulation of contraction (Klinke, 2005). Each 
tropomyosin protein is associated with a troponin complex, composed of three subunits – troponin T 
(tropomyosin-associated troponin), troponin I (inhibitory troponin) and troponin C (Ca
2+
-binding 
troponin). When the intracellular calcium [Ca
2+
]i concentration in the muscle fibers is lower than 10
-7
 
mol/L tropomyosin sterically obstructs the myosin binding sites on the actin filaments. However, 
when the Ca
2+
 concentration rises above this level, Ca
2+
 binds to the troponin C proteins, which act as 
Ca
2+
 sensors, and induce rearrangement in the troponin complex and the tropomyosin associated with 
it (Klinke, 2005). Thus, actin’s myosin binding sites become exposed to build cross bridges with 
myosin and facilitate muscle contraction.  
Titin, the biggest known mammalian protein (3,000 to 3,700 kDa) makes up the main part of the third 
type of myofilaments – the titin filaments (Fig. 2). In contrast to actin and myosin, titin does not 
actively contribute to muscle contraction but is vital for passive force and dynamic stiffness 
development (Bartoo, Linke, & Pollack, 1997). Moreover, the titin filaments integrate multiple 
signaling cascades, as various signaling proteins and molecules bind to the titin filaments (Kruger & 
Kotter, 2016; Linke & Kruger, 2010).Titin filaments’ NH2-termini are anchored at the Z-discs and 
stretch through the I- and A-bands up to the M-line (Linke & Kruger, 2010). In the I-bands the titin 
filaments possess flexible domains that act as a molecular spring. In the A-Bands they bind to the 
myosin filaments.  
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A fourth filament system, consisting of the giant protein nebulin, is also involved in the sarcomeric 
structure and functions (Fig. 2). More specifically, nebulin binds to the thin filaments and determines 
their length by influencing the minimum length of actin polymerization (Ottenheijm & Granzier, 
2010). Nebulin also maintains myofibrillar alignment by regulating desmin localization, a key protein 
linking adjacent Z-disc (Shah et al., 2002). Additionally, nebulin affects muscle contractility by 
regulating the cross-bridge cycling kinetics and Ca
2+
-sensitivity of force generation (Bang et al., 
2009; Chandra et al., 2009). 
The Z-discs, marking the lateral boundaries of the sarcomeres and acting as an anchoring point for 
the myofilaments discussed above, are multiprotein complexes consisting largely of a backbone 
made of antiparallel α-actinin homodimers (Frank, Kuhn, Katus, & Frey, 2006). Various additional 
structure and signaling proteins like desmin, the muscle lim protein (MLP), and telethonin take part 
in the buildup and functions of the Z-discs (Fig. 3) (Clark et al., 2002). Peripheral Z-disc proteins 
bind to proteins from the muscle fiber plasma membrane – the sarcolemma – and form complex 
structures, linking the sarcomeres and the sarcolemma called “costameres” (Ervasti, 2003). Since the 
Z-discs anchor the myofilaments and together with the costameres facilitates the link between the 
sarcolemma and the muscle’s contractile machinery, they play a central role in mechanosensing and 
mechanotransduction (Frank et al., 2006). 
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Fig. 3: Z-disc and costamere structure. 
The scheme represents the multitude of proteins and molecules that have been identified as components of the Z-discs 
and costameres. Abbreviations stand for: MYOZ2, myozenin 2 (carsarin 1); Cn, calcineurin; PDZ-3LIM, one-PDZ and 
three-LIM domain protein; PDZ-1LIM, one-PDZ and one-LIM domain protein; MLP/CRP3, muscle-specific LIM 
protein/cysteine-rich protein 3; FHL2, four-and-a-half LIM protein 2; MAPRs, muscle ankyrin repeat proteins; MURFs, 
muscle-specific ring-finger proteins; nbr1, neighbor of Brca1 gene 1; mink, misshapen-like kinase 1. Modified from 
(Hoshijima, 2006). 
1.1.4 Skeletal muscle architecture, metabolism and fiber type 
The contractile properties of the different skeletal muscles are determined by a variety of factors like 
muscle architecture, metabolism and by the types of fibers (Lieber & Friden, 2000; Schiaffino & 
Reggiani, 2011). Structural differences like muscle and fiber length, as well as the physiological 
cross-sectional area and the angle of the fibers relative to the axis of force generation (pennation 
angle) contribute to the specific mechanical properties of different skeletal muscles (Lieber & Friden, 
2000). Furthermore, the composition and the mechanical properties of the sarcolemma and the 
extracellular matrix (ECM) also influence skeletal muscle’s contractile functions directly (Campbell 
& Stull, 2003; Gillies & Lieber, 2011). 
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The energy demands of skeletal muscle can drastically fluctuate dependent on its activity and the 
frequency and strength of contraction. During exercise skeletal muscle can consume more than 
100-fold more energy than during rest, requiring rapid metabolic adaptations (Sahlin, Tonkonogi, & 
Soderlund, 1998). Moreover, skeletal muscle is a primary site for glucose uptake and acts as a 
reservoir for carbohydrates, amino acids and proteins that can be distributed to other parts of the 
body under stress conditions or illness (Argiles, Campos, Lopez-Pedrosa, Rueda, & Rodriguez-
Manas, 2016). Skeletal muscle fibers use ATP as their primary energy source and therefore utilize 
both anaerobic and aerobic pathways in order to avoid ATP depletion (Sahlin et al., 1998). Anaerobic 
pathways used for ATP generation – mostly phosphocreatine degradation and glycogen breakdown – 
are more common during short high-intensity physical activity (Westerblad, Bruton, & Katz, 2010). 
Aerobic metabolism, on the other hand, dominates during long submaximal exercise, and consists 
mostly of β-oxidation of fatty acids or degradation of carbohydrates via the citric acid cycle 
(Westerblad et al., 2010). Hence, a substantial part of the skeletal muscle fibers’ volume is taken up 
by mitochondria, where the aerobic ATP production takes place (Lundby & Jacobs, 2016).  
The skeletal muscle fibers are not homogenous in terms of their contractile and metabolic properties, 
but can be divided into several fiber types. Several criteria have been used for fiber classification into 
different types and their results are not always in agreement with one another (Scott, Stevens, & 
Binder-Macleod, 2001). Initially myofibers were divided into “red”, “white” or “intermediate” based 
on their color; and into “fast-twitch” or “slow-twitch” based on their contractile kinetics (Barnard, 
Edgerton, Furukawa, & Peter, 1971). Later, in accordance with their energy metabolism, myofibers 
were classified into “slow oxidative”, “fast oxidative, glycolytic” and “fast glycolytic” (Barnard et 
al., 1971; Greising, Gransee, Mantilla, & Sieck, 2012; Schiaffino & Reggiani, 2011). On the basis of 
the pH lability of actomyosin ATPase staining, myofibers can be also classified as type I, IIa, IIb and 
IIx (Greising et al., 2012). Each of the latter fiber types has also been found to express a specific 
isoform of MyHC, specifically MyHCslow, MyHC2A, MyHC2B and MyHC2X in the type I, IIa, IIb and 
IIx fibers, respectively (Schiaffino & Reggiani, 2011). Some muscles composed of type IIb fibers 
have also been shown to co-express MyHC2B and MyHC2X (Greising et al., 2012). Additionally, two 
developmental MyHC isoforms have been identified – embryonic MyHCemb and neonatal MyHCneo, 
which predominate during embryonic and early postnatal development (Agbulut, Noirez, Beaumont, 
& Butler-Browne, 2003; Greising et al., 2012). 
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1.2 Skeletal muscle development 
1.2.1 Myogenesis – definition and models 
Myogenesis – the generation of muscle tissue – is a complex multistep process that has been a 
subject of intensive studies (Asfour, Allouh, & Said, 2018; Bentzinger, Wang, & Rudnicki, 2012; 
Edgeworth, 1899; Read, Takeda, & Kirkaldy-Willis, 1971). Generally one can discriminate between 
developmental and regenerative myogenesis – the first one begins in the embryonic development and 
describes the de novo formation of skeletal muscle, whereas the second one occurs upon muscle 
injury or atrophy and serves for the production of new muscle fibers in place of the damaged ones. 
Very similar processes take place in both types of myogenesis; however there are also some specific 
distinctions (Tajbakhsh, 2009). Failure in the proper execution of either type of myogenesis can 
cause a wide range of diseases like myopathies, rhabdomyosarcoma and cachexia; as well as severe 
developmental disorders like the Duchenne and Becker muscular dystrophies (Emery, 2002). 
Multiple in vitro and in vivo models are being utilized in the physiological and pathophysiological 
studies of skeletal myogenesis, each having advantages and disadvantages (Abmayr & Pavlath, 2012; 
Chal & Pourquie, 2017). Diverse in vitro models spanning from classical muscle cell lines like 
C2C12 through pluripotent stem cells (PSCs)-derived cell lines to modern lab-on-a-chip models are 
rapidly improving and constitute homogenous systems allowing easy handling, quick results and 
personalized patient-specific analysis (Agrawal, Aung, & Varghese, 2017; Burattini et al., 2004; Chal 
& Pourquie, 2017). Nevertheless, up to now they have not been able to reproduce the full structural 
and functional complexity of the entire skeletal muscle organ and lack vital components of the 
skeletal muscle microenvironment like fiber innervation, the crosstalk with the ECM and with other 
organs, all contributing to proper muscle development (Fredette & Landmesser, 1991; Nassari, 
Duprez, & Fournier-Thibault, 2017). The in vivo models for myogenesis comprise versatile 
vertebrate and invertebrate model organisms (Abmayr & Pavlath, 2012; Kim, Jin, Duan, & Chen, 
2015; Sparrow, Hughes, & Segalat, 2008). While each of them has a set of advantages and 
drawbacks, the in vivo models pose a more physiological and accurate representation of myogenesis 
and can be better related to the myogenic events in humans. The main limitations of using in vivo 
myogenic models are that they are often more costly, harder to generate and to handle, the 
experiments require more time, the observed myogenic events might differ from those in humans and 
there are significant ethical concerns and limitations (Hartung, 2008). A lot of the fundamental work 
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elucidating the mechanisms of myogenesis has been performed on chick embryos (Allen & Pepe, 
1965; McLennan, 1983; Read et al., 1971; Shellswell, 1977). Caenorhabditis elegans, Drosophila 
melanogaster and zebrafish have also proven themselves as valuable models for the examination of 
different aspects of muscle development (Abmayr & Pavlath, 2012; Armant, Gourain, Etard, & 
Strahle, 2016; Fox et al., 2007; Sparrow et al., 2008; Te & Reggiani, 2002). However, in the last 
several decades the mouse has emerged as probably the most frequently used in vivo model for 
myogenesis in (patho)physiological research (Durbeej & Campbell, 2002; Tondeleir, Vandamme, 
Vandekerckhove, Ampe, & Lambrechts, 2009). As a mammalian model, it has the advantages that it 
closely resembles the myogenic events in the human, has a high degree of genetic similarity to 
humans and can be easily genetically manipulated (Kablar & Rudnicki, 2000). Despite the 
differences that inevitably arise when comparing different species and the disadvantages of in vivo 
models discussed above, the mouse is one of the most advantageous and exploited model for skeletal 
myogenesis (Abmayr & Pavlath, 2012; Kablar & Rudnicki, 2000; Tajbakhsh, 2009; Watson, 
Riordan, Pryce, & Schweitzer, 2009). 
1.2.2 Myogenesis in the mouse 
In mice skeletal muscle development begins in utero and continues 2-3 weeks after birth (Fig. 4). The 
prenatal period begins between the 8
th
 and 9
th
 embryonic day (E8.5 – E9) and lasts approximately 
until E18.5 or until birth (Tajbakhsh, 2009). It involves a number of events and different muscle 
precursor and progenitor cells, normally described by the presence and expression of specific 
myogenic markers, which undergo several successive differentiation steps before reaching maturity 
(Bryson-Richardson & Currie, 2008). The prenatal myogenesis can roughly be divided into three 
main developmental stages that partially overlap – somitogenesis, primary and secondary 
myogenesis. 
Around E4.5 the primary tissue types – trophectoderm, epiblast and primitive endoderm are 
established (Arnold & Robertson, 2009). Subsequently, around E6.0 under the influence of regional 
differences in gene expression they form the tree germ layers of the prepatterned embryo – the 
ectoderm, mesoderm and endoderm (Arnold & Robertson, 2009). In respect to the midline of the 
embryo the mesoderm is separated into tree anatomical layers – the paraxial, intermediate and lateral 
mesoderm (Bentzinger et al., 2012). 
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Fig. 4: Mouse myogenesis timeline. 
In the mouse the first myogenic events take place at E8.5/E9 when the somites are formed, giving rise to myotomal cells 
which subsequently differentiate into the first myocytes. The somatic dermomyotome also releases stem/progenitor cells 
which further differentiate into embryonic and fetal myoblasts and satellite cells (SCs) –quiescent myogenic cells, 
important for postnatal muscle regeneration. From the mid-late stages (E10.5-E12.5) to the end of embryonic 
development at E14.5, primary (1°) fibers are formed from the embryonic myoblasts via several steps of differentiation. 
The myogenic events up to E14.5 constitute the primary myogenesis. From E14.5 until birth (around E18.5 to E20.5) the 
fetal development in the mice coincides with a second wave of myogenic events called secondary myogenesis, in which 
fetal myoblasts develop into secondary (2°) fibers. The first SCs arise approximately 2 days prior birth (E16.5) and 
contribute to the muscle growth, maturation and hypertrophy from the perinatal period into adulthood. Some non-somitic 
progenitor cells are also implicated in the adult muscle regeneration. Modified from (Tajbakhsh, 2009) and (Biressi, 
Molinaro, & Cossu, 2007a). 
Around E8.5 oscillations of gene expression and gradients of morphopgene concentration leads to 
pair-wise concentration of the paraxial mesoderm left and right of the neural tube into transitory 
spherical epithelial structures called somites that develop in the direction from the head to the tail 
(Fig. 5) (Kablar & Rudnicki, 2000). All skeletal muscles except the superficial neck muscles develop 
from the somites (Deries & Thorsteinsdottir, 2016). A polarity within the somites is then established 
and they develop dorso-ventral compartments. The ventral compartments gives rise to the 
mesenchymal sclerotome which later develops into cartilage and bones, and the dorsal part of the 
somites forms the dermomyotome (Bentzinger et al., 2012). All skeletal muscles with the exception 
of some muscles of the head in mice and other vertebrates arise from cells of the dermomyotome. 
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Multiple signaling molecules and pathways are involved in the formation of the dermomyotome and 
the subsequent muscle development (Fig. 5) (Bentzinger et al., 2012). As the embryo develops, 
terminally differentiated, mononucleated cells emerge from the dorsomedial and ventrolateral lips of 
the dermomyotome and form the primary myotome (Bentzinger et al., 2012; Biressi et al., 2007a). 
This process involves muscle progenitor cells (MPCs) translocating from the dermomyotome to a 
ventrically-located domain, followed by MPC elongation so that at the end the cells span the entire 
somite length along the cranio-caudal axis of the embryo (Biressi et al., 2007a). A population of 
satellite cells that remain until adulthood are also formed (Gros, Manceau, Thome, & Marcelle, 
2005). The epaxial part of the dermomyotome gives rise to the dorsal muscles and its hypaxial part to 
the trunk and limb muscles (Bentzinger et al., 2012). 
Only a small fraction of cells are terminally differentiated during the formation of the primary 
myotome. The somatic dermomyotome produces Pax3
+
/Pax7
+
 double positive MPCs that 
differentiate into embryonic and fetal myoblasts and satellite cells, that will later differentiate into 
primary, secondary and adult muscle fibers (Fig. 4) (Biressi et al., 2007a). From approximately E10.5 
to E14.5 an intensive myogenic phase called primary myogenesis takes place (Biressi et al., 2007a). 
Several differentiation steps occur simultaneously at this stage: Early on, around E11 embryonic 
myoblasts invade the myotome and most probably fuse with the myotomal myocyes. At the same 
time embryonic myoblasts migrate to the limb buds and fuse into multinucleated primary (1°) fibers. 
A small number of myotubes participate in the composition of the skeletal muscles during primary 
myogenesis (Biressi et al., 2007a). 
From E14.5 until birth (E18.5 to E20.5), coinciding with the fetal development in the mouse, another 
wave of myogenic events takes place – the secondary myogenesis (Tajbakhsh, 2009). During 
secondary myogenesis fetal myoblasts fuse and differentiate into secondary (2°) fibers that initially 
form in the vicinity of the zones of innervation, initiating the neuromuscular junctions (NMJs) 
formation (Duxson, Usson, & Harris, 1989; Tajbakhsh, 2009). Additionally, at the end of secondary 
myogenesis, around E16.5, the first juvenile satellite cells emerge and are ensheathed under a basal 
lamina (Tajbakhsh, 2009). The skeletal muscles grow substantially and the first spontaneous 
movements can be detected around at E14.5 (Kodama & Sekiguchi, 1984). It has been shown that 
embryonic and fetal myoblasts – the MPCs generating the 1° and 2° fibers, respectively, have distinct 
global expression profiles (Biressi et al., 2007b). 
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Fig. 5: Somitogenesis. 
The early (A) and late (B) stages of somitogenesis are schematically represented. (A) In the early somite the development 
of the sclerotome (SC) and dermomyotome (DM) is initiated via morphogens and signaling molecules secreted from 
different parts of the embryo. On the one hand the bone morphogenic proteins (BMPs) from the lateral plate of the somite 
maintain the undifferentiated state of the somites. On the other hand, the dorsal neural tube (NT) and the surface 
ectoderm (SE) secrete Wnts, which together with the Sonic hedgehog (Shh) signaling factor, secreted from the neural 
tube floor plate and the notochord (NC), promote the formation of the sclerotome. (B) In the later stages of somite 
development, muscle progenitor cells (MPCs) leave the dorsomedial (DML) and ventrolateral (VLL) lips of the 
dermomyotome and differentiate into the myotome (MY). Limb bud formation is initiated by Pax3-positive (Pax3
+
) 
MPCs that delaminate and migrate from the ventrolateral lips of the dermomyotome. Modified from (Bentzinger et al., 
2012). 
Consequently, the 1°and 2° fibers differ in their expression of MyHC isoforms – 1° express 
embryonic, phenotypically slow MyHC, whereas 2° fibers express neonatal, phenotypically fast 
MyHC (Biressi et al., 2007a). Other muscle-specific genes like muscle creatine kinase, β-enolase and 
protein kinase C theta (PKCϴ) are also differentially regulated in 1° and 2° muscle fibers (Biressi et 
al., 2007a). Thus, the primary myogenesis lays the pattern of the developing skeletal muscle, whereas 
the secondary myogenesis is the period for growth and differentiation. Further postnatal muscle 
growth and maturation is achieved primarily via the consecutive fusion of neonatal fibers with each 
other and with satellite cells (Biressi et al., 2007a; Tajbakhsh, 2009). 
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1.2.3 Signaling cascades during myogenesis 
Each step of the myogenic program is executed under the strict control of a plethora of 
interconnected signaling pathways and cascades. Due to their versatile nature, different groups of 
muscles emerge under the control of specific regulatory networks (Tajbakhsh, 2009). The following 
sections will focus mainly on the regulatory mechanisms throughout prenatal limb myogenesis.  
1.2.3.1 Myogenic regulatory factors (MRFs) 
The myogenic regulatory (MRFs) are a group of transcription factors (TFs) that induce, control and 
maintain the myogenic fate of MPCs and muscle cells at each stage of their differentiation pre- and 
postnatally (Asfour et al., 2018). The first identified MRF – the myogenic determination factor 1 
(MyoD) was described for its properties that upon activation it induces myogenic transformation of a 
fibroblast cell line (Davis, Weintraub, & Lassar, 1987). Since then another three TFs have been 
identified having similar properties – myogenic factor 5 (Myf5), myogenin (MyoG) and myogenic 
regulatory factor 4 (Mrf4, a.k.a. Myf6 and herculin) (Braun, Buschhausen-Denker, Bober, Tannich, 
& Arnold, 1989; Rhodes & Konieczny, 1989; Wright, Sassoon, & Lin, 1989).These four classical 
MRFs share three very similar structure domains, listed from the N- to the C-terminus of the 
proteins: a cysteine/histidine domain, a basic helix-loop-helix (bHLH) domain, and a 
serine/threonine-rich domain (Asfour et al., 2018). The bHLH domain is the most important one for 
the activation of a cellular myogenic program, as it can bind a DNA sequence, known as E-box, 
present in the promoters and enhancers of downstream muscle-specific genes and activate their 
expression (Berkes & Tapscott, 2005). Prior to DNA binding MRFs form homo-, or more frequently 
heterodimers with other bHLH proteins, often with the class of E2A proteins which are ubiquitously 
expressed (Massari & Murre, 2000). The expression levels and activity of the MRFs are controlled 
via multiple signaling networks and TFs like the myocyte enhancer factor 2 (MEF-2) family. 
Furthermore, some MRFs can enhance their own expression (MyoD and MyoG) or direct that of 
other MRFs (Asfour et al., 2018). The MRFs have partly overlapping and redundant myogenic 
functions. For example, knock out mouse models for Myf5 or MyoD have a normal skeletal muscle 
phenotype other than a short delay in the embryonic myogenesis in the Myf5 knockout (KO), 
whereas double Myf5:MyoD null mutants are completely devoid of muscles and myogenin (Braun, 
Rudnicki, Arnold, & Jaenisch, 1992; Rudnicki, Braun, Hinuma, & Jaenisch, 1992; Rudnicki et al., 
1993). Therefore, Myf5 and MyoD exhibit a functional redundancy and at least one of them is 
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necessary for normal myogenesis. Conversely, homozygous MyoG KO mice have a severe reduction 
of skeletal muscle and a prevalence of undifferentiated myoblasts, although they have normal levels 
of MyoD (Hasty et al., 1993). This data shows that Myf5 and MyoD are important for myoblast 
specification early in the embryonic development, whereas MyoG acts downstream and is essential 
for late muscle development and differentiation. Mrf4 KO mice have higher MyoG levels and a 
phenotypically normal skeletal muscle but Mrf4:MyoD double KOs display a severe muscle 
deficiency similar as the MyoG null mice (Rawls et al., 1998). This indicates that Mrf4 represses 
MyoG expression and that there is some redundancy in the Mrf4 and MyoD roles for muscle 
differentiation. 
Four other TFs have proven to be indispensable for early commitment to the myogenic program and 
induction of the initial myogenic events (Bentzinger et al., 2012). These are the paired-homeobox 
transcription factors 3 and 7 (Pax3/7) and the Sine oculis-related homeobox TFs 1 and 4 (Six1/4), 
which due to their contribution to the myogenic program can also be viewed as MRFs (Bentzinger et 
al., 2012). In all vertebrates at least one of the Pax3 and Pax7 TFs is conserved (Noll, 1993). 
Dermomyotomal cells and all MPCs express Pax3 and Pax7, however long-range migrating MPCs 
that form the initial limb musculature only express Pax3 (Bentzinger et al., 2012). Loss-of-function 
Pax3 mouse mutants do not form the hypaxial domain of the somite, resulting in loss of limb and 
diaphragm muscles, although they develop some epaxial-derived muscles (Bentzinger et al., 2012; 
Bober, Franz, Arnold, Gruss, & Tremblay, 1994). Pax3 acts upstream of MyoD and Pax3:Myf5:Mrf4 
triple KOs mouse do not form any skeletal muscles and lack MyoD expression (Bentzinger et al., 
2012). Pax7 KO mice did not exhibit abnormalities in embryonic muscle development but showed a 
requirement for Pax7 for satellite cell specification (Seale et al., 2000). Pax3 and Pax7 also exhibit 
some functional redundancy, since the Pax3:Pax7 mouse double mutant has a more severe phenotype 
than the Pax3 mutant alone, characterized by an almost complete failure in the embryonic 
myogenesis and a development only of the primary myotome (Relaix, Rocancourt, Mansouri, & 
Buckingham, 2005). Experiments with conditional deletions of either Pax3
+
 or Pax7
+
 cell populations 
have shown that Pax3 ablation is embryonically lethal, whereas loss of Pax7 leads to impairment of 
later myogenic stages, leading to smaller muscles with fewer myofibers at birth (Bentzinger et al., 
2012; Hutcheson, Zhao, Merrell, Haldar, & Kardon, 2009; Seale et al., 2000). Thus, the Pax3
+
 cells 
are characterized as founder MPCs that set the template for myogenesis in the limbs, whereas Pax7
+
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cells contribute at a later stage to the secondary fiber formation and satellite cells specification 
(Bentzinger et al., 2012). 
The Six1 and Six4 TFs act upstream of Pax3 and are crucial for the specification and commitment of 
the MPCs to the myogenic lineage (Fig. 6) (Bentzinger et al., 2012). Six1 and Six4 bind the 
eyes-absent homologs Eya1 and Eya2 that act as transcriptional cofactors and translocate to the 
nucleus, where they induce the transcription of downstream MRFs like Pax3, MyoD, MyoG and 
Mrf4 (Grifone et al., 2005). While Six4 KO mice do not exhibit significant developmental changes, 
Six1 KO neonates die at birth and show severe developmental abnormalities of multiple organs, 
including skeletal muscle (Laclef et al., 2003; Ozaki et al., 2001). Moreover, double KOs mice for 
Six1:Six4 or Eya1:Eya3 fail to upregulate Pax3 expression and hence do not develop limb and 
hepaxial trunk musculature (Grifone et al., 2007; Grifone et al., 2005). These results demonstrate that 
there is some redundancy in the functions of the TFs Six1 and Six4, as well as in these of their 
cofactors Eya1 and Eya2. The hepaxial (but not the epaxial) dermomyotome has active enhancer 
binding regions for both Six TFs and Pax3 in the Myf5 gene, indicating that the Six TFs and Pax3 
drive Myf5 transcription in these muscles (Bentzinger et al., 2012). 
 
Fig. 6: MRFs hierarchy during myogenesis. 
The expression and activation patterns of the MRF genes directs the proper transition of the myogenic stages and 
differentiation events in the MPCs. Six1/4 and Pax3/7 regulate the early embryonic progenitor cell specification; Myf5 
and MyoD commit cells to the myogenic program; and MyoG and Mrf4 guide myocyte and myotubes fusion required for 
terminal differentiation. Modified from (Bentzinger et al., 2012).  
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Because of the strict spatiotemporal expression and activity of the MRFs in different populations of 
cells from the myogenic lineage, the presence of specific MRFs is also used as a marker for these cell 
populations and the corresponding developmental stages (Fig. 6). 
1.2.3.2. Morphogens and signaling pathways involved in myogenesis 
As mentioned above many major signaling pathways are involved in muscle development. One of 
them is the Wnt signaling pathway that comprises a canonical Wnt/β-catenin pathway, and several 
non-canonical Wnt pathways the main two of which are the Wnt/jun N-terminal kinase (JNK) 
pathway; and the Wnt/calcium pathway (Rao & Kuhl, 2010). The mechanism of action of all 
pathways involves secreted glycoproteins – the Wnts – that bind to receptors of the Frizzled (Fzd) 
family located on the plasma membrane that in turn often activate G-protein coupled receptors 
(GPCRs) and trigger various downstream cellular responses (Rao & Kuhl, 2010). The Wnt pathways 
control not only myogenesis but also the development of many other organs and structures, as well as 
bone development and limb patterning (Church & Francis-West, 2002). Multiple Wnts and their 
respective Fzd receptors regulate the expression of the MRFs and, as mentioned above (Fig. 5), 
induce the specification of MPCs in the somites (Bentzinger et al., 2012). For example, Wnt1 and 
Wnt3 secreted from the neural tube upregulate Pax3 and Myf5, whereas Wnt6 and Wnt7a positively 
regulate the expression of MyoD (Bentzinger et al., 2012). Wnts are also important for cell 
migration, morphology, terminal muscle differentiation and muscle fiber specification (Church & 
Francis-West, 2002). It has been demonstrated that in the mouse limb development the canonical 
β-catenin pathway is necessary for fetal myoblast specification and therefore, for secondary 
myogenesis and fiber type predetermination (Hutcheson et al., 2009).  
Another signaling pathway that positively regulates early myogenic specification is the Hedgehog 
(Hh) signaling pathway, with the Sonic hedgehog (Shh) secreted protein being indispensable for 
myogenesis (Bentzinger et al., 2012). The notochord and neural tube secrete Shh that – like the Wnts 
– binds to receptors on the plasma membrane and triggers a downstream cascade, leading to an 
upregulation of the expression of group of TFs called GLI (Tickle & Towers, 2017). Together with 
certain Wnts, they induce the expression of Myf5 and MyoD, thus promoting MPCs to myogenic 
commitment and differentiation (Borello et al., 2006; Munsterberg, Kitajewski, Bumcrot, McMahon, 
& Lassar, 1995; Voronova et al., 2013). KO mice lacking Shh die perinatally and exhibit severe 
developmental abnormalities, including the absence of limb formation (Chiang et al., 1996). 
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Contrary to the positive effects of the Wnt and the Shh pathways for myogenic specification and 
differentiation, a subclass of the transforming growth factor beta (TGF-β), the bone morphogenic 
proteins (BMPs), inhibit certain MRFs and thus – the myogenic progression (Gaarenstroom & Hill, 
2014). BMPs exert their functions in the somites through SMAD TFs promoting Pax3 expression, 
while inhibiting the expression of Myf5 and MyoD (Gaarenstroom & Hill, 2014). Wnts and Shh 
increase the secretion of Noggin that binds and inactivates BMPs and thus induces MyoD expression 
(Reshef, Maroto, & Lassar, 1998). In this way BMPs ensure the accumulation of MPCs prior the 
onset of muscle differentiation (Ono et al., 2011). The signals from the Wnt and BMP pathways are 
integrated in the periodic activity of the Notch signaling pathway, which similarly to the BMPs 
suppresses myogenic progression and prevents premature differentiation of MPCs (Hofmann et al., 
2004; Kuroda et al., 1999). Furthermore, proper Notch signaling is imperative for the generation of 
satellite cells during fetal development (Vasyutina, Lenhard, & Birchmeier, 2007). 
The mitogen-activated protein kinase (MAPK) pathway – a cascade of several consecutive 
phosphorylation steps, each activating a downstream kinase – is one of the most robust cellular 
signaling networks (Pearson et al., 2001). It includes three major signaling pathways: the 
extracellular signal-regulated kinases 1 and 2 (ERK1/2) pathway; the c-Jun N-terminal kinase (JNK) 
pathway; and the p38 pathway – all of which are implicated in the regulation of myogenesis (Jones, 
Fedorov, Rosenthal, & Olwin, 2001; Perdiguero et al., 2007; Xie et al., 2018). All three MAPK 
branches involve multiple steps and molecular interaction during the signal transmission. In short, the 
p38 pathway is a positive and the JNK pathway is a negative regulator of myogenic differentiation, 
whereas the ERK1/2 pathway has dual functions (Jones et al., 2001; Li & Johnson, 2006; Lluis, 
Perdiguero, Nebreda, & Munoz-Canoves, 2006; Xie et al., 2018; Yang et al., 2006). 
The phosphoinositide 3-kinase (PI3K), the protein kinase B (Akt) and mammalian target of 
rapamycin (mTOR) form another global signaling pathway – the PI3K/Akt/mTOR pathway that 
positively regulates muscle differentiation and hypertrophy (Ge & Chen, 2012). In particular, mTOR 
stimulates primary and secondary fusion involved in the formation of nascent myotubes and 
myofibers, respectively (Ge & Chen, 2012).  
As evident from the examples above, the regulation of skeletal myogenesis involves multiple 
signaling pathways that often overlap and interact with each other (their function is summarized in 
Table 1). Furthermore, the development of the limbs and their muscles is not only controlled by the 
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mere presence or absence of a particular signal but is fine-tuned by concentration gradients of FGFs, 
Wnts and other morphogens (Bentzinger et al., 2012). In addition, signals in the form of morphogens 
and mechanical stimuli from non-muscle cells and tissues like fibroblasts, nerves, blood vessels, 
bones and tendons, as well as the ECM, contribute to myogenesis and their own development is in 
turn regulated by muscle-derived factors and muscle contraction (Deries & Thorsteinsdottir, 2016). 
In the last decade micro RNAs (miRNAs) – small non-coding RNAs with a length of approximately 
22 nucleotides (nts), designated as Mir# or miR#, whrere # is the miRNA number – have gained a 
growing attention due to their versatile regulatory roles in virtually all cellular processes, including 
development and differentiation (Bartel, 2004). The majority of miRNAs act as posttranscriptional 
repressors and have multiple mRNA targets which they bind complementary, preventing their 
expression and reducing their molecular stability (Bartel, 2004). Many miRNAs have been 
implicated in skeletal myogenesis and their number grows as high-throughput analysis methods 
become more accessible (Castel et al., 2018). A group of 3 muscle-specific miRNA families – 
Mir206, Mir1 and Mir133 – the last two of which contain more than one family members, are called 
MyoMirs due to their intense regulation of every step of skeletal muscle development (Table 1) (Luo, 
Nie, & Zhang, 2013). While Mir206 and Mir1 promote muscle differentiation and exit from the cell 
cycle, Mir133 inhibits differentiation and promotes myoblast proliferation (Chen et al., 2006; Luo et 
al., 2013). The MyoMirs are regulated and in turn regulate the expression of the MRFs and contribute 
to the elaborate myogenic regulatory network (Horak, Novak, & Bienertova-Vasku, 2016). 
Table 1: Summary of the functions of diverse signaling pathways in myogenesis 
Signaling pathway / 
molecules 
Functions in myogenesis  
Wnt pathway ↑ MPCs specification in the somites 
↑Myf5, MyoD expression 
• Regulates cell migration, morphology, terminal muscle differentiation and muscle fiber 
specification 
Shh pathway ↑Myf5, MyoD expression 
↑ myogenic commitment 
↑ muscle differentiation  
BMP pathway ↑ MPCs proliferation 
↓ muscle differentiation 
Notch pathway ↑ MPCs proliferation 
↑ satellite cells formation 
↓ muscle differentiation 
MAPK pathway • p38 pathway: ↑ muscle differentiation 
• JNK pathway: ↓ muscle differentiation 
• ERK1/2 pathway: ↑ myoblast proliferaton and fusion  
                                ↓ muscle growth 
PI3K/Akt/mTOR pathway ↑ primary and secondary fusion 
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Signaling pathway / 
molecules 
Functions in myogenesis  
↑ differentiation and hypertrophy 
miRNAs • Mir1 and Mir 206: ↑ muscle differentiation 
• Mir133: ↑ myoblast proliferation 
                ↓ muscle differentiation 
• other miRNAs – versatile roles in myogenesis 
 
1.2.3.3. Ca
2+
 and mechanotransduction in skeletal muscle development 
A further level of complexity in skeletal muscle is added by the signaling events elicited by Ca
2+
 and 
mechanotransduction in the major function of this organ – the muscle contraction. Calcium is a 
potent second messenger that is involved in virtually all cellular processes and signaling pathways in 
all organs and tissues (Clapham, 2007). It has important functions in both developmental and 
regenerative myogenesis, influencing each myogenic stage including cell cycle transition, MPCs 
proliferation, MRF expression and terminal differentiation (Benavides Damm & Egli, 2014; Hauser, 
Saarikettu, & Grundstrom, 2008). Next to its roles in other signaling cascades, in skeletal muscle 
Ca
2+
 homeostasis and dynamics is vital for contraction, as described above (Klinke, 2005). Upon 
contraction initiation the [Ca
2+
]i can rise up to a 100-fold in comparison to its concentration at rest 
(resting [Ca
2+
]i) and thus, significantly influences a number of Ca
2+
-sensitive regulatory proteins and 
pathways (Gehlert, Bloch, & Suhr, 2015). The mechanical stress derived from muscle contraction 
itself triggers an intricate downstream network of mechanotransduction responses that largely 
overlap, regulate and amplify the Ca
2+
-mediated signaling events. Thus, the interplay between rises 
of [Ca
2+
]i and the resulting mechanotransduction signaling is pivotal for normal myogenesis and is a 
part of probably the most researched process in skeletal muscle – the excitation-contraction coupling 
(Benavides Damm & Egli, 2014; Gehlert et al., 2015). 
1.3 Excitation-contraction coupling (ECC) 
The term excitation-contraction coupling (ECC) describes the translation of the electrical signals 
transmitted from the motor neurons into the mechanical response of muscle contraction (Sandow, 
1952). At specific pre-patterned regions at the surface of each myofibers, called motor endplates, the 
projections of the motor neuron axons form chemical synapses – the neuromuscular junctions 
(NMJs) (Hescheler, 2008). Thus, NMJs are the foci of muscle innervation and their proper 
development is under a strict control of a complex three-way communication between the muscle, the 
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motor neurons and presynaptic Schwann cells (Darabid, Perez-Gonzalez, & Robitaille, 2014). Each 
myofiber is innervated by one of the axonal terminals of a motor neuron and the sum of all fibers 
innervated by the same motor neuron (including the motor neuron itself) constitutes a motor unit 
(Buchthal & Schmalbruch, 1980). The number of motor units and their fiber type determines the 
mechanical properties of the individual muscles and muscle groups (Buchthal & Schmalbruch, 1980).  
In myofibers ECC is achieved by a rapid transient rise in [Ca
2+
]i in response to electrical stimulation, 
leading to Ca
2+
 binding to the TnC of the troponin complex and a subsequent contraction initiation 
(Klinke, 2005). Contrary to cardiac muscle contraction that requires Ca
2+
 flow into the cell from the 
extracellular space, the skeletal muscle contraction relies solely on Ca
2+
 released into the cytoplasm 
from the sarcoplasmic reticulum (SR) – the main internal Ca2+ storage in skeletal muscle (Armstrong, 
Bezanilla, & Horowicz, 1972; Lamb, 2000). 
In the NMJs ECC begins as an action potential (AP) reaches a nerve terminal and causes exocytosis 
of the neurotransmitter acetylcholine (ACh) from the neuron’s presynaptic membrane into the 
synaptic cleft (Sine, 2012). ACh then binds to nicotinic ACh receptors (nAChRs) that are densely 
clustered on the muscle’s postsynaptic membrane (Sine, 2012). This leads to a local membrane 
depolarization that activates juxtaposed voltage-gated sodium (Na
+
) channels that produce an inward 
Na
+
 current, resulting in a further membrane depolarization and transmission of the AP along the 
sarcolemma (Catterall, 1988; Flucher & Daniels, 1989). As the AP propagates, it leads to 
depolarization of deep vertical invaginations of the sarcolemma – a tubular membrane network called 
the T-tubuli. The T-tubuli are located in a close proximity to the terminal cisternae of the SR, 
forming specific junctional structures known as triads that consist of a T-tubule surrounded by two 
SR terminal cisternae (Fig. 7) (Fahrenbach, 1965). Precisely the triadic junctions, also called 
“junctional feet”, are the point of signal transmission translating the depolarization of the sarcolemma 
into a Ca
2+
 efflux from the SR (Dulhunty, 2006). In the context of ECC, this signal transmission is 
facilitated by the interplay of two Ca
2+
 channels: the 1,4-dihydropyridine receptor (DHPR), located 
on the T-tubular membrane and acting as a voltage sensor; and the type 1 ryanodine receptor 
(RYR1), located on the SR membrane and forming the SR Ca
2+
 release unit (Rios & Brum, 1987; 
Takeshima et al., 1994). Although not demonstrated directly, a model of direct mechanical coupling 
between DHPR and RYR1 is supported by an accumulating body of evidence and is widely accepted 
as the basis of skeletal type ECC (Adams, Tanabe, Mikami, Numa, & Beam, 1990; Block, Imagawa, 
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Campbell, & Franzini-Armstrong, 1988; Rios & Brum, 1987; Takekura, Bennett, Tanabe, Beam, & 
Franzini-Armstrong, 1994; Tanabe, Beam, Powell, & Numa, 1988). 
 
Fig. 7: Triad structure. 
Left: An electron micrograph of a triad in a frog skeletal muscle, consisting of a centrally located T-tubule (T), flanked 
by two terminal cisternae of the SR. The electron dense regions indicated by the arrows are the junctional feet between 
the T-tubules and the terminal SR cisternae. Modified from (Dulhunty, 2006). Right: A schematic representation of a 
skeletal myofibers internal structure highlighting the T-tubuli – SR network and its position in relation to the myofibrils 
and the sarcomeric regions. Modified from (Al-Qusairi & Laporte, 2011). 
1.3.1 DHPR: structure and functions of the Cav1.1 principal subunit 
DHPR belongs to the family of L-type Ca
2+
 channels, owing their name to their sensitivity to 
1,4-dihydropyridines (Reuter, Porzig, Kokubun, & Prodhom, 1985). Unlike the L-type Ca
2+
 channels 
in other tissues, the skeletal DHPR is characterized by a slow activation and even slower inactivation 
(Bannister & Beam, 2013). DHPR is a heterotetrameric channel, consisting of one principal subunit – 
Cav1.1 (also called α1S) – that spans the T-tubular membrane and acts as a voltage sensor; and three 
auxiliary subunits – β1a, α2δ-1 and γ1 (Fig. 8A) (Catterall, 2000). Cav1.1, encoded by the gene 
Cacna1s, forms the channel pore and transduces the AP signal to the Ca
2+
 release unit, RYR1, 
therefore Cav1.1 is often used instead of DHPR as a description of the whole channel (Bannister & 
Beam, 2013; Wu et al., 2016). The auxiliary subunits modulate the localization and 
electrophysiological properties of Cav1.1-mediated Ca
2+
 currents and have a different degree of 
importance for ECC. The intracellular cytosolic subunit β1a is necessary for proper targeting, 
expression and gating of Cav1.1, and is implicated in the interaction between Cav1.1 and RYR1 in the 
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course of ECC (Gregg et al., 1996; Lacerda et al., 1991; Rebbeck et al., 2011). The γ1 subunit is a 
transmembrane protein that negatively regulates Cav1.1 conductance, as well as voltage-dependent 
Ca
2+
 entry and Ca
2+
 release (Freise et al., 2000; Ursu, Schuhmeier, Freichel, Flockerzi, & Melzer, 
2004).  
 
Fig. 8: Structure and properties of DHPR 
(A) DHPR is a heterotetramer consisting of one principal subunit – Cav1.1 – and three auxiliary subunits – β1a, α2δ-1 and 
γ1. Cav1.1 forms the channel pore (shown as gray cylinder in the middle of Cav1.1), carries the voltage sensor for 
membrane depolarization, and activates RYR1 during ECC. Modified from (Obermair, Tuluc, & Flucher, 2008). (B) 
Schematic structure of Cav1.1, consisting of four homologous repeats (I - IV) connected via cytoplasmic linkers called 
loops. Each of the four repeats comprises of six transmembrane α-helices, with the fourth α-helix carrying a sequence of 
basic AAs – the voltage sensor (shown as blue cylinders with three pluses). The I-II loop binds the β1a subunit and 
promotes the channel trafficking to the T-tubular membrane. The II-III loop is believed to be a crucial element in the 
postulated mechanical coupling to RYR1, which it activates upon membrane depolarization and thus has a pivotal role in 
ECC. Pivotal for this coupling is the so called “critical domain” (shown in red) in the middle of the II-III loop that binds 
Stac3 – a protein that is also necessary for the signal transmission to RYR1. The Cav1.1 repeat IV carries exon 29 (e29, 
shown in red) that undergoes developmentally regulated alternative splicing and alters Cav1.1’s conductance properties. 
Both the N- and C-terminus are cytoplasmic. Modified from (Bannister & Beam, 2013) and (Polster, Nelson, 
Papadopoulos, Olson, & Beam, 2018a). (C) A scanning electron photograph of a freeze-fracture through the surface 
membrane of myotubes, showing groups of Cav1.1 tetrads (exemplified in circles). Modified from (Takekura et al., 
1994). (D) Comparison of the voltage dependence of charge movements (black triangles), Cav1.1 Ca
2+
 currents (black 
circles) and Ca
2+
 transients before and after Ca
2+
 current inhibition by Cd
2+
 and La
3+
 (hollow circles and hollow triangles, 
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respectively). The graph demonstrates that contraction initiating Ca
2+
 transients precede Cav1.1 Ca
2+
 currents and are not 
impeded by their inhibition. Modified by (Garcia, Tanabe, & Beam, 1994). 
The α2δ-1 subunit consists of the α2 extracellular peptide and the δ single-pass membrane peptide, 
linked via disulfide bonds. This is the only DHPR subunit that is significantly expressed also in 
tissues other than skeletal muscle (Bannister & Beam, 2013; Obermair et al., 2008). Its main known 
functions in skeletal muscle are to slow DHPR’s activation kinetics and to facilitate Ca2+ transients 
during prolonged membrane depolarization (Gach et al., 2008; Obermair et al., 2005). While Cav1.1 
and β1a are essential for ECC and organism survival, the loss of α2δ-1 or γ1 does not have significant 
effects on ECC (Bannister & Beam, 2013; Obermair et al., 2008). Cav1.1 is a central player in ECC. 
It senses membrane depolarization and induces opening of RYR1, thus facilitating Ca
2+
 release and 
consequently muscle contraction (Beam & Bannister, 2010; Rios & Brum, 1987). The primary 
structure of Cav1.1 was originally obtained for rabbit skeletal muscle and the rabbit Cav1.1 isoform is 
still utilized in many experiments (Fig. 8B) (Martinez-Ortiz & Cardozo, 2018; Tanabe et al., 1987; 
Wu et al., 2016). It consists of four homologous repeats (I, II, III and IV), each containing six α-
helices (termed S1 to S6) that span the sarcolemma (Bannister & Beam, 2013; Catterall, 1995). The 
fourth α-helix (S4) of each repeat carries a region of equally spaced basic amino acids (AAs) that 
gate the opening and closing of Cav1.1 (Bezanilla, 2000). At rest, the sarcolemma is in a 
hyperpolarized state, having a membrane potential on the inner side of approximately –80 mV in 
comparison with the outer side (MacIntosh, Holash, & Renaud, 2012). During ECC initiation the AP 
depolarizes the membrane to approximately +30 mV, leading to a topological reorientation of the 
positively charged AAs in the S4 segments, recorded as a gating current (a.k.a. charge movements) 
and causing downstream conformational rearrangements and a subsequent Ca
2+
 release from the SR 
(Bezanilla, 2000). Therefore, the S4 segments of Cav1.1 (and in a broader sense, the whole Cav1.1) 
constitute the voltage sensors during ECC (Bannister & Beam, 2013; Beam, Knudson, & Powell, 
1986; Rios & Brum, 1987). 
The four homologous Cav1.1 repeats are connected via three cytoplasmic linkers, called loops, 
carrying the names of the repeats they are attached to – the I-II, II-III and III-IV loops (Fig. 8B). The 
I-II loop has a binding site for the β1a subunit and is necessary for the proper Cav1.1 targeting to the 
T-tubular membrane (Bannister & Beam, 2013). The II-III loop has been the subject of extensive 
studies since initial experiments suggested an immediate role in RYR1 activation upon ECC 
initiation (el-Hayek, Antoniu, Wang, Hamilton, & Ikemoto, 1995; Grabner, Dirksen, Suda, & Beam, 
1999; Tanabe, Beam, Adams, Niidome, & Numa, 1990). Especially important for this interaction is a 
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45 AAs region in the middle of the II-III loop, termed the “critical domain”, that determines the 
specific properties of skeletal type in contrast to cardiac type ECC (Nakai, Tanabe, Konno, Adams, 
& Beam, 1998). It has been recently demonstrated that the SH3 and cysteine rich domain 3 (Stac3), a 
protein that is also necessary for skeletal ECC, binds to the critical domain and most likely 
participates in the Cav1.1-to-RYR1 signal transmission (Polster et al., 2018a). 
Scanning electron microscopy of myotubes freeze fractures suggests that Cav1.1 molecules are 
ordered in arrays of membrane particles in groups of four (tetrads, Fig. 8C) (Takekura et al., 1994). 
Cav1.1 KO myotubes lack tetrad formation and ectopic expression of Cav1.1 restores junctional 
tetrads (Takekura et al., 1994). 
A combination of electrophysiological approaches and fluorescence microscopy have demonstrated 
that in cultured myotubes charge movements in response to electrical stimulation precede Ca
2+
 
transients that in turn appear prior Cav1.1 Ca
2+
 conductance (Fig. 8D) (Garcia et al., 1994). This 
comes to show that the L-type Ca
2+
 current from Cav1.1 is not required for contraction-related Ca
2+
 
transients, which is one of the major differences between skeletal and cardiac type ECC. 
Furthermore, next to the “orthograde” signal transduction from Cav1.1 to RYR1 in ECC initiation, a 
second “retrograde” signaling from RYR1 to Cav1.1 augments Cav1.1 Ca
2+
 conductance and the 
kinetics of current traces (Nakai et al., 1996). In RYR1-null myotubes only very low amplitude of 
L-type currents are observed that could be rescued by RYR1 expression (Nakai et al., 1996). Since 
the L-type Ca
2+
 currents are not necessary for ECC, their physiological function has been a subject of 
a vigorous discussion. While some propose that Ca
2+
 currents from Cav1.1 may help replenish 
internal Ca
2+
 store during prolonged activity, others have demonstrated that ablation of these currents 
do not affect muscle performance (Bannister & Beam, 2013; Dayal et al., 2017). Interestingly, during 
embryonic and early fetal development, an alternatively spliced Cav1.1 isoform lacking exon 29 (Δ29 
Cav1.1) is being highly expressed in murine skeletal muscle and its expression diminishes with the 
developmental progression (Tuluc et al., 2009). Unlike the adult full length Cav1.1, the Δ29 Cav1.1 
conducts strong Ca
2+
 currents and activates at a lower voltage (Tuluc et al., 2009). The Δ29 Cav1.1 
has been implicated in the regulation of muscle nAChR prepatterning and seems to play an important 
role for the correct innervation of the developing skeletal muscle (Flucher & Tuluc, 2011). 
Cav1.1 acts as a voltage sensor not only for RYR1 during ECC, but it also mediates the 
depolarization-induced activation of 1,4,5-trisphosphate (IP3) receptors (IP3Rs) (Araya et al., 2003). 
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IP3Rs are Ca
2+
 channels located on the SR that, unlike RYR1, produce slow Ca
2+
 transients that do 
not trigger muscle contraction. The IP3R-mediated Ca
2+
 transients are involved in the regulation of 
the expression of multiple genes and since IP3Rs are also activated by membrane depolarization, 
their regulatory activity has been described as “excitation-transcription coupling” (Arias-Calderon et 
al., 2016; Juretic, Urzua, Munroe, Jaimovich, & Riveros, 2007). 
1.3.2 RYR1: structure and functions 
The three types of ryanodine receptors in mammals – RYR1, RYR2 and RYR3 – are intracellular 
Ca
2+
 release channels, located on the SR or the endoplasmic reticulum (ER) membrane (Flucher et 
al., 1993). RYRs are the largest known ion channels and owe their name to their susceptibility to 
ryanodine – a plant-derived alkaloid that interacts with open RYRs and at low concentrations 
(≤70 µM) locks the receptors in a semi-conducive state, whereas at high concentrations (≥200 µM) 
inhibits their conductance (Buck, Zimanyi, Abramson, & Pessah, 1992). RYR1 is expressed in 
skeletal muscle and is located on the SR membrane, where it acts as the Ca
2+
 release unit for ECC 
(Inui, Saito, & Fleischer, 1987; Marks et al., 1989). RYR2 is expressed primarily in cardiac muscle 
and has similar functions in cardiac-type ECC. The main difference to RYR1 is that unlike RYR1, 
RYR2 is activated by extracellular Ca
2+
 entering the cardiac cells via cardiac DHPR (Cav1.2) in a 
process called Ca
2+
-induced Ca
2+
 release (CICR) (Lamb, 2000; Van Petegem, 2012). The third 
subtype, RYR3, was originally discovered in the brain but is also transiently expressed in many other 
tissues, including in some skeletal muscles (Conti, Gorza, & Sorrentino, 1996; Nakashima et al., 
1997; Protasi et al., 2000). Although RYR3 does not directly participate in ECC, it is involved in 
muscle development and assists RYR1-mediated CICR in neonatal skeletal muscle (Bertocchini et 
al., 1997; Yang et al., 2001). 
The RYR1 Ca
2+
 channel is a giant homotetramer with a staggering molecular weight of 
approximately 2.2 mega Da (Takeshima et al., 1989). Each RYR1 subunit consists of around 5000 
AAs, more than 80% of which form a large N-terminal cytoplasmic region, containing multiple 
functional domains, and the rest ~ 500 AAs, a C-terminal transmembrane domain that forms the 
channel pore (Du, Sandhu, Khanna, Guo, & MacLennan, 2002; Efremov, Leitner, Aebersold, & 
Raunser, 2014; Yan et al., 2014; Zalk et al., 2014) (Fig. 9A). Although only separate RYR1 domains 
have been successfully crystalized, the development of super resolution microscopy techniques and 
in particular of electron cryomicroscopy (cryoEM) in the last four years has led to near-atomic 
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models of RYR1 structure (Efremov et al., 2014; Yan et al., 2014; Zalk et al., 2014). These models 
have shown that multiple long range allosteric interactions as distant as 200 Å away from the channel 
pore can influence its conductance state (Van Petegem, 2015). Nevertheless, higher resolution 
models are needed for more precise detection of the exact points of interaction between Cav1.1 and 
RYR1.  
 
Fig. 9: Structure and properties of RYR1 
(A) A pseudoatomic model of RYR1 at a 4.8 Å resolution obtained from cryoEM data displays RYR1 in view from the 
plane of the SR membrane (black lines, left) and from the cytosol (right). The colors designate different structural 
domains found within one protomer. Modified from (Zalk et al., 2014). (B) The scheme exemplifies the direct mechanical 
coupling between a Cav1.1 tetrad on the T-tubular membrane and an opposing a RYR1 channel on the SR membrane. 
Activation of channel conductance is transmitted from Cav1.1 to RYR1 via orthograde signaling and from RYR1 to 
Cav1.1 via retrograde signaling. Modified from (Dulhunty, 2006). (C) A RYR1 2D checkerboard pattern model shows the 
interactions between individual RYR1s (gray squares) and between RYR1s and Cav1.1s (pink dots). Each second RYR1 
is coupled to a Cav1.1 tetrad. Upon activation via orthograde signals the RYR1s that are coupled to Cav1.1 activate the 
neighboring RYR1s via a proposed allosteric coupled gating mechanism. Modified from (Van Petegem, 2015) and (Yin, 
D'Cruz, & Lai, 2008). (D) The scheme shows a partial overview of proteins, small molecules and ions known to 
positively (+) or negatively (-) modulate RYR1 conductance. Some modulators (Ca
2+
, CaM) have a dual action in this 
respect, dependent on their concentration or complex formation. Abbreviations stand for: cADPR, cyclic ADP ribose; 
S100A1, S100 calcium-binding protein A1; CaM, calmudulin; NO, nitric oxide; CamKII, calmodulin kinase II; ATP, 
adenosine triphosphate; 4-CmC, 4-chloro-m-cresol; FKBP12, 12-kDa FK506-binding protein; PP1, protein phosphatase 
1; PP2A, protein phosphatase 2A. Modified from (Zalk et al., 2014) and (Van Petegem, 2015). 
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As described above, RYR1 and Cav1.1 are involved in an intricate bi-directional communication, 
composed of an orthograde signaling from Cav1.1 to RYR1, and a retrograde signaling from RYR1 
to Cav1.1 so that each channel modulates the activity of the other one (Nakai et al., 1996) (Fig. 9B). 
In addition to RYR1 activation, Cav1.1 also stabilizes RYR1 at rest and reduces RYR1 passive Ca
2+
 
leak (Eltit et al., 2011). The retrograde signaling from RYR1 enables the slow L-type Ca
2+
 currents 
through Cav1.1, which are greatly reduced in RYR1 null mutant cells (Avila & Dirksen, 2000; Nakai 
et al., 1996). Moreover, the absence of RYR1 leads to an impairment of tetradic formation 
(Takekura, Nishi, Noda, Takeshima, & Franziniarmstrong, 1995). Several domains on the 
cytoplasmic part of RYR1 seem to be involved in the interaction with Cav1.1 and β1a (Van Petegem, 
2015). Especially important for ECC and tetrad formation is the divergent region 2, located between 
two SPRY (SplA kinase ryanodine receptor domain) domains (Perez, Mukherjee, & Allen, 2003; 
Sheridan et al., 2006). We have recently shown that a protein containing the first 4300 AAs of the 
rabbit RYR1 that is entirely cytosolic (termed RYR1 soluble foot or RYR11:4300) is targeted to the 
triadic junctions, co-localizes with Cav1.1 and restores retrograde signaling (Polster et al., 2018b). 
Hence, the most important determinants for the Cav1.1-RYR1 bidirectional communication from the 
RYR1 side are most likely contained entirely in the cytoplasmic RYR1 region. 
RYR1 channels can form highly ordered 2D crystalline arrays in which the corners of each channel 
face those of another four RYR1s, forming a checkerboard-resembling pattern (Fig. 9C) (Yin & Lai, 
2000). Each of the four RYR1 subunits interacts with one of the four Cav1.1 molecules in a tetrad 
(Fig. 9C). However, only every second RYR1 interacts with Cav1.1s (Yin et al., 2008). The 
orthograde signals from Cav1.1 are transmitted to the rest of the RYR1 very likely via allosteric 
interactions with their Cav1.1-bound neighbors – the postulated phenomenon of coupled gating 
(Marx, Ondrias, & Marks, 1998). 
In addition to Cav1.1, a large number of other proteins, peptides, ions and other molecules bind to 
and modulate RYR1, contributing to the complexity of this channel’s regulation (Fig. 9D) (Dias & 
Vogel, 2009; Van Petegem, 2015). An important RYR1 activator is the 12-kDa FK506-binding 
protein (FKBP12) – a small protein that binds each RYR1 subunit and stabilizes RYR1’s closed state 
(Van Petegem, 2015). Some modulators can have dual roles, such as cytosolic Ca
2+
 that activates 
RYR1 at lower concentrations and inactivates it at higher concentrations. SR luminar Ca
2+
 and the 
Ca
2+
-buffering protein calsequestrin together with other luminar proteins like triadin and junctin also 
modulate RYR1 conductance (Wei, Gallant, Dulhunty, & Beard, 2009). Similarly, calmodulin (CaM) 
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– an EF-hand-containing protein with a high affinity for Ca2+ – directly binds to RYR1 and 
dependent on the cytosolic Ca
2+
 concentration activates or inhibits it (Tripathy, Xu, Mann, & 
Meissner, 1995). Furthermore, RYR1’s conductance is affected by a variety of post-translational 
modifications like oxidation, phosphorylation, palmitoylation and S-nitrosylation (Witherspoon & 
Meilleur, 2016). This intricate multimolecular fine-tuning underlines the importance of the correct 
ECC signal transmission and proper RYR1-mediated Ca
2+
 release. 
1.3.3 Cav1.1 and RYR1: diseases and animal models 
Due to the large size of the of Cav1.1 and RYR1, the multitude of their interactions with other 
proteins and molecules, and the potent outcome of their functions – Ca2+ release and muscle 
contraction – disturbances in their action or regulation have been linked to diverse diseases. Around 
75% of the cases of hypokalemic periodic paralysis type 1 (HPP-1) – a disease characterized by 
periods of muscle weakness and paralysis – are caused by mutations in Cav1.1 (Striessnig, Bolz, & 
Koschak, 2010). Mutations in RYR1 are the leading cause of malignant hyperthermia (MH) – a life-
threatening pharmacogenetic disorder triggered by certain anesthetics and characterized by a 
hypermetabolic state, fever and rhabdomyolysis (Mathews & Moore, 2004). Mutations in Cav1.1 
have also been linked to MH. In addition, various mutations in both channels have been liked to 
congenital myopathies like central core disease, multiminicore disease and CACNA1S congenital 
myopathy (Jungbluth et al., 2018; Mathews & Moore, 2004; Schartner et al., 2017). Manifestation of 
these diseases often starts in early age and progresses with development. Therefore, information 
about the full spectrum of the roles of Cav1.1 and RYR1 in muscle development is urgently needed. 
Different in vitro and in vivo models have been utilized in the analysis of Cav1.1 and RYR1 
properties (Chelu et al., 2005; Dayal et al., 2017; Powell, Petherbridge, & Flucher, 1996; Zvaritch et 
al., 2007). Two mouse models – the Cav1.1 null dysgenic and the RYR1 null dyspedic mice – have 
proven to be invaluable for the examination of the structural and functional properties of these 
channels in the context of ECC (Buck, Nguyen, Pessah, & Allen, 1997; Chaudhari, 1992; Pai, 1965b; 
Takeshima et al., 1994). Both models have very similar phenotypes. Namely, the heterozygous mice 
(RYR1
+/-
 and Cav1.1
+/-
) are phenotypically undistinguishable from their wild type (WT, 
+/+
) 
littermates and exhibit no changes in their lifespan, fertility and ECC. On the contrary, the skeletal 
muscle of homozygous dyspedic and dysgenic mice (for clarity referred to as RYR1
-/-
 and Cav1.1
-/-
 in 
the following text) cannot support ECC, thus they are paralyzed and die at birth from asphyxia. In 
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addition, both RYR1
-/-
 and Cav1.1
-/-
 mice appear smaller than their WT and heterozygous littermates, 
possess a characteristic spinal curvature, small limbs and enlarged necks (Fig. 10). Skeletal muscle 
from RYR1
-/-
 and Cav1.1
-/-
 neonates bears features of structural and developmental impairment (Pai, 
1965b; Takeshima et al., 1994). Still, the full range of the alterations caused by the absence of RYR1 
or Cav1.1 throughout the development of the skeletal muscle remains unknown. 
 
Fig. 10: Cav1.1 and RYR1 null mice. 
Photographs show comparisons of homozygous (
-/-
), and “normal” (+/(+), heterozygous or WT) Cav1.1 (A, C) and RYR1 
(B, D) new born littermates. Compared to their respective +/
-
 or 
+/+
 littermates, homozygous Cav1.1
-/-
 and RYR1
-/-
 
neonates are smaller, have smaller limbs and a marked spinal curvature. (A, B) Photographs are modified from the 
original publication describing the mouse models for the first time (Pai, 1965a) and (Takeshima et al., 1994); (C, D) 
Photographs of typical neonates used in the present work. Note that the RYR1
-/-
 mice used in this work carry the mutation 
causing loss of RYR1 on a slightly different position (RYR1 exon 10) than in (B, RYR1 exon 2) (Buck et al., 1997). 
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1.4 Aims 
This work aims to examine the global gene expression changes caused by the absence of RYR1 or 
Cav1.1 throughout skeletal muscle development, utilizing limb skeletal muscle as a model. More 
precisely, two major aims are addressed: 
I. The first part of this work aims to determine how the absence of RYR1 affects the 
skeletal muscle transcriptome at E18.5 – the end of fetal development. Specifically, the 
limb muscle histology and the transcriptomic profiles of RYR1
-/-
 and RYR1
+/-
 E18.5 
littermates are compared. The expression changes of muscle’s structure proteins and 
developmental markers are evaluated and the differential regulation of impacted signaling 
pathways is analyzed. 
 
II. The second part of this work aims to compare the changes caused by the absence of either 
RYR1 or Cav1.1 in the beginning (E14.5) and the end (E18.5) of secondary myogenesis. 
At each time point, the histological and transcriptomic profiles of WT (
+/+
), heterozygous 
(
+/-
) and homozygous (
-/-
) RYR1 and Cav1.1 limb skeletal muscles are compared. The 
differences and similarities in the structural and expression changes between the RYR1 
and Cav1.1 lines are analyzed in respect to the developmental time point – E14.5 or E18.5 
and in respect to the developmental dynamics of these changes from E14.5 to E18.5. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Instruments and Reagents 
Instruments and Reagents Supplier / Source 
Antibodies 
Anti-mouse activated caspase-3 , rabbit (clone C92-605) BD Biosciences 
Anti-rabbit, goat, biotinylated Vector Laboratories 
 
Chemicals 
2-methylbutane (C5H12) Merk 
3,3`-Diaminobenzidine tetrahydrochloride hydrate (DAB) Sigma Aldrich 
6X DNA Loading Dye Thermo Fisher 
Acetone Carl Roth 
Bovine serum albumin (BSA) Sigma 
Chloroform (CHCl3) Merk 
CutSmart Buffer, 10x NEB 
D-Glucose Merk 
Dimethyl sulfoxide (DMSO) Sigma Aldrich 
dNTP (Deoxynucleotide) solution mix [10 mM] Thermo Fisher 
DreamTaq Green PCR Buffer (2x) Thermo Fisher 
Eosin G-solution Carl Roth 
Ethanol DAB 96%  Merck  
Ethylenediaminetetraacetic acid (EDTA) Fluka  
Glacial acetic acid Merk 
Hematoxylin solution modified acc. To Gill II Merk 
HEPES Sigma Aldrich 
Hidrogen peroxide (H2O2) Merk 
LE Agarose Biozym 
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Instruments and Reagents Supplier / Source 
Normal Goat Serum Vector Laboratories 
Phosphate buffered saline (PBS), solution Biochrom 
Phosphate-buffered saline (PBS) tablets Thermo Fisher 
Potassium chloride (KCl) Fluka 
RNAlater Qiagen 
Sodium chloride (NaCl) Carl Roth 
Sodium hydroxide (NaOH) Riedel-de Haën 
Tissue-Tek® O.C.T. Compound Sakura® Finetek 
Tris base Sigma Aldrich 
Trizma-HCl Sigma Aldrich 
Water, nuclease free Promega 
Xylene Carl Roth 
  
Enzymes 
DreamTaq
®
 DNA Polymerase  Thermo Fisher 
EarI Fermentas 
  
Equipment and Instrumentation 
AxioCam MRc camera Zeiss 
Axiophot Zeiss microscope Zeiss 
Benchtop Centrifuge 5415 D Eppendorf 
CM3050 S Leica cryostat Leica 
Consort E122 Powersupply Consort 
GeneChip® Fluidics Station-450 Affymetrix / Thermo Fisher 
GeneChip® Hybridization Oven-645 Affymetrix / Thermo Fisher 
GeneChip® Scanner-3000-7G Affymetrix / Thermo Fisher 
Gel documentation system, version 3.28.16.01.2009 INTAS 
KL 1500 electronic Halogen cold light source Schott 
Lab-Line Titer Plate Shaker Thermo Fisher 
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Instruments and Reagents Supplier / Source 
Magnetic Stand for 96-well plates Ambion 
Mastercycler® Gradient thermal cycler Eppendorf 
Micro forceps Aesculap 
Micro scissors Aesculap 
MicroAmp® Fast 96-Well Reaction Plates (0.1 mL) Applied Biosystems 
MicroAmp™ Optical Adhesive Film Applied Biosystems 
MoGene 2.0 ST arrays, format 100 Affymetrix / Thermo Fisher 
Mouse Genome 430 2.0 arrays Affymetrix / Thermo Fisher 
NanoDrop; 1000 Spectrophotometer Thermo Fischer 
Olympus Fluoview1000 system Olympus 
Pestles, steel neoLab 
StepOne™ Plus Real-Time PCR System  Applied Biosystems 
Wild Heerbrugg M3 stereomicrpscope Leica 
  
Kits 
AMV First Strand cDNA Synthesis Ki NEB 
GeneChip® 3′ IVT Express Kit Affymetrix / Thermo Fisher 
GeneChip® Hybridization, Wash, and Stain (HWS) Kit Affymetrix / Thermo Fisher 
GeneChip® WT PLUS Reagent Kit Affymetrix / Thermo Fisher 
GoTaq® qPCR Master Mix kit Promega 
Maxwell® 16 LEV simplyRNA Tissue Kit Promega 
QuantiTect® Reverse Transcription Kit Qiagen 
Vectastain® Elite® ABC-HRP Kit Vector Laboratories 
  
Markers 
DNA Ladder 100 bp, 1kb Thermo Fisher 
RiboRuler High Range RNA Ladder Thermo Fisher 
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Instruments and Reagents Supplier / Source 
Software 
ClustVis online tool https://biit.cs.ut.ee/clustvis/ 
CorelDRAW X5  Corel Corporation 
Database for Annotation, Visualization and Integrated Discovery (DAVID) https://david.ncifcrf.gov/ 
Enrichr online enrichment tool http://amp.pharm.mssm.edu/Enrichr/ 
Expression Console™ Software 1.4 Affymetrix / Thermo Fisher 
Fluoview, FV10-ASW 2.1 Viewer Olympus 
GeneChip® Command Console (AGCC) Affymetrix / Thermo Fisher 
GeneChip® Operating Software (GCOS) Affymetrix / Thermo Fisher 
GraphPad Prism 4.00 GraphPad 
LIMMA-package (Smyth, 2004) 
OligoPerfect™ Designer Thermo Fisher 
Primer-BLAST NCBI 
R-package (Irizarry, 2003) 
StepOne Software v2.3 Applied Biosystems 
Transcriptome Analysis Console 3.0 Affymetrix / Thermo Fisher 
ZEN Imaging Software Zeiss 
2.1.2 Primers 
All forward (Fwd) and reverse (Rev) primers (Table 2) were dissolved in Tris-EDTA buffer (TE, 10 
mM Tris, 1 mM EDTA, pH 7.5) to 100 mM stock solutions and 10 mM working solutions. All 
primers were supplied by Sigma Aldrich. 
Table 2. Primers sequences and amplicon size used for PCR and qRT-PCR analyses. 
Gene Primers (5’ to 3’) Amplicon (bp) 
Primers used in genotyping PCR analyses 
Ryr1 
(WT allele) 
Fwd: GGACTGGCAAGAGGACCGGAGC 
Rev: GGAAGCCAGGGCTGCAGGTGAGC 419 
Ryr1 
(
-/-
 allele) 
Fwd: GGACTGGCAAGAGGACCGGAGC 
Rev: CCTGAAGAACGAGATCAGCAGCCTCTGTCCC 300 
Cacna1s 
Fwd: GCTTTGCAGATGTTCGGGAAGATCGCCATGG 
Rev: GCAGCTTTCCACTCAGGAGGGATCCAGTGT 271 
Primers used PCR analyses of Cav1.1 full length and Δ29 splice variants 
Cacna1s 
Exons 28-32 
Fwd: TCCTAATCGTCATCGGCAGC 
Rev: TTTATCTGCGTCCCGTCCAC 343 / 286 
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Gene Primers (5’ to 3’) Amplicon (bp) 
Primers used in qRT-PCR analyses 
Abra 
Fwd: GCCCCCAAAACTCTGTCTCC 
Rev: GACAACCGTTCTGGTCACCT 111 
Actb 
Fwd: GCCTCACTGTCCACCTTCCA  
Rev: AAAACGCAGCTCAGTAACAGTC 115 
Ankrd1 
Fwd: CCTGCGAGGCTGATCTCAAT 
Rev: CGCACCGAAGGTCATCAAGA 110 
Bai3 
Fwd: AGTATGGAGGAAGGCCCTGT 
Rev: GTGGCTCCATGAACTCCATT 107 
Cacna1s 
exons 10-11 
Fwd: GCCACTCTGGTTGACCCATT 
Rev: GGACATGAAGTACTGGCGCA 115 
Cdh3 
Fwd: CAACGAAGCCCCTGTGTTTG 
Rev: CTCCTTGTCTGGGTCCTGTG 109 
Col19a1 
Fwd: TTGGATTGCCAGGAGAACAT 
Rev: CAGCATCACCCTTCAGACCT 114 
Creb5 
Fwd: AGGGAGTTGAAGGCTACTGGA 
Rev: TCTGCAGCTCCGACCTATCT 107 
Cytb 
Fwd: CCATTCTACGCTCAATCCCCA 
Rev: AGGCTTCGTTGCTTTGAGGT 109 
Derl3 
Fwd: ATGCTCTTCGTGTTCCGCTA 
Rev: GCAGAGTCATAAGAACACCACC 109 
Eda2r 
Fwd: AGAGGATGGATTTGATCTGTTGTTG 
Rev: AAGGCAGTTGTCACGCTCTC 106 
Flcn 
Fwd: GCTGGGATTACCGAACTGAG 
Rev: AGGCGATCTGTCGTAACACC 110 
Fn1 
Fwd: GGTTCGGGAAGAGGTTGTGA 
Rev: ATGGCGTAATGGGAAACCGT 105 
c-Fos 
Fwd: AGTCAAGGCCTGGTCTGTGT 
Rev: TCCAGCACCAGGTTAATTCC 100 
Gapdh 
Fwd: AGTGTTTCCTCGTCCCGTAG 
Rev: TGATGGCAACAATCTCCACT 119 
Hbb-y 
Fwd: TTGGCTAGTCACTTCGGCAAT 
Rev: AGGGCTCAGTGGTACTTGTG 107 
Hdac4 
Fwd: CCAATGCCAATGCTGTCCAC 
Rev: TGCGCCTCAATCAGAGAGTG 112 
Irx2 
Fwd: GTCTACACGTCGACTCGCTC 
Rev: ACACTCTGAGCCTGATTCGC 107 
Jun 
Fwd: GAAAAGTAGCCCCCAACCTC 
Rev: ACAGGGGACACAGCTTTCAC 106 
Klf4 
Fwd: TACCCCTACACTGAGTCCCG 
Rev: GGAAAGGAGGGTAGTTGGGC 110 
Mcpt4 
Fwd: GTGGGCAGTCCCAGAAAGAA  
Rev: GCATCTCCGCGTCCATAAGA 107 
Mlip 
Fwd: AAGCATGAACCAGGAAGCTCA 
Rev: CTGGACCCTCTCTTGTTTGCT 114 
Mrf4 
Fwd: GCAGAGGGCTCTCCTTTGTA 
Rev: AACGTGTTCCTCTCCACTGC 105 
Mybpc2 
Fwd: ACACTGAACATCCGCCGAC 
Rev: TGTGGCACTCGGACATCCA 113 
Myf5 
Fwd: GAAGGTCAACCAAGCTTTCG 
Rev: GCTCTCAATGTAGCGGATGG 109 
Myl2 
Fwd: AAAGAGGCTCCAGGTCCAAT  
Rev: CACCTTGAATGCGTTGAGAA 105 
Mylpf Fwd: ATAACCCCAGAAGAACTGCTCC 108 
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Gene Primers (5’ to 3’) Amplicon (bp) 
Rev: TTCTCTTGGCCTTCTTGGGTG 
MyoD 
Fwd: GGCTACGACACCGCCTACTA 
Rev: GTGGAGATGCGCTCCACTAT 110 
MyoG 
Fwd: CTGCACTCCCTTACGTCCAT 
Rev: CCCAGCCTGACAGACAATCT 103 
Nefl 
Fwd: TTCAGGATCTATGGCAATGTGA 
Rev: TCCCATGAGGTTGCACATGAA  115 
Nell1 
Fwd: ATCAGAGGAAGGCGTTTGGG 
Rev: AGCACGGAGACTCAACAACC 111 
Pax3 
Fwd: AAACCCAAGCAGGTGACAAC 
Rev: AGACAGCGTCCTTGAGCAAT 115 
Pax7 
Fwd: ATTACCTGGCCAAAAACGTG 
Rev: AGTAGGCTTGTCCCGTTTCC 105 
Rplp0 
Fwd: GATTCGGGATATGCTGTTGG 
Rev: TCGGGTCCTAGACCAGTGTT 108 
Six1 
Fwd: CCTGGGGCAAAATGATGTAT 
Rev: CAAAGCATGAGCAAGCCAAC 112 
Six4 
Fwd: GGCCAGAGGTTGTTGTTTGT 
Rev: GGCAGCCAAGCTGTGTAAGT 109 
Sox10 
Fwd: TACCTTTGCCTTGCACCCTT 
Rev: AAAGGGGCAGCGATGTGTTA 111 
Trib1 
Fwd: TAACAAACTCCCCCTTGCTG 
Rev: CAACGCAGAACAGTCATGGT 105 
Trpm3 
Fwd: AAGGCTTTGACTTTCTGTCATCTG 
Rev: TTCAACAGTGGGTCCAATAGCA 105 
Uba52 
Fwd: ATTGAGCCATCCCTTCGTCAG 
Rev: CTTCTTCTTGCGGCAGTTGAC 111 
Ucp1 
Fwd: GGAGGTGTGGCAGTGTTCAT 
Rev: AAGCATTGTAGGTCCCCGTG 112 
2.2 Methods 
All procedures were performed as described in (Filipova et al., 2016) and (Filipova et al., 2018).  
2.2.1 Ethics statement 
All animal experiments were carried out in accordance with the guidelines of the European 
Commission (Directive 2010/63/EU) and of the German animal welfare act (TierSchG). The mice 
were housed in the Animal Facility of the Center for Molecular Medicine Cologne (CMMC), a part 
of the Medical Faculty of the University of Cologne according to the European Union 
Recommendation 2007/526/EG. All experimental protocols and procedures were approved by the 
local governmental authorities (Landesamt für Natur, Umwelt und Verbraucherschutz, North Rhine-
Westphalia, license № AZ84-02.05.20.13.080 and 84-02.04.2015.A054). Effort was taken to 
minimize animal suffering. 
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2.2.2 Animal procedures and skeletal muscle preparation 
All mice (the RYR1
+/-
 dyspedic (ry142) and the Cav1.1
+/-
 dysgenic mouse (mdg) lines) were from the 
C57BL/6J background (Buck et al., 1997; Pai, 1965b). Heterozygous RYR1
+/-
 or Cav1.1
+/-
 male and 
female mice were subjected to timed mating with the duration of 31 hours (pairing was only among 
lines: either RYR1
+/-
 x RYR1
+/-
 or Cav1.1
+/-
 x Cav1.1
+/-
). The pregnant females of each line were 
sacrificed either at day 14.5 and or at day 18.5 post coitum by cervical dislocation; the fetuses were 
rapidly sacrificed by decapitation and used immediately for skeletal muscle preparation. Each fetus 
was handled separately (Filipova et al., 2018; Filipova et al., 2016).  
2.2.2.1 Morphological analyses 
Comparison of the overall morphology, body shape and size of littermates from different genotypes, 
was carried out after taking whole-body photographs of animal fetuses (n = 3) at E14.5 and E18.5 of 
each of the following genotypes: RYR1
+/+
 (WT), RYR1
+/-
, RYR1
-/-
; Cav1.1
+/+
 (WT), Cav1.1
+/-
, and 
Cav1.1
-/-
. Representative photographs from each group are shown (Figs. 13 and 22). 
2.2.2.2 Skeletal muscle preparation 
The fetuses were kept on ice during skeletal muscle sample collection. The skin from the front and 
hind limbs was removed with the help of micro forceps and micro scissors. The limb skeletal muscle 
of each fetus was dissected and pooled for each animal in RNAlater on ice. Subsequently the samples 
were centrifuged for 10 min at 16,000 x g, the RNAlater was then removed and the samples were 
immediately frozen in liquid nitrogen and stored at -80 °C until use.  
The fetuses were genotyped via PCR as described below. For the analysis of E18.5 RYR1
-/-
 vs. 
RYR1
+/-
 (3.1 Results part I) the limb skeletal muscle samples either from two heterozygous RYR1
+/-
 
and two homozygous RYR1
-/-
 littermates from two litters were used (n = 4 biological replicates = 4 
animals for each group). For the analysis of both RYR1
-/-
 and Cav1.1
-/-
 at E14.5 and E18.5 (3.2 
Results part II) from each litter the limb skeletal muscle samples from one WT, one heterozygous 
(either RYR1
+/-
 or Cav1.1
+/-
) and one homozygous (either RYR1
-/-
 or Cav1.1
-/-
) mutant littermate were 
used in the subsequent analyses (n = 3 biological replicates = 3 animals for each group).  
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2.2.2.3 Genotyping 
A small terminal segment from the tail of each fetus was lysed in 100 µl lysis buffer (25 mM NaOH, 
0.1 mM EDTA) at 95 °C for 30 minutes, followed by an addition of 100 µl ice-cold neutralization 
buffer (40 mM Trizma-HCl) on ice. One µl of each sample was used as a template for genotyping 
PCRs using the DreamTaq Polymerase as per manufacturer’s instructions (Table 3). For genotyping 
the RYR1 line (Ryr1 gene) the WT (+) allele and the mutant (-) allele were amplified in separate 
PCR reactions with the primers from Table 2. For genotyping the Cav1.1 line (Cacna1s gene), the 
genomic Cacna1s locus carrying the mutation – a single nucleotide deletion (Chaudhari, 1992), was 
amplified via PCR with the primers indicated in Table 2. The resulting PCR products were 
subsequently subjected to a restriction analyses via EarI. EarI digests only the PCR product from the 
WT Cav1.1 allele but not the mutant allele. PCR products and EarI digestions were analyzed via runs 
on 2% agarose gels. 
Table 3. Genotyping PCR reactions composition and PCR program. 
PCR reactions PCR program RYR1 PCR program Cav1.1 
18.25 µl H2O 1 x 94 °C 5 min 1 x 95 °C 2 min 
2.50 µl 10x DreamTaq Green Buffer 
30x 
94 °C 40 sec 
35x 
95 °C 30 sec 
0.50 µl 10 mM dNTPs 72 °C 30 sec 60 °C 45 sec 
1.25 µl 10 µM Fwd primer 72 °C 30 sec 72 °C 50 sec 
1.25 µl 10 µM Rev primer 1 x 72 °C 5 min 1 x 72 °C 7 min 
0.25 µl DreamTaq Polymerase Hold 4 °C  Hold 4 °C  
1.00 µl Tissue lysate       
2.2.3 Histological analysis and immunohistochemistry 
The preparation and analysis of histological cross-sections, stainings and immunohistochemical 
reactions were performed with the kind assistance of PD Dr. Anna Brunn and Mariana Carstov from 
the group of Prof. Dr. Martina Deckert from the Department of Neuropathology at the University 
Hospital of Cologne. 
2.2.3.1 Preparation of cryosections  
Immediately after the fetuses have been sacrificed, the lower limbs were vertically positioned on 
cardboard slices coated with Tissue-Tek® O.C.T. Compound and additional Tissue-Tek® was 
applied to cover the limbs. The cardboard slices with the limbs were snap-frozen in dry ice – 
2-methylbutane mixture at approximately -79 °C for at least 10 minutes (min.). The limbs were 
stored at -80 °C until further use. Limb transverse sections with a thickness of 10 µm were produced 
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on a CM3050 S Leica cryostat with a chamber temperature of -20 °C and transferred on microscope 
slides. The sections were stored -80 °C until further use. 
2.2.3.2 Fixation 
The sections were fixed via incubation in acetone for 10 min, followed by incubation in chloroform 
for 7 min. Subsequently the fixed sections were allowed to dry out for 15 min. All procedures were 
performed at room temperature. 
2.2.3.3 Hematoxylin and eosin (H&E) staining 
The microscope slides with the fixed histological sections were stained with H&E according to 
Table 4 and subsequently sealed with microscope cover slips. All procedures were performed at 
room temperature. 
Table 4. H&E staining protocol. 
Procedure Reagent (Cat. #, Source) Incubation 
1) Hematoxylin 
staining 
Hematoxylin solution modified acc. To Gill II 
3 min. 
2) Wash Tap H2O 5 min. 
3) Eosin staining Eosin G-solution, 0.5 %  3 min. 
4) Rinse Distilled H2O (d H2O) ~ 10 sec. 
5) Dehydration 
50 % EtOH ~ 30 sec. 
70 % EtOH ~ 30 sec. 
90 % EtOH ~ 30 sec. 
100 % EtOH 2 x 5 min. 
Xylene 2 x 5 min. 
2.2.3.4 Immunohistochemical stainings of activated caspase-3 
The microscope slides with the fixed histological sections were stained for activated caspase-3 
according to Table 5 and subsequently sealed with microscope cover slips. All procedures were 
performed at room temperature. 
Table 5. Activated caspase-3 staining protocol. 
Procedure Reagent (Cat. #, Source) Incubation 
1) Blocking 5 % BSA + 5 % Normal Goat Serum  20 min. 
2) Primary antibody 
Monoclonal rabbit anti-mouse activated 
caspase-3 (clone C92-605; BD Biosciences, Heidelberg, Germany), 
diluted 1:500 in PBS 
60 min 
3) Washing PBS  10 min. 
4) Secondary antibody 
5 µl Biotinylated Goat anti-rabbit (Cat. # BA-1000, Vector 
Laboratories, Burlingame, CA, USA) + 15 µl 5 % Normal Goat 
Serum per 1 ml PBS 
 
5) Wash PBS 10 min. 
6) Avidin-Biotin 
complex formation 
Vectastain® Elite® ABC-HRP Kit: 10 µl Reagent A + 10 µl Reagent 
B + 1 ml PBS 
30 min. 
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Procedure Reagent (Cat. #, Source) Incubation 
7) Washing PBS 10 min. 
8) Visualization 
1.4 mM 3,3`-Diaminobenzidine tetrahydrochloride hydrate (DAB) + 
0.07 % H2O2  
10 min. 
9) Wash dH2O 10 min. 
10) Hematoxylin 
staining 
Same as in Table 4, steps 1), 2) and 5)  
2.2.3.5 Microscopy 
The histological and immunohistological stainings were analyzed under an Axiophot Zeiss 
microscope and photographed with an AxioCam MRc camera. Scale bars were calculated via the 
ZEN Imaging Software. 
2.2.4 RNA extraction 
Total RNA from frozen skeletal muscle tissue was extracted with the Maxwell 16 LEV simplyRNA 
Tissue Kit using a Maxwell 16 instrument according to the manufacturer’s instructions. Briefly, prior 
RNA extraction a 1-Thioglycerol/Homogenization Solution mixture was prepared (20 μl of 
1-Thioglycerol per 1 ml of Homogenization Solution, 200 µl mixture per sample) and lyophilized 
DNAze I was dissolved in 275 µl of nuclease-free H2O + 5 µl of Blue Dye. For each sample One 
Maxwell® 16 LEV Cartridge (MCE) was positioned on a Maxwell® 16 LEV Cartridge Rack and a 
LEV Plunger was positioned in well #8 of each cartridge. Labelled 0.5 ml elution tubes containing 50 
µl of nuclease-free H2O each were positioned in front of each MCE. 
Samples were transported in liquid nitrogen. 200 µl of ice-cold 1-Thioglycerol/Homogenization 
Solution mixture was added to each sample on ice and the samples were rapidly homogenized 
mechanically via a steel micropestle. 200 µl of Lysis Buffer was added to each homogenate, 
subsequently the samples were vortexed for 15 sec. The total amount of each sample (~ 400 µl) was 
transferred to well #1 of a MCE. 5 µl of DNase I were pipetted to well #4 of each MCE. The 
Maxwell® 16 LEV Cartridge Rack carrying the MCEs with the samples was inserted into a Maxwell 
16 instrument and the “simplyRNA” protocol was utilized for RNA extraction. 
One µl of each sample was used for measurement of the RNA concentration via a NanoDrop 1000 
Spectrophotometer. RNA samples were diluted to a concentration of 100 ng/µl and 250 or 500 ng of 
each RNA sample were analyzed via runs on 2% agarose gels next to 2 µl of RiboRuler High Range 
RNA Ladder. 
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2.2.5 cDNA synthesis 
Reverse transcription reactions of total RNA were performed for cDNA synthesis via the AMV First 
Strand cDNA Synthesis Kit as per manufacturer’s instructions and as described in (Filipova et al., 
2016); or via the QuantiTect® Reverse Transcription Kit as per manufacturer’s instructions and as 
described in (Filipova et al., 2018). Below is a brief description of both protocols. 
AMV First Strand cDNA Synthesis Kit. 100 ng total RNA from each sample were used in each 
reaction. 2 µl of 50 µM d(T)23 VN primer and nuclease-free H2O to a final volume of 8 µl were 
added to each sample. The samples were incubated at 70 °C for 5 minutes and placed on ice. 10 µl of 
AMV Reaction Mix and 2 µl of AMV Enzyme Mix were added to each sample. The samples were 
incubated at 42 °C for one hour, followed by an inactivation at 80 °C for 5 minutes. Samples were 
then put on ice and diluted with nuclease-free H2O to a final volume of 50 µl. All cDNA samples 
were stored at -20 °C. 
QuantiTect® Reverse Transcription Kit. One µg (10 µl of 100 ng/µl) total RNA was used for cDNA 
synthesis. Genomic DNA elimination reactions were prepared according to Table 6 and incubated at 
42 °C for 2 minutes. Subsequently, reverse transcription reactions (Table 6) were prepared and 
incubated at 42 °C for 30 minutes, followed by an inactivation at 95 °C for 3 minutes. All cDNA 
samples were diluted to a final volume of 1 ml and stored at -20 °C. 
Table 6. QuantiTect® Reverse Transcription reactions setup. 
Component Volume 
Genomic DNA elimination 
gDNA Wipeout Buffer, 7x 2 µl 
Total RNA (100 ng/µl) 10 µl 
nuclease-free H2O 2 µl 
Total volume 14 µl 
Reverse-transcription 
Quantiscript Reverse Transcriptase  1 µl 
Quantiscript RT Buffer, 5x 4 µl 
RT Primer Mix 1 µl 
Entire genomic DNA elimination reaction 14 μl 
Total volume 20 µl 
2.2.6 Quantitative real-time PCR (qRT-PCR) 
Quantitative real-time PCRs (qRT-PCRs) were used for determination of the relative gene expression 
changes of selected genes of interest. All primers (Table 2) were designed using the OligoPerfect™ 
Designer (Thermo Fisher) or Primer-BLAST (Ye et al., 2012) with a melting temperature (Tm) range 
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of 58 °C – 60 °C , an optimal length of 20 bases and an amplicon between 100 and 120 bp, and were 
purchased from Sigma Aldrich. The qRT-PCR reaction mixtures were mixed in 0.1 ml MicroAmp 
Fast 96-well Reaction Plates. The GoTaq® qPCR Master Mix kit was used for preparation of the 
reaction mixtures according to the manufacturer’s instructions in a final volume of 20 µl per reaction. 
cDNAs were diluted 1:10 with nuclease-free H2O and 4 µl of the dilutions were used as a reaction 
template in the qRT-PCR reactions (Table 7). qRT-PCRs were performed in a StepOnePlus™ 
real-time thermal cycler. Technical triplicates of each sample were assayed in one run (40 cycles) 
composed of three stages: 1. Activation at 95°C for 10 min, 2. Denaturation at 95°C for 15 s and 
annealing/extension at 60°C for 1 min for each cycle, 3. Melt curve at 95°C for 15 s, 60°C for 1 min 
and 95°C for 15 s. 
Table 7. qRT-PCR reactions composition. 
Component Volume 
GoTaq® qPCR Master Mix, 2X 10 µl 
CXR Reference Dye 0.2 µl 
10 µM Fwd primer 2 µl 
10 µM Rev primer 2 µl 
cDNA (diluted 1:10) 4 µl 
nuclease-free H2O 1.8 µl 
Total volume 20 µl 
 
qRT-PCR data were analyzed using relative quantification and the Ct method (Ct is the threshold 
cycle) as described previously (Yuan, Reed, Chen, & Stewart, 2006), with the reference genes Gapdh 
or Cytb genes as the endogenous control (described in the Results and Discussion parts). For each 
biological sample and analyzed gene an average Ct value was calculated from the values of the 
technical triplicates. The level of gene expression was calculated by subtracting the averaged Ct 
values for endogenous control from those of the gene of interest, resulting in a ΔCt value, as in 
equation (1). The relative expression was calculated as the difference (ΔΔCt) between the ΔCt of the 
test sample (e.g. RYR1
-/-
 or Cav1.1
-/-
) minus that of the control sample (e.g. WT) as in equation (2). 
The relative expression of genes of interest were calculated as a fold change (FC) relative to the 
expression of the same genes in the control sample and expressed as 2
-ΔΔCt
, as shown in equation (3). 
Equations for calculation of the relative gene expression level in qRT-PCR experiments: 
(1) ΔCt = Ct Target – Ct Reference 
(2) ΔΔCt = ΔCt Test sample – ΔCt Control sample  
(3) FC Target gene in test sample = 2
-ΔΔCt
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2.2.7 Analysis of Cav1.1 full length and Δ29 splice variants  
The relative amount of Cav1.1 transcripts containing or lacking exon 29, i.e. Cav1.1 full length and 
Δ29, respectively, was determined within each sample by PCRs using the cDNA produced from 
10 ng of total RNA from each sample as a template. The region between Cav1.1 exons 28 and 32 was 
amplified using the primers indicated in Table 2. PCRs were performed using the DreamTaq 
Polymerase according to the manufacturer’s protocol and as indicated in Table 8. The PCR program 
consisted of an initial DNA denaturing step at 95°C for 3 minutes, followed by 35 cycles of 95°C for 
30 seconds, 55°C for 30 seconds and 72°C for 1 minute; with a subsequent 5 minute elongation step 
at 72°C and a final holding step at 4°C. Full length Cav1.1 transcripts containing exon 29 produced a 
343 bp PCR product, while those lacking exon29, Cav1.1 Δ29, resulted in a smaller product, 286 bp. 
The two PCR products were separated electrophoretically on 2 % agarose gels and the bands were 
digitized via the INTAS documentation system. Band intensities were quantified with the image 
analysis module implemented in the FluoView1000 software. In the process of band intensity 
quantification, background correction was performed locally for each lane. Subsequently, the 
intensity integral of each band was calculated by summing the intensity values of all pixels belonging 
to that band. The sum of the two intensity integrals was regarded as 100%, so that the fractional 
intensity (in %) of each band, with or without exon 29, could be calculated 
Table 8. PCR reactions composition of the Cav1.1 Δ29 analysis. 
Component Volume 
H2O 14.25 µl 
10x DreamTaq Green Buffer 2.50 µl 
10 mM dNTPs 0.50 µl 
10 µM Fwd primer 1.25 µl 
10 µM Rev primer 1.25 µl 
DreamTaq 0.25 µl 
cDNA 5.00 µl 
Total volume 25.00 µl 
2.2.8 Microarrays 
All microarray (MA) reagents, kits and instruments were purchased from Affymetrix (Thermo 
Fisher) or from the suppliers recommended in the respective Affymetrix manuals. The first MA 
analysis, examining the global transcriptomic changes in E18.5 RYR1
-/-
 vs. RYR1
+/-
 limb skeletal 
muscle, was performed with Mouse Genome 430 2.0 array chips and the GeneChip® 3′ IVT (in vitro 
transcription) Express Kit. The second MA analysis, examining the gene expression profiles of E14.5 
and E18.5 WT (
+/+
), heterozygous (
+/-
) and homozygous (
-/-
) mutant RYR1 and Cav1.1 limb skeletal 
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muscle was performed with MoGene 2.0 ST array chips and the GeneChip® WT PLUS Reagent Kit. 
All procedures were carried out according to the manufacturer’s recommendations. In both analyses 
sample hybridization to the array chips, as well as arrays wash and stain procedures were performed 
via the GeneChip® Hybridization, Wash, and Stain (HWS) Kit according to the manufacturer’s 
instructions. All array chips were scanned in a Gene-Chip Scanner-3000-7G instrument. Detailed 
manuals about experimental procedures, kits specifications and instrument operations are freely 
available at the manufacturer’s web site, http://www.thermofisher.com/. Below is a brief description 
of the main experimental procedures of each of the performed MA analysis. Technical handling of 
array chips was performed with the kind assistance of Margit Henry and Tamara Rotshteyn from the 
Gene Expression Affymetrix Facility at the Center for Molecular Medicine Cologne (CMMC). 
2.2.8.1 MA analysis of E18.5 RYR1
-/-
 vs. RYR1
+/-
 limb skeletal muscle 
An overview of the main steps and incubation times in the MA analysis of E18.5 RYR1
-/-
 vs. 
RYR1
+/-
 limb skeletal muscle is shown in Fig. 11. All thermal incubation steps were performed via a 
thermal cycler except if otherwise indicated. 
All procedures were performed with components of the GeneChip® 3′ IVT Express Kit as described 
in (Filipova et al., 2016) and according to the kit user manual. Briefly, 100 ng of total RNA from 
each biological replicate (limb skeletal muscles from 4 RYR1
-/-
 and 4 RYR1
+/-
 E18.5 fetuses) were 
used in the initial first-strand single-stranded (ss)-cDNA synthesis reaction. On ice, 2 µl of 
1:5.000.000 diluted Poly-A RNA controls, serving as internal positive controls, were mixed with 
each RNA sample and nuclease-free H2O was added to each sample to a final volume of 5 µl. For the 
first-strand cDNA synthesis procedure 5 µl of First-Strand Master Mix was added to each sample, 
followed by incubation at 42 °C for 2 hours. Next, the second-strand cDNA synthesis step was 
performed by adding 20 µl of Second-Strand Master Mix to each sample on ice. Samples were 
incubated at 16 °C for 1 hour, followed by 65 °C for 10 minutes. In vitro transcription (IVT) of the 
double-stranded (ds)-cDNA, yielding amplified RNA (aRNA) and aRNA biotin labeling was 
performed by adding 30 µl of IVT Master Mix to each ds-cDNA sample, followed by an incubation 
at 40 °C for 16 hours. 
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Fig. 11: A schematic workflow of the E18.5 RYR1
-/-
 vs. RYR
+/-
 MAs. 
The scheme depicts the main experimental steps and incubation conditions in MAs preparation, starting with total RNA 
samples up to hybridization to Mouse Genome 430 2.0 array chips. The GeneChip® 3′ IVT Express Kit was used in all 
experiments up to the hybridization step. Master mixes containing all reagents except the RNA-derived sample were used 
in all steps to assure equal handling and conditions of all samples. Modified from the GeneChip® 3′ IVT Express Kit 
User Manual (Thermo Fisher). 
In the following aRNA purification reaction unbound ribonucleotide triphosphates (NTPs), salts, 
enzymes and inorganic phosphate are removed. Purification of aRNA is achieved by the addition of 
60 µl of aRNA Binding Mix (containing 10 µl of RNA binding beads) to each aRNA sample in a 96-
well U-Bottom Plate, followed by the addition of 120 µl of 100% ethanol to each sample and gently 
shaking of the U-Bottom Plate at a plate shaker for 2 minutes. The U-Bottom Plate was then 
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transferred on a magnetic stand for 5 minutes to capture the aRNA-bound magnetic beads. The beads 
were then washed two times with 100µl of aRNA Wash Solution and again captured via a magnetic 
stand. The purified aRNAs was eluted in 50 µl of preheated (60 °C) aRNA Elution Solution and kept 
on ice or stored at -80 °C. Next, the aRNAs concentrations were measured via a NanoDrop 
spectrophotometer. 15 μg of each biotin-aRNA was fragmented via an addition of 8 µl of 5x Array 
Fragmentation Buffer and nuclease-free H2O up to 40 µl total volume per reaction. The 
fragmentation was induced by an incubation at 94 °C fo 35 minutes. Samples were placed on ice or 
stored at -20 °C. 
The following steps were performed via the GeneChip® Hybridization, Wash and Stain Kit (HWS). 
12.5 µg of each biotin-labeled aRNA sample were added to the Hybridization Cocktail (Table 9, 
left). The Hybridization Cocktail was heated at 99 °C for 5 minutes and at 45 °C for 5 minutes. 200 
µl of Pre-Hybridization Mix was added to each of the Mouse Genome 430 2.0 array chips and the 
chips were incubated at 45 °C for 10 minutes in a GeneChip® Hybridization Oven-645 with rotation. 
The Pre-Hybridization Mix was extracted from the array chips and replaced by 200 µl of 
Hybridization Cocktail. The sample hybridization to the array chips was done at 45 °C with rotation 
at 60 rpm for 16 hours in a GeneChip® Hybridization Oven-645.  
Table 9. Hybridization Cocktail for a single probe array. 
Mouse Genome 430 2.0 arrays MoGene 2.0 ST arrays 
Components Amount Components Amount 
Fragmented and labelled aRNA 12.5 µg (33.3 µl)  Fragmented and labelled ss-DNA 3.5 µg (41 µl) 
Control Oligonucleotide B2 (3 nM) 4.2 µl Control Oligonucleotide B2 (3 nM) 2.5 µl 
20x Hybridization Controls 
(bioB, bioC, bioD, cre) 
12.5 µl 20x Hybridization Controls 
(bioB, bioC, bioD, cre) 
7.5 µl 
2x Hybridization Mix 125 µl 2x Hybridization Mix 75 µl 
DMSO 25 µl DMSO 10.5 µl 
Nuclease-free H2O 50 µl Nuclease-free H2O 13.5 µl 
Total volume 250 µl Total volume 150 µl 
 
After hybridization a project containing all necessary sample and experimental information was 
defined in a GeneChip® Command Console (AGCC) project. Each of the Mouse Genome 430 2.0 
array chips were washed and stained with 600 µl of Stain Cocktail I, 600 µl of Stain Cocktail II and 
800 µl of Array Holding Buffer from the HSW kit on a GeneChip® Fluidics Station-450. 
Subsequently, the array chips were scanned in an Affymetrix GeneChip® Scanner-3000-7G. 
Washing, staining and scanning was performed as described in the GeneChip® Expression Analysis 
Technical Manual (Thermo Fisher). Affymetrix GCOS software was used for the generation of .dat 
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and .cel files. Microarray data are available in the ArrayExpress database 
(www.ebi.ac.uk/arrayexpress) under the accession number E-MTAB-3608. 
2.2.8.2 MA analysis of E14.5 and E18.5 of  
+/+
, 
+/-
 and 
-/-
 RYR1 and Cav1.1 limb skeletal muscle 
An overview of the main steps and incubation times in the MA analysis of E14.5 and E18.5 WT (
+/+
), 
heterozygous (
+/-
) and homozygous (
-/-
) mutant RYR1 and Cav1.1 limb skeletal muscle is shown in 
Fig. 12. All thermal incubation steps were performed via a thermal cycler except if otherwise 
indicated. 
All procedures were performed with components of the GeneChip® WT PLUS Reagent Kit as 
described in (Filipova et al., 2018) and according to the kit user manual (Fig. 12).  
In brief, from each sample 250 ng total RNA were used for first-strand cDNA synthesis. 5 µl of First-
Strand Master Mix were added to each sample that has been previously mixed with Poly-A RNA 
controls as per the GeneChip® WT PLUS Reagent Kit User Manual instructions. The reactions were 
incubated at 25 °C for 1 h, then at 42 °C for 1 h and then at 4 °C for at least 2 minutes. Next, second-
strand cDNA synthesis and RNA degradation by RNase H were simultaneously performed by 
addition of 20 µl of Second-Strand Master Mix to each sample and an incubation at 16 °C for 1 h, 
then at 65 °C for 10 minutes and then at 4 °C for at least 2 minutes. Next, the ds-cDNAs were used as 
template for in vitro transcription (IVT) reactions via the T7 RNA polymerase, resulting in 
complimentary RNAs (cRNAs). For this purpose 30 µl of IVT Master Mix were added to each 
sample, followed by incubation at 40 °C for 16 h, then at 4 °C until further use. Next, the cRNAs 
were purified from enzymes, salts, unbound NTPs and inorganic phosphates by adding 100 µl of 
Purification Beads to each cRNA sample in a 96-well U-bottom plate. The cRNA-bound Purification 
Beads were captured on a magnetic stand and washed 3 times with 200 µl of 80% ethanol. The 
cRNAs were eluted in 27 µl of preheated (65 °C) nuclease-free H2O. The cRNAs concentrations 
were measured via a NanoDrop spectrophotometer. Next, 15 µg of each cRNA sample were used for 
a 2
nd
-cycle ss-cDNA synthesis by adding 4 µl of 2
nd
-Cycle Primers, containing the unnatural dUTP, 
to each cRNA sample and incubating the samples at 70 °C for 5 minutes, then at 25 °C for 5 minutes 
and then at 4 °C for 2 minutes. 
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Fig. 12: A schematic workflow of the E14.5 and E18.5 
+/+
, 
+/-
 and 
-/
- RYR1and Cav1.1 MAs. 
The scheme depicts the main experimental steps and incubation conditions in MAs preparation, starting with total RNA 
samples up to hybridization to MoGene 2.0 ST array chips. The GeneChip® WT PLUS Reagent Kit was used in all 
experiments up to the hybridization step. Master mixes containing all reagents except the RNA-derived sample were used 
in all steps to assure equal handling and conditions of all samples. Modified from the GeneChip® WT PLUS Reagent Kit 
User Manual (Thermo Fisher). 
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Then, 12 µl of 2
nd
-cycle ss-cDNA Master Mix were added to each sample on ice and the reactions 
were incubated at 25 °C for 10 minutes, then at 42 °C for 90 minutes, then at 70 °C for 10 minutes 
and then at 4 °C for at least 2 minutes. The cRNA templates were then hydrolyzed by an addition of 
4 µl of RNase H to each sample and incubation at 37 °C for 45 minutes, then at 95 °C for 5 minutes 
and then at 4 °C for 2 minutes. Next, 11 µl of nuclease-free H2O were added to each sample, bringing 
the total volume of the reactions to 55 µl. The 2
nd
-cycle ss-cDNAs were than purified via 100 µl of 
Purification Beads per sample, 1 x washing with 150 µl of 100% ethanol and 3 x washing with 200 
µl of 80% ethanol as described above. The purified ss-cDNAs were eluted in 30 µl of preheated 
(65 °C) nuclease-free H2O and their concentration was measured on a NanoDrop spectrophotometer. 
Next, 5.5 µg of each ss-cDNA sample were fragmented via a Fragmentation Master Mix containing 
uracil-DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE1) that introduce 
breaks at the dUTP residues. To each ss-cDNA sample 16.8 µl of the Fragmentation Master Mix 
were added and the reactions were incubated at 37 °C for 1 h, then at 93 °C for 2 minutes and at 4 °C 
for at least 2 minutes. 45 µl of the fragmented ss-cDNAs were terminally labeled with biotin via 15 
µl of Labeling Master Mix, containing terminal deoxynucleotidyl transferase (TdT). The reactions 
were incubated at 37 °C for 1 h, then at 70 °C for 10 minutes and at 4 °C for at least 2 minutes. 
Samples were placed on ice or stored at -20 °C. 
The following steps were performed via the GeneChip® Hybridization, Wash and Stain Kit (HWS), 
similar to the procedures described above (in 2.2.8.1). 3.5 µg of each fragmented and labeled 
ss-DNA were used in the preparation of the Hybridization Cocktail (Table 9, right) and treated as 
described above. 130 µl of each Hybridization Cocktail were pipetted into MoGene 2.0 ST array 
chips (1 sample per array chip). Hybridization, wash, stain and scanning procedures were performed 
as described above (in 2.2.8.1). Microarray data are available in the ArrayExpress database 
(www.ebi.ac.uk/arrayexpress) under the accession number E-MTAB-5755. 
2.2.9 Statistical analyses 
All statistical analyses are performed as described in (Filipova et al., 2016) and (Filipova et al., 
2018). In all analyses * indicates a P-value < 0.05; ** indicates a P-value < 0.01; *** indicates a 
P-value < 0.001. 
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2.2.9.1 Statistical analysis of qRT-PCR data 
The relative expression values presented as a FC (2
-ΔΔCt
) for each biological sample from all qRT-
PCRs were analyzed in GraphPad Prism version 4.00 (GraphPad Software, La Jolla California USA, 
www.graphpad.com). Unpaired t-test analyses were done when comparing the relative expression 
levels of one test group versus one control and one-way ANOVA followed by Bonferroni’s multiple 
comparisons test was performed when comparing multiple groups. Relative quantification values are 
presented as FCs plus/minus the standard error of the mean (S.E.M.) relative to the control group, 
which was normalized to an expression rate of 1.  
2.2.9.2 Statistical analysis of Cav1.1 full length and Δ29 PCR data 
The Cav1.1 full length and Δ29 band intensity values (as % of total intensity) were analyzed in 
GraphPad Prism version 4.00 (GraphPad Software, La Jolla California USA, www.graphpad.com). 
Unpaired t-test analyses were performed comparing the intensity of the Cav1.1 full length and Δ29 
band in each biological sample. 
2.2.9.3 Statistical analysis of the Mouse Genome 430 2.0 Microarrays 
Robust Multiarray Analysis (RMA) was used for background correction, summarization and 
normalization (Bolstad, Irizarry, Astrand, & Speed, 2003). The quantile normalization method was 
implemented to normalize the raw dataset executable with R-package (Irizarry, 2003), carried out at 
the probe feature level. The differentially expressed genes were described by a linear model 
implementing R and the LIMMA packages (Smyth, 2004). Differentially regulated genes were 
determined based on cut-off values of 5% error rate (P<0.05), calculated by Moderated t- statistics 
according to Benjamini and Hochberg (Multiple Testing Correction). Additionally, to identify 
significantly expressed genes between the control and dysp sample groups, the degree of change with 
the threshold value ≥ ± 1.5 was used. Principal component (PC) analysis was performed using the 
Stats package in R using the prcomp function. The "x" attribute of the prcomp object was used to 
generate 2 dimensional scatter plots. Bioinformatical analyses in R were performed with the kind 
assistance of Dr. John A. Gaspar from the group of Prof. Dr. Agapios Sachinidis from the Institute 
for Neurophysiology at the University Hospital of Cologne. 
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2.2.9.4 Statistical analysis of the MoGene 2.0 ST Microarrays 
The .cel files obtained by the microarray analyses were subjected to background correction, 
summarization and normalization by Robust Multiarray Analysis (RMA) and used for generation of 
.chp summarization files via the Expression Console™ Software 1.4 (Affymetrix / Thermo Fisher), 
and subsequently were used to produce a three dimensional PCA plot. The .chp files were used for 
gene level differential expression quantification, accompanied by One-Way Between-Subject 
ANOVA statistical analysis via the Transcriptome Analysis Console 3.0 (Affymetrix). Transcripts 
having a P-value ≤ 0.05 and a linear FC ≥ ± 2 for comparison of E18.5 vs. E14.5 sample groups, or a 
FC ≥ ± 1.5 for E14.5 vs. E14.5 and E18.5 vs. E18.5 sample groups, were considered as differentially 
expressed genes (DEGs). Volcano plots were generated using the Transcriptome Analysis Console 
3.0 (Affymetrix / Thermo Fisher). 
2.2.10 Enrichment Analyses 
Gene enrichment analyses for DEGs identified upon the comparisons of different groups were 
performed with the databases Gene Ontology for Biological Process (GO BP, versions 2015 and 
2017) and Cellular Component (GO CC, versions 2015 and 2017), Kyoto Encyclopedia of Genes and 
Genomes (KEGG, version 2015), Reactome (version 2015), Panther (version 2015) as well as with 
Wiki Pathways (WP, version 2016) using the Enrichr online enrichment tool (Chen et al., 2013). A P-
value ranking was applied to all enrichment analyses. 
The David GO (version 6.7) and MGI GO (version 2015) databases (Huang da, Sherman, & 
Lempicki, 2009; Smith et al., 2014), as well as manual data mining were additionally applied to 
identify DEGs directly connected to skeletal muscle. 
2.2.11 Heatmaps and hierarchical clustering 
Heatmaps and hierarchical clustering analyses were performed via the ClustVis online tool (Metsalu 
& Vilo, 2015) using unit variance row scaling. Hierarchical average linkage clustering measuring the 
average Euclidean distance was applied for both rows and columns.
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3 Results 
3.1 Part I: Analysis of fetal skeletal muscle lacking RYR1 at E18.5 
The first objective of this work was to analyze how the absence of RYR1 affects fetal limb skeletal 
muscle morphology in general, and to detect the accompanying changes in global gene expression of 
this organ, in particular. To address these questions, I compared the gross body shape, limb skeletal 
muscle histology, and transcriptomic profiles of homozygous RYR1
-/-
 and heterozygous RYR1
+/-
 
(control) littermates at E18.5, as reported in (Filipova et al., 2016). The heterozygous RYR1
+/-
 
animals were used as controls instead of WTs since they have been reported to show no phenotypic 
changes in respect to viability, fertility, muscle structure and performance (Buck et al., 1997). 
Moreover, by using the RYR1
+/-
 animals as controls the transcriptomic analysis results remain 
unaffected by possible genetic compensatory mechanisms, arising from the presence of a single 
functional copy of the Ryr1 gene, which would not play a role in the formation of the RYR1
-/-
 
phenotype. The main findings of this part of the results were reported in (Filipova et al., 2016). 
3.1.1 Absence of RYR1 leads to an impairment of gross body morphology and 
limb skeletal muscle histology  
In accordance to earlier studies (Buck et al., 1997; Takeshima et al., 1994), E18.5 RYR1
-/-
 fetuses 
already displayed severe abnormalities when compared to their control RYR1
+/-
 littermates (Fig. 13). 
An analysis of fetuses obtained from three different female mice at E18.5 revealed that the RYR1
-/-
 
mice exhibited an overall smaller body size, thinner limbs, enlarged necks and a typical spinal 
curvature. These changes indicated that the overall developmental program is severely affected in the 
RYR1
-/-
 fetuses.  
In order to gain a more detailed view on how skeletal muscle morphology is affected by the absence 
of RYR1, histological cross-sections of the distal hind limbs of control (RYR1
+/-
) and RYR
-/-
 
littermates at E18.5 were prepared and analyzed. 10 µm thick cryo cross-sections were stained with 
H&E and the limb skeletal muscle structure was examined under a bright-field microscope at three 
different magnifications – 50-fold, 200-fold and 400-fold (Fig. 14).  
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Fig. 13: Gross fetal morphology at E18.5. 
Photographic representations of heterozygous RYR1
+/-
 controls (left) and homozygous RYR1
-/-
 (right) littermates at day 
E18.5 from three different litters (I, II and III). Modified from (Filipova et al., 2016). 
The control limb skeletal muscle exhibited a normal, advanced degree of development with clearly 
visible fascicles, covered by a fascia (Fig. 14A left, and middle), consisting of terminally 
differentiated fetal fibers with peripherally located nuclei (Fig. 14A right). The RYR1
-/-
 limb skeletal 
muscle, on the other hand, was characterized by disorganization (Fig. 14B). In these muscles no 
fascia could be observed, fascicles were almost entirely missing, with only small groups of cells 
visible (Fig. 14B left, middle). The predominant cell type in the RYR1
-/-
 muscles were myotubes 
with only a few disorganized, immature fibers (Fig. 14A right).  
These evident changes in the limb skeletal muscles of E18.5 RYR1
-/-
 animals, compared to their 
control littermates, strongly hint at a developmental retardation in these animals. At E18.5 – at the 
end of prenatal development in the mouse – the formation of the limb skeletal muscle is almost 
complete (Tajbakhsh, 2009). Therefore, the impaired development of the RYR1
-/-
 limb skeletal 
muscle may be caused by an active pause of the myogenic program at an earlier stage or by reactive 
processes of degeneration and elimination of muscle fibers, or by a combination of both.  
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Fig. 14: E18.5 limb muscle histology. 
Histological cross sections of distal hind limbs of E18.5 control (A) and RYR1
-/-
 (B) littermates. (A) A well-developed 
internal muscular organization with structured fascicles, covered by a fascia (arrows) and consisting predominantly of 
terminally differentiated myofibers (*) were observed in the control animals. (B) In contrast, the RYR1
-/-
 skeletal muscle 
was not well structured, fascia and fascicles were missing and only individual immature fibers with centrally-located 
nuclei were present (arrows). (A & B) H&E staining; original magnification x 50 (left panels), × 200 (insets I, middle); 
× 400 (insets II, right). Micrographs were taken by PD Dr. Anna Brunn. Modified from (Filipova et al., 2016). 
3.1.2 Transcriptomic analysis of RYR1-/- skeletal muscle reveals multiple 
differentially regulated genes (DEGs) 
One of the main aims of this study was to elucidate in detail the whole spectrum of transcriptomic 
changes occurring in RYR1
-/-
 limb skeletal muscles at E18.5 that may be connected to the formation 
of the specific muscle phenotype described above. In order to address this question, the skeletal 
muscles of the fore- and hind limbs of 4 RYR1
-/-
 and 4 control RYR1
+/-
 littermates (n = 4 biological 
replicates per group) at E18.5 from 2 litters were dissected and pooled for each animal. The samples 
from all animals were handled separately and used for RNA extraction. The quality and 
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concentrations of the resulting RNAs were analyzed (Fig. 15) and subjected to microarray analyses 
(MAs, Fig. 16) (Filipova et al., 2016). 
 
Fig. 15: RNA quality assessment. 
Total RNA was extracted from the skeletal muscles of the fore- and hind limbs of 4 RYR1
-/-
 (RYR1
-/-
 samples 1 to 4) and 
4 control (Ctrl samples 1-4) E18.5 mouse fetuses and 5 µl of each RNA sample were tested via an electrophoretic run on 
a 2% agarose gel next to 5 µl of RiboRuler High Range RNA Ladder as size marker (marked as “M” with bp size of each 
band given on the left, Thermo Fisher Scientific). The RNA concentration of each sample is given in the table under the 
photograph. For each sample clear and distinct bands corresponding to the 18S and 28S rRNAs were observed indicating 
a high degree of RNA integrity. Modified from (Filipova et al., 2016). 
After background correction, summarization and normalization via a Robust Multi-array Analysis 
(RMA), the microarrays yielded information about the expression of 41,101 transcript clusters, 
spanning 21,569 unique annotated genetic loci. A subsequent t-test statistical analysis combined with 
a Benjamini-Hochberg false discovery rate (FDR) test revealed that the expression of 417 genomic 
loci was significantly differentially regulated in the RYR1
-/-
 limb skeletal muscle, meeting the criteria 
of fold change FC ≥ 1.5 or ≤ -1.5 and an FDR-adjusted P-value ≤ 0.05. Of these 417 genomic loci, 
394 mapped within annotated genes and after correcting for genes which were detected multiple 
times, 318 unique genes were identified as differentially expressed genes (DEGs). Interestingly, 
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exactly 50% of the DEGs (159 DEGs) were negatively regulated and 50% (159 DEGs) were 
positively regulated in RYR1
-/-
 skeletal muscle (Table 10). 
 
Fig. 16: Workflow scheme for the gene expression analysis of E18.5 RYR1
-/-
 vs. RYR
+/-
 limb skeletal muscle. 
Two heterozygous RYR1
+/-
 male and female mice were subjected to timed pairings. The pregnant females were sacrificed 
at day 18.5 post coitum (E18.5)and the skeletal muscles from the front- and hind limbs of 2 RYR1
-/-
 and 2 control 
(RYR1
+/-
) E18.5 fetuses were collected and used for RNA extractions. Equal amounts of total RNA from each sample 
were used for individual hybridizations to Affymetrix Mouse Genome 430 2.0 array chips and microarray analysis was 
performed as described in Materials and Methods. Additionally, equal amounts of the total RNAs were used in reverse 
transcription reactions and the resulting cDNAs were used in qRT-PCR analyses. Modified from (Filipova et al., 2016). 
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Table 10. E18.5 RYR1
-/-
 vs. RYR
+/-
 DEGs.  
 Total DEGs Annotated DEGs Unique annotated DEGs 
All 417 394 318 
Downregulated 205 202 159 
Upregulated 212 192 159 
Numbers of the total, annotated and total annotated DEGs (FC ≤ -1.5 or ≥ 1.5; FDR-adjusted P-value ≤ 0.05) identified in 
the RYR1
-/-
 vs. RYR1
+/-
 microarray analysis. 
3.1.3 Principal component analysis (PCA) shows segregation of RYR1-/- and 
control samples in discrete groups 
In order to assess the similarity and the variation between the individual samples based on their 
global transcriptomic profiles, a two-dimensional PCA plot was generated using the intensity levels 
of all transcripts detected in the MAs for all probes (i.e. the entire limb skeletal muscle transcriptome 
of each sample, Fig. 17A).  
The PCA is a mathematical algorithm that reduces the dimensionality of data sets which contain a 
high number of variables, but retains most of the variation in the data set (Ringner, 2008). Each of 
the biological RYR1
-/-
 and control replicates can be viewed as a data set, in which the different 
transcripts (genes) are the variables that differ in respect to their expression levels. Thus, the PCA 
algorithm combines the original variables for each data set (i.e. each biological sample), resulting in 
much fewer new variables – the principal components (PCs) – that still represent most of the 
variation of the original data sets. By definition, the principal component 1 (PC1) is the direction 
representing the highest percentage of the original variation between the samples. The principal 
component 2 (PC2) is defined as the direction uncorrelated to PC1 along which the samples show the 
second highest percentage of variation. 
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Fig. 17: E18.5 RYR1
-/-
 vs. RYR
+/-
 – PCA plots. 
Two-dimensional principal component analysis (PCA) of the RYR1
-/-
 (orange dots) and control (blue dots) samples 
(biological replicates 1 to 4) subjected to MAs. The expression of the entire transcriptome (A) and of the detected DEGs 
(B) was plotted. Samples from animals of the same litter (Litters 1 and 2) occupy the same shaded area. PCAs were 
performed with the help of Dr. John A. Gaspar. Modified from (Filipova et al., 2016). 
The PCA plot generated from the data of the entire skeletal muscle transcriptome for all samples 
(Fig. 17A) showed a significant separation along PC1 (35%) between the samples obtained from 
animals of the two different litters. This suggests that the variation of the transcriptomic signature of 
the limb skeletal muscle samples is highly impacted by the specific sets of individual characteristics 
of the parents (genotype, SNPs, mutation pool, etc.) and probably by the small differences in the time 
of gestation time (± 0.5 day) of the individual litters. However, a clear separation between RYR1
-/-
 
and control samples was observed along PC2 (20%), indicating that the RYR1
-/-
 skeletal muscles 
exhibits evident global transcriptomic changes when compared to the skeletal muscle of the control 
animals. 
Next, a PCA was performed with the values of the DEGs (FC ≥ 1.5 or ≤ -1.5 and P-value ≤ 0.05) 
found in the RYR1
-/-
 samples (Fig. 17B). This time the most significant proportion of the variation 
(PC1 = 87.2%) between the sample was evidently due to the samples’ genotype as the RYR1-/- and 
the control biological replicates formed two distinct sample groups along PC1. Still, a smaller but 
present variation (4.9%) between the samples coming from different litters was observed along PC2. 
These results indicate that the absence of RYR1 changes the global transcriptomic profile of the 
developing limb skeletal muscle and more specific, that it highly impacts the expression of the 318 
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DEGs identified in the MAs. Between-litter variability also influences the global transcriptomic 
profile of murine E18.5 limb skeletal muscles. 
3.1.4 Validation of the MAs via qRT-PCR 
In order to validate the results obtained by the MAs, the relative expression levels of 4 
downregulated (Trib1, c-Jun, c-Fos and Myl2) and 3 upregulated (Flcn, Bai3 and Col19a1) genes 
were analyzed via qRT-PCRs. These genes were randomly chosen to cover the whole spectrum of 
detected DEGs in respect to the direction (down- and upregulated) and FC magnitude (high or low 
FC). For both, the MA and qRT-PCR analyses, the FC of the control samples was set to 1. Gapdh 
was used as an endogenous control in the qRT-PCRs. The qRT-PCR results demonstrated that all 
tested genes exhibit the same direction of regulation (down- or upregulation) and similar FCs as 
detected in the MAs (Fig. 16) and thus, validated the results obtained by the MAs. 
 
Fig. 18: Validation of the results obtained in the MA analysis via qRT-PCRs. 
The expression level of (A) four downregulated DEGs: Trib1 (FC -1.50), c-Jun (FC -2.07), c-Fos (FC -2.43), Myl2 
(FC -10.85); as well as (B) three upregulated DEGs: Flcn (FC 1.50), Bai3 (FC 2.02), Col19a1 (FC 5.13) were tested via 
qRT-PCRs. Gapdh was used as an endogenous control. The mean relative expression levels of the four control (RYR1
+/-
) 
samples were set as FC = 1. The FC of each of the 4 biological replicates per group (RYR1
-/-
 and control) were 
normalized to the mean FC of the control group. Error bars are S.E.M. Modified from (Filipova et al., 2016). 
3.1.5 The DEGs with the highest FCs are related to muscle and ECM structure 
Next, the ten DEGs with the highest positive and negative FCs in the RYR1
-/-
 skeletal muscle were 
analyzed (Table 11). The strongest downregulation was observed for the genes encoding the cardiac 
slow myosin light chain 2 (Myl2, FC = -10.85) and smoothelin-like 1 (Smtnl1, FC = -9.68). Among 
the top 10 downregulated DEGs were also other genes encoding proteins associated with the 
structure and function of muscle and the the musculoskeletal system like– Tppp3 (FC = -4.56), 
encoding a marker for tendon sheath and synovial joints differentiation (Staverosky, Pryce, Watson, 
& Schweitzer, 2009); Irf6 (FC = -3.58), encoding a transcription factor (TF) involved in limb, 
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craniofacial and tongue development (Goudy et al., 2013; Ingraham et al., 2006); and Cnn1 (FC 
= -3.25), encoding a marker for smooth muscle differentiation in late embryonic development 
(Duband, Gimona, Scatena, Sartore, & Small, 1993). The DEG showing the highest upregulation in 
the RYR1
-/-
 samples was a collagen-coding gene (Col25a1, FC = 6.51). and the expression of another 
collagen-coding gene found in the top 10 most upregulated genes (Col19a1, FC = 5.11 and 5.13) has 
been demonstrated to diminish towards the final stages of differentiation of fetal limb skeletal muscle 
(Sumiyoshi, Laub, Yoshioka, & Ramirez, 2001). Other highly upregulated genes included the gene 
encoding myoglobin (Mb, FC = 4.75), controlled by hypoxia and Ca
2+
 signaling in skeletal muscle 
(Kanatous et al., 2009). Additionally, the gene encoding the RUNX1 TF (Runx1, FC = 3.94 and 4.08) 
known for its protective functions against muscle wasting, myofibrillar disorganization and 
autophagy in skeletal muscle (Wang et al., 2005) was highly upregulated as well. 
Table 11. E18.5 RYR1
-/-
 vs. RYR
+/-
 – Top 10 DEGs. 
Probe Set ID Gene Title Gene Symbol FC 
Downregulated genes 
1448394_at myosin, light polypeptide 2, regulatory, cardiac, slow Myl2 -10.85 
1419145_at smoothelin-like 1 Smtnl1 -9.68 
1416713_at tubulin polymerization-promoting protein family member 3 Tppp3 -4.56 
1452766_at tubulin polymerization promoting protein Tppp -3.91 
1418395_at solute carrier family 47, member 1 Slc47a1 -3.66 
1418301_at interferon regulatory factor 6 Irf6 -3.58 
1418714_at dual specificity phosphatase 8 Dusp8 -3.37 
1418511_at Dermatopontin Dpt -3.34 
1455203_at RIKEN cDNA A930003A15 gene A930003A15Rik -3.30 
1417917_at calponin 1 
 
Cnn1 -3.25 
Upregulated genes 
1438540_at collagen, type XXV, alpha 1 Col25a1 6.51 
1440085_at ectodysplasin A2 receptor Eda2r 5.73 
1438059_at cortexin 3 Ctxn3 5.23 
1421698_a_at collagen, type XIX, alpha 1 Col19a1 5.13 
1456953_at collagen, type XIX, alpha 1 Col19a1 5.11 
1451203_at myoglobin Mb 4.75 
1447807_s_at pleckstrin homology domain containing, family H (with 
MyTH4 domain) member 1 
Plekhh1 4.52 
1422864_at runt-related transcription factor 1 Runx1 4.08 
1422865_at runt-related transcription factor 1 Runx1 3.94 
1418203_at phorbol-12-myristate-13-acetate-induced protein 1 Pmaip1 3.69 
The ten DEGs exhibiting the highest down- and upregulation in RYR1
-/-
 fetal limb skeletal muscle. Modified from 
(Filipova et al., 2016). 
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3.1.6 Processes and pathways enriched with RYR1-/- specific DEGs 
In order to gain a better understanding of the biological processes which were affected in the RYR1
-/-
 
skeletal muscle, the detected DEGs were subjected to a Gene Ontology enrichment analysis for 
Biological Process (GO BP, Fig. 19A). Interestingly, the most significantly enriched GO BP category 
was “Skeletal muscle cell differentiation”. Other processes related to differentiation and development 
like “Oligodendrocyte differentiation”, “Regulation of cell growth”, “Glial cell differentiation” and 
“Regulation of endothelial cell proliferation” were also detected as being significantly enriched with 
DEGs. Two categories – “Response to oxygen levels” and “Response to decreased oxygen levels” 
suggested significant changes in the expression of genes related to oxygen metabolism in the RYR1
-/-
 
samples. Indications for changes in the expression of genes involved in the structure and composition 
of the ECM were represented by the presence of the GO BP categories “Extracellular matrix 
organization” and “Extracellular structure organization”. Those were among the 10 most significantly 
affected biological processes in RYR1
-/-
 samples. 
Next, to assess which processes and signaling pathways were most significantly affected in the 
RYR1
-/-
 skeletal muscle, the DEGs found in the RYR1
-/-
 samples were used in enrichment analyses 
utilizing the KEGG (Fig. 19B), Reactome (Fig. 19C), and Panther (Fig. 19D) databases. These data 
bases resemble and are partly connected to the GO database, however their focus differs in respect to 
type of interactions, functional categories and analyzed organisms (Chowdhury & Sarkar, 2015). 
The KEGG enrichment analysis indicated the „MAPK signaling pathway” as the most significantly 
represented with DEGs (Fig. 19B). The MAPK pathway was also among the 10 most significantly 
enriched categories in Reactome (“MAPK targets / Nuclear events mediated by MAP kinases”) and 
Panther (“p38 MAPK pathway” and “Insulin / IGF pathway / MAP kinase cascade”). Other 
processes and pathways found multiple times as very significantly enriched in the different databases 
include processes related to muscle contraction ( Reactome: “Muscle contraction” and “Striated 
muscle contraction”), oxidative stress (Panther: “Oxidative stress response” and GO BP categories 
“Response to oxygen levels” and “Response to decreased oxygen levels”) and the ECM (KEGG: 
“Focal adhesion” and “ECM receptor interaction”; Reactome: “Extracellular matrix organization” 
and “Collagen formation”). 
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Fig. 19: Enrichment analysis of the DEGs detected in the RYR1
-/-
 vs. RYR1
+/-
 MAs. 
The DEGs were subjected to an enrichment analysis using the GO BP (A), KEGG (B), Reactome (C) and Panther (D) 
databases using the Enrichr online gene list analysis tool (Chen et al., 2013; Kuleshov et al., 2016). P-value ranking was 
used in the analyses, represented by the bar length (A – D). The values on the x-axis correspond to the measured 
P-values. Modified from (Filipova et al., 2016). 
3.1.7 Signaling pathways enriched with DEGs in RYR1-/- skeletal muscle 
The enrichment analyses of the DEGs found in RYR1
-/-
 skeletal muscle at E18.5 (Fig. 19A-D) 
identified several affected major signaling pathways and networks that. In order to gain a deeper 
insight into the degree and the direction in which these signaling pathways were regulated, the DEGs 
encoding proteins and peptides involved in the MAPK, Wnt, PI3K/Akt/mTOR, G protein-coupled 
receptors (GPCRs) pathways and other TFs were closely examined (Table 12).  
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Table 12. E18.5 RYR1
-/-
 vs. RYR
+/-
 – DEGs involved in signaling pathways. 
Probe Set ID Gene Title Gene Symbol FC 
MAPK signaling pathway 
1418714_at  dual specificity phosphatase 8 Dusp8 -3.37 
1438933_x_at RAS, guanyl releasing protein 2 Rasgrp2 -2.94 
1419625_at heat shock protein 1-like Hspa1l -2.81 
1423100_at FBJ osteosarcoma oncogene Fos -2.43 
1448694_at Jun oncogene Jun -2.07 
1417164_at dual specificity phosphatase 10 Dusp10 -2.06 
1438883_at fibroblast growth factor 5 Fgf5 -2.05 
1427582_at fibroblast growth factor 6 Fgf6 -2.03 
1448830_at dual specificity phosphatase 1 Dusp1 -1.95 
1418401_a_at dual specificity phosphatase 16 Dusp16 -1.76 
1449117_at Jun proto-oncogene related gene D Jund -1.75 
1439205_at nuclear factor of activated T cells, cytoplasmic, calcineurin 
dependent 2 
Nfatc2 -1.64 
1438030_at RAS, guanyl releasing protein 3 Rasgrp3 -1.63 
1449773_s_at growth arrest and DNA-damage-inducible 45 beta Gadd45b -1.62 
1435196_at neurotrophic tyrosine kinase, receptor, type 2 Ntrk2 1.52 
1421897_at ELK1, member of ETS oncogene family Elk1 1.56 
1417856_at avian reticuloendotheliosis viral (v-rel) oncogene related B Relb 1.58 
1421324_a_at thymoma viral proto-oncogene 2 Akt2 1.65 
1420895_at transforming growth factor, beta receptor I Tgfbr1 1.72 
1440343_at ribosomal protein S6 kinase, polypeptide 5 Rps6ka5 1.75 
1436912_at calcium channel, voltage-dependent, beta 4 subunit Cacnb4 1.83 
Wnt signaling pathway 
1449425_at wingless-related MMTV integration site 2 Wnt2 -2.54 
1423760_at CD44 antigen Cd44 -2.29 
1451031_at secreted frizzled-related protein 4 Sfrp4 -2.20 
1418136_at transforming growth factor beta-1-induced transcript 1 Tgfb1i1 -1.82 
1427138_at coiled-coil domain containing 88C Ccdc88c -1.80 
1417985_at Notch-regulated ankyrin repeat protein Nrarp -1.72 
1455689_at frizzled homolog 10 (Drosophila) Fzd10 -1.56 
1429506_at naked cuticle 1 homolog (Drosophila) Nkd1 1.53 
1451689_a_at SRY-box containing gene 10 Sox10 1.59 
1460187_at secreted frizzled-related protein 1 Sfrp1 2.36 
PI3K/Akt/mTOR signaling pathway 
1451038_at apelin Apln -1.96 
1449022_at nestin Nes -1.62 
1421679_a_at cyclin-dependent kinase inhibitor 1A (P21) Cdkn1a 1.52 
1421324_a_at thymoma viral proto-oncogene 2 Akt2 1.65 
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Probe Set ID Gene Title Gene Symbol FC 
1425515_at phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 
(p85 alpha) 
Pik3r1 1.73 
G protein-coupled signaling 
1444409_at rabphilin 3A-like (without C2 domains) Rph3al -2.37 
1417625_s_at chemokine (C-X-C motif) receptor 7 Cxcr7 -2.18 
1455466_at G protein-coupled receptor 133 Gpr133 -2.10 
1451038_at apelin Apln -1.96 
1440009_at olfactory receptor 78 Olfr78 -1.81 
1431326_a_at tropomodulin 2 Tmod2 -1.68 
1455689_at frizzled homolog 10 (Drosophila) Fzd10 -1.56 
1418394_a_at CD97 antigen Cd97 -1.56 
1420940_x_at regulator of G-protein signaling 5 Rgs5 -1.54 
1417327_at caveolin 2 Cav2 -1.53 
1416286_at regulator of G-protein signaling 4 Rgs4 -1.50 
1460440_at latrophilin 3 Lphn3 1.62 
1451411_at G protein-coupled receptor, family C, group 5, member B Gprc5b 1.63 
1456833_at G protein-coupled receptor 17 Gpr17 1.68 
1442082_at complement component 3a receptor 1 C3ar1 1.81 
1436912_at calcium channel, voltage-dependent, beta 4 subunit Cacnb4 1.83 
1420401_a_at receptor (calcitonin) activity modifying protein 3 Ramp3 1.86 
1454782_at brain-specific angiogenesis inhibitor 3 Bai3 2.02 
1434172_at cannabinoid receptor 1 (brain) Cnr1 2.11 
1432466_a_at apolipoprotein E Apoe 2.17 
1460123_at G protein-coupled receptor 1 Gpr1 2.37 
1450875_at G protein-coupled receptor 37 Gpr37 2.54 
1436889_at gamma-aminobutyric acid (GABA) A receptor, subunit alpha 1 Gabra1 2.54 
Other transcription factors and transcriptional modulators 
1455267_at estrogen-related receptor gamma Esrrg -3.04 
1449363_at activating transcription factor 3 Atf3 -2.58 
1418572_x_at tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a -2.39 
1418762_at CD55 antigen Cd55 -2.14 
1425518_at Rap guanine nucleotide exchange factor (GEF) 4 Rapgef4 -1.73 
1422742_at human immunodeficiency virus type I enhancer binding protein 
1 
Hivep1 -1.72 
1420696_at sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C 
Sema3c -1.68 
1456796_at snail homolog 3 (Drosophila) Snai3 -1.66 
1418936_at v-maf musculoaponeurotic fibrosarcoma oncogene family, 
protein F (avian) 
Maff -1.61 
1451932_a_at ADAMTS-like 4 Adamtsl4 -1.58 
1425896_a_at fibrillin 1 Fbn1 -1.57 
1418394_a_at CD97 antigen Cd97 -1.56 
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Probe Set ID Gene Title Gene Symbol FC 
1459372_at neuronal PAS domain protein 4 Npas4 -1.51 
1424880_at tribbles homolog 1 (Drosophila) Trib1 -1.50 
1428983_at scleraxis Scx 1.53 
1429841_at multiple EGF-like-domains 10 Megf10 1.53 
1422210_at forkhead box D3 Foxd3 1.57 
1441107_at doublesex and mab-3 related transcription factor like family A2 Dmrta2 1.58 
1435775_at circadian locomotor output cycles kaput Clock 1.60 
1457342_at IKAROS family zinc finger 4 Ikzf4 1.60 
1452650_at tripartite motif-containing 62 Trim62 1.61 
1449164_at CD68 antigen Cd68 1.61 
1452021_a_at hairy and enhancer of split 6 Hes6 1.66 
1434458_at follistatin Fst 1.93 
1450042_at aristaless related homeobox Arx 2.18 
1454693_at histone deacetylase 4 Hdac4 2.36 
1418937_at deiodinase, iodothyronine, type II Dio2 2.87 
1422864_at runt related transcription factor 1 Runx1 4.08 
1440085_at ectodysplasin A2 receptor Eda2r 5.73 
DEGs in RYR1
-/-
 skeletal muscle involved in the MAPK, Wnt, PI3K/mTor, GPCR and other signaling pathways. 
Downregulated DEGs are highlighted in blue and upregulated DEGs – in orange. Modified from (Filipova et al., 2016). 
The MAPK pathway, identified as one of the most significantly affected pathways in all four 
enrichment analyses (GO, KEGG, Reactome and Panther, Fig. 19), was represented by 21 DEGs, 14 
of which were negatively and 7 were positively regulated (Fig. 20). The observed DEGs encode 
proteins from the MAPK/ERK and the p38/JNK pathways. Interestingly, the majority of the 
downregulated DEGs encode proteins that are involved in the late and final steps of the pathway, like 
the calcineurin-dependent nuclear factor of activated T cells 2 (Nfatc2), the Jun oncogene (c-Jun), the 
FBJ osteosarcoma oncogene (c-Fos), and the Jun proto-oncogene-related gene D (Jund). The 
products of these genes are global TFs involved in the regulation and modulation of multiple 
physiological cellular processes like differentiation, proliferation, programmed cell death and 
inflammation. The products of c-Fos, c-Jun and JunD can exert their regulatory functions alone or 
after dimerization with one another participating in the composition of the activating protein 1 
(AP-1). AP-1 is a pleiotropic TF that is involved, among other things, in muscle cell differentiation 
and during pathological alternations – in muscle wasting (Andreucci et al., 2002; Moore-Carrasco et 
al., 2006). On the other hand, three upregulated DEGs from the MAPK pathway encoded cell surface 
receptor proteins – the beta 4 subunit of voltage-dependent calcium channels (Cacnb4), the 
neurotrophic tyrosine kinase receptor type 2 (Ntrk2), and the transforming growth factor beta 
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receptor I (Tgfbr1). A downregulation was observed for four dual specificity phosphatase transcripts 
(Dusp1, Dusp8, Dusp10 and Dusp16), and one heat shock protein (Hspa1l) gene, all of which 
inactivate ERK, JNK or p38.  
 
Fig. 20: DEGs in the MAPK pathway. 
A simplified schematic representation of the MAPK pathway in KEGG pathways. The proteins encoded by 
downregulated DEGs are shown as blue boxes, the ones encoded by upregulated DEGs – as orange boxes, and those 
proteins for which no change in expression was detected – by grey boxes. If multiple genes encoding proteins from the 
same category or protein subunits were detected as differentially expressed, these genes are shown in brackets in the 
respective boxes. Solid lines stand for direct and broken lines – for indirect interactions. Arrowhead ends indicate 
activation and blunt ends represent inhibition. 
Furthermore, among the DEGs related to signaling processes, several altered genes encoded key 
proteins connecting the MAPK cascade to other signaling pathways. For example, the upregulated 
thymoma viral proto-oncogene 2 (Akt2) encodes a central member of the PI3K/Akt/mTOR pathway, 
a pathway regulating skeletal muscle hypertrophy (Bodine et al., 2001). Other DEGs from this 
pathway included the Akt’s activator p85 alpha regulatory subunit of the phosphatidylinositol 
3-kinase (Pik3r1) and a Akt’s target, the gene encoding the cyclin-dependent kinase inhibitor 1A 
(P21) (Cdkn1a). All three (Akt2, Pik3r1 and Cdkn1a) were upregulated in RYR1
-/- 
samples. Annother 
major signaling pathway in muscle development, the Wnt pathway, was represented by 10 DEGs, 7 
of wich were downregulated, including the wingless-related MMTV integration site 2 (Wnt2), 
secreted frizzled-related protein 4 (Sfrp4) and the induced transcript 1 of transforming growth factor 
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beta 1 (Tgfb1i1). Three DEGs from the Wnt pathways were upregulated, on e of which – the secreted 
frizzled-related protein 1 (Sfrp1), inhibits myoblast fusion (Descamps et al., 2008). 
Other DEGs encode GPCRs or modulators of GPCR-mediated signaling, as well as various TFs, 
revealing a complex and entangled network of expression changes influencing the majority of the 
cellular signaling pathways in the RYR1
-/-
 skeletal muscle. 
3.1.8 DEGs in processes related to muscle function and structure 
The enrichment analyses of the DEGs found in the RYR1
-/-
 samples revealed multiple processes and 
pathways related to muscle structure, functions and development (Fig. 19A-D). Changes in these 
processes are of special interest in the frame of this project, since they can directly infer which 
physiological parameters of the skeletal muscle organ are most likely affected by the absence of 
RYR1, the RYR1-mediated Ca
2+
 release and the resulting excitation-contraction uncoupling. 
Therefore, the entire set of DEGs identified in the MAs was subjected to additional enrichment 
analyses using the David GO and MGI GO databases (Huang da et al., 2009; Smith et al., 2014), as 
well as to manual data mining in order to assess which and how many DEGs were directly connected 
to skeletal muscle. The results were sorted in two main groups – muscle contraction and mechanical 
force generation, and muscle structure and morphogenesis (Table 13), although many DEGs 
contribute to both categories. Multiple genes involved in muscle contraction, additionally take part in 
the structure of the sarcomeres. The majority of them were systematically downregulated, especially 
genes coding myosin light chain isoforms (Myl2, Myl3, Myl9) and coding Z-disc and costamere 
proteins (Ankrd1, Krt8, Nrap, Csrp3, Pdlim1, Fhl1, Crip1). Only one DEG involved in the sarcomere 
structure was mildly upregulated – Tnnt2 (FC = 1.59), coding for a troponin T isoform. The 
expression of the Dbndd1 gene, encoding a protein participating in the costamere structure, was also 
slightly higher in the RYR1
-/-
 samples (FC = 1.75). Some of the detected DEGs encode protein 
isoforms that are described as typically expressed not in skeletal, but rather in cardiac muscle. 
However, during embryonic and fetal development many such genes, like for example the genes 
encoding the myosin light chain and actin isoforms, are expressed in skeletal, cardiac and smooth 
muscle and their specific expression pattern is laid later during the postnatal development (Takano-
Ohmuro, Obinata, Kawashima, Masaki, & Tanaka, 1985; Woodcockmitchell et al., 1988). 
The transcription levels of multiple genes related to focal adhesion, ECM structure and organization, 
collagen matrix formation and ECM-receptor interactions were also changed in the RYR1
-/-
 samples. 
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Since these processes are also intimately connected to the function and morphogenesis of the skeletal 
muscle organ, the detected DEGs were analyzed and listed under “Muscle morphogenesis” (Table 
13). A total of 22 such DEGs were identified, 14 of which were downregulated and 8 – upregulated. 
A strong upregulation was observed for two collagen genes – Col19a1 and Col25a1 – both 
associated with the development of the skeletal muscle organ. 
Table 13. DEGs in RYR1
-/-
 skeletal muscle involved in muscle contraction, structure and morphogenesis. 
Probe Set ID Gene Title Gene 
Symbol 
Fold 
Change 
Localization / Function / 
Reference 
Muscle contraction and mechanical force 
1448394_at myosin, light polypeptide 2, 
regulatory, cardiac, slow 
Myl2 -10.85 Sarcomere; part of myosin 
filaments (Sheikh, Lyon, & Chen, 
2015) (Schiaffino, Rossi, Smerdu, 
Leinwand, & Reggiani, 2015) 
1419145_at smoothelin-like 1 Smtnl1 -9.68 Sarcomere; binds calmodulin and 
tropomyosin (Ulke-Lemee, 
Ishida, Chappellaz, Vogel, & 
MacDonald, 2014) 
1417917_at calponin 1 Cnn1 -3.25 Sarcomere; binds tropomyosin 
and inhibits cross-bridge cycle in 
a Ca
2+
-dependent manner 
(Winder, Walsh, Vasulka, & 
Johnson, 1993) 
1449996_a_at tropomyosin 3, gamma Tpm3 -3.24 Sarcomere; actin filament 
associated; increases contractility 
and decreases Ca
2+
-sensitivity 
(Pieples et al., 2002) 
1420991_at ankyrin repeat domain 1 (cardiac 
muscle) 
Ankrd1 -2.99 Sarcomere; Z-disc, 
Part of titin-N2A mechanosensory 
complex (Miller et al., 2003) 
1427768_s_at myosin, light polypeptide 3 Myl3 -2.93 Sarcomere; part of myosin 
filaments (Schiaffino et al., 2015) 
1439204_at sodium channel, voltage-gated, 
type III, alpha 
Scn3a -2.93 Sarcolemma; Na
+
 channel; binds 
to CaM, and is regulated by CaM 
and Ca
2+
 (Lee-Kwon, Goo, 
Zhang, Silldorff, & Pallone, 
2007); regulates ECC (Aronsen, 
Swift, & Sejersted, 2013) 
1452670_at myosin, light polypeptide 9, 
regulatory 
Myl9 -2.65 Involved in actomyosin 
contractility and 
stress fiber assembly (Licht et al., 
2010) 
1420647_a_at keratin 8 Krt8 -2.58 Sacomere; Z-disc and M-line 
domains, at costameres, at the 
sarcolemmal membrane (Ursitti et 
al., 2004) 
1421253_at nebulin-related anchoring protein Nrap -2.41 Sarcomere; Z-disc; terminal actin 
binding (Luo, Herrera, & 
Horowits, 1999) 
1460318_at cysteine and glycine-rich protein 3 Csrp3 -2.37 Sarcomere; Z-disc (Knoll, 
Buyandelger, & Lab, 2011) 
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Probe Set ID Gene Title Gene 
Symbol 
Fold 
Change 
Localization / Function / 
Reference 
1416554_at PDZ and LIM domain 1 (elfin) Pdlim1 -2.31 Sarcomere; Z-disc; Interaction 
with α-actinin (Knoll et al., 2011) 
1435767_at sodium channel, voltage-gated, 
type III, beta 
Scn3b -2.23 Sarcolemma; Na
+
 channel; 
regulates ECC (Aronsen et al., 
2013) 
1417872_at four and a half LIM domains 1 Fhl1 -1.94 Sarcomere; Z-disc (Knoll et al., 
2011) 
1416326_at cysteine-rich protein 1 (intestinal) Crip1 -1.76 Sarcomere; Z-disc; Interaction 
with α-actinin (Knoll et al., 2011) 
1422635_at acetylcholinesterase Ache -1.71 Neuromuscular junctions; 
Regulation of ECC (Quinn, 1987) 
1450650_at myosin X Myo10 1.57 Link between integrins and 
cytoskeleton (Marotta et al., 
2009) 
1424967_x_at troponin T2, cardiac Tnnt2 1.59 Sarcomere; interaction with 
tropomyosin of actin filaments 
1449307_at dysbindin (dystrobrevin binding 
protein 1) domain containing 1 
Dbndd1 1.75 Costamere; part of dystrophin-
glycoprotein complex (DGC) 
(Hijikata et al., 2008) 
1436912_at calcium channel, voltage-
dependent, beta 4 subunit 
Cacnb4 1.83 Sarcolemma; couples electrical 
activity to gene expression 
(Tadmouri et al., 2012) 
1418852_at cholinergic receptor, nicotinic, 
alpha polypeptide 1 (muscle) 
Chrna1 2.28 Neuromuscular junctions; muscle 
excitation (Beeson, Jeremiah, 
West, Povey, & Newsom-Davis, 
1990) 
Muscle structure and morphogenesis 
1418511_at dermatopontin Dpt -3.34 Cell-matrix adhesion (Okamoto & 
Fujiwara, 2006) 
1449082_at microfibrillar associated protein 5 Mfap5 -3.13 ECM; glycoprotein associated 
with microfibrils like elastin 
(Llano-Diez, Gustafson, Olsson, 
Goransson, & Larsson, 2011) 
1450798_at tenascin XB Tnxb -2.85 ECM; collagen formation 
(Voermans, Gerrits, van Engelen, 
& de Haan, 2014) 
1456344_at tenascin C Tnc -2.63 ECM; glycoprotein; interaction 
with fibronectin (Mackey et al., 
2011) 
1416697_at dipeptidylpeptidase 4 Dpp4 -2.25 Cell surface peptidase; cell-cell 
connections (Lambeir, Durinx, 
Scharpe, & De Meester, 2003) 
1424701_at protocadherin 20 Pcdh20 -2.35 Transmembrane protein; cell-cell 
connections (Suzuki, 2000) 
1423760_at CD44 antigen Cd44 -2.29 Cell surface glycoprotein; 
migration and myoblast fusion 
(Mylona, Jones, Mills, & Pavlath, 
2006) 
1449388_at thrombospondin 4 Thbs4 -2.14 ECM glycoprotein; Ca
2+
 binding 
(Greco et al., 2010) 
1426529_a_at transgelin 2 Tagln2 -1.93 Cytoskeleton; Actin-gelling 
protein (Shapland, Hsuan, Totty, 
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Probe Set ID Gene Title Gene 
Symbol 
Fold 
Change 
Localization / Function / 
Reference 
& Lawson, 1993) 
1437218_at fibronectin 1 Fn1 -1.74 ECM glycoprotein; cell adhesion; 
regulation of fiber organization 
(Snow, Peterson, Khalil, & 
Henry, 2008) 
1434928_at growth arrest-specific 2 like 1 Gas2l1 -1.72 Cytoskeleton; Crosslinking of 
microfilaments and microtubules 
(Goriounov, Leung, & Liem, 
2003) 
1449022_at nestin Nes -1.62 Cytoskeleton; intermediate 
filament, co-localized with 
desmin in Z-disc of embryonic 
skeletal muscle (Sejersen & 
Lendahl, 1993) 
1451932_a_at ADAMTS-like 4 Adamtsl4 -1.58 ECM; glycoprotein; microfibril 
biogenesis (Gabriel et al., 2012) 
1425896_a_at fibrillin 1 Fbn1 -1.57 ECM glycoprotein; microfibril 
biogenesis (Gabriel et al., 2012) 
1436425_at KN motif and ankyrin repeat 
domains 4 
Kank4 1.56 Control of actin polymerization 
(Zhu, Kakinuma, Wang, & 
Kiyama, 2008) 
1434709_at neuron-glia-CAM-related cell 
adhesion molecule 
Nrcam 1.64 Transmembrane cell adhesion 
protein; axon guidance 
(Kostrominova, Dow, Dennis, 
Miller, & Faulkner, 2005) 
1418204_s_at allograft inflammatory factor 1 Aif1 1.68 Actin-polymerizing protein 
(Autieri, Kelemen, & Wendt, 
2003) 
1419050_at transmembrane protein 8C Tmem8c 1.74 Transmembrane cell surface 
protein; myoblast fusion (Millay 
et al., 2013) 
1429861_at protocadherin 9 Pcdh9 1.90 Transmembrane protein; Ca
2+
 -
dependent cell-cell 
communication (Wang et al., 
2012) 
1418139_at doublecortin Dcx 2.03 Marker for Pax7+MyoD− 
subpopulation contributing to 
myofiber maturation during 
muscle regeneration (Ogawa et 
al., 2015) 
1456953_at collagen, type XIX, alpha 1 Col19a1 5.11 ECM; expressed during muscle 
development (Sumiyoshi et al., 
2001) 
1438540_at collagen, type XXV, alpha 1 Col25a1 6.51 ECM; branching of axon bundles 
within the muscle (Tanaka et al., 
2014) 
Downregulated DEGs are highlighted in blue and upregulated DEGs – in orange. Modified from (Filipova et al., 2016). 
3.1.9 Elevated mRNA levels of several MRFs 
The complex multistep skeletal myogenic program is regulated by a variety of extrinsic and intrinsic 
signals (Bentzinger et al., 2012). Eight TFs transmit some of the most potent intrinsic signals in the 
Results 
75 
 
progression of the skeletal myogenesis and thus constitute canonical myogenic regulatory factors 
(MRFs). These MRFs are encoded by the genes Six1, Six4, Pax3, Pax7, Myf5 MyoD, MyoG and 
Mrf4, each expressed in a particular cell population from the myogenic lineage. Their spatiotemporal 
expression patterns safeguards and reflects the proper developmental transitions during myogenesis 
(Bentzinger et al., 2012; Goulding, Chalepakis, Deutsch, Erselius, & Gruss, 1991; Grifone et al., 
2005; Jostes, Walther, & Gruss, 1990; Pownall, Gustafsson, & Emerson, 2002; Sassoon et al., 1989) 
(Fig. 21A). The MAs detected no significant changes in the expression for any of these genes (FC ≥ 
± 1.5, FDR-adjusted P-value ≤ 0.05), although there were indications for a putative tendencies for 
some of them: Six4 (FC = 1.38, P = 0.0027), Pax7 (FC = 1.27, P = 0.0074), Myf5 (FC = 1.25, 
P = 0.04), MyoD (FC = 1.53, P = 0.0018) and MyoG (FC = 1.46, P = 0.0001). Because of the eminent 
importance of these MRFs for muscle development, their mRNA levels in the RYR1
-/-
 and RYR1
+/-
 
samples were more precisely examined via qRT-PCRs (Fig. 21B). Significant (p ≤ 0.05) upregulation 
in RYR1
-/-
 vs. RYR1
+/-
 samples was observed for Six1, Six4, Pax7, MyoD, MyoG and Mrf4 (Table 
14). These increases in the MRFs expression levels, that are physiologically downregulated in 
differentiated myofibers, indicate a delay in RYR1
-/-
 skeletal myogenesis. 
Table 14. MRFs expression levels. 
 Microarray analyses qRT-PCR analyses 
Gene FC S.E.M. P-value FC S.E.M. P-value 
Six1 1.04 ± 0.05 0.717 1.27 ± 0.07 0.014 
Six4 1.38 ± 0.09 0.003** 1.66 ± 0.19 0.014* 
Pax3 0.93 ± 0.02 0.165 0.69 ± 0.19 0.234 
Pax7 1.27 ± 0.02 0.007** 1.57 ± 0.18 0.018* 
Myf5 1.25 ± 0.04 0.040* 1.40 ± 0.23 0.139 
MyoD 1.53 ± 0.08 0.002** 2.39 ± 0.30 0.005** 
MyoG 1.46 ± 0.05 0.0001*** 1.97 ± 0.18 0.002** 
Mrf4 1.38 ± 0.18 0.217 1.50 ± 0.19 0.034* 
Comparison of MAs and qRT-PCR analysis. FC, S.E.M. and P-value (from unpaired t-tests) of the examined MRFs 
found in the RYR1
-/-
 samples in the MAs and in the qRT-PCR analyses. FC values are relative to the expression in 
control samples. * represents a P-value ≤ 0.05, ** represents a P-value ≤ 0.01 and *** represents a P-value ≤ 0.001. 
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Fig. 21: MRFs expression during myogenesis. 
 (A) Progression of the skeletal myogenic lineage throughout myogenesis and expression levels of the MRFs Six1, Six4, 
Pax3, Pax7, Myf5, MyoD, MyoG and Mrf4 (modified from (Bentzinger et al., 2012)). (B) Expression levels of the MRFs 
shown in (A) in RYR1
-/-
 skeletal muscle measured as FC of the respective MRF mRNA levels in RYR1
+/-
 (control) 
skeletal muscle samples. Four biological replicates (n = 4) were tested in each group. Hollow bars represent the results 
from the MAs and crossed bars represent the results of the qRT-PCRs using the Gapdh transcript as endogenous control. 
For each gene the FCs were normalized to the mean FC of the control group, thus each RYR1
+/-
 control group (in MAs 
and qRT-PCRs) has a mean FC = 1. Unpaired t-tests were performed for RYR1
-/-
 vs. control for each gene, * represents a 
P-value ≤ 0.05, ** represents a P-value ≤ 0.01 and *** represents a P-value ≤ 0.001. Error bars are S.E.M. 
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3.2 Part II: Analysis of the embryonic (E14.5) and fetal (E18.5) 
skeletal muscle lacking RYR1 or Cav1.1 
The second part of this thesis analyzes the changes occurring in the developing murine limb skeletal 
muscle in the absence of either RYR1 or Cav1.1. Precisely, the end of the embryonic marking the 
beginning of fetal development (E14.5) and the end of fetal development shortly before birth (E18.5) 
were analyzed and compared. The limb skeletal muscle morphology, developmental markers, and 
global gene expression were closely examined and evaluated. At both time points – E14.5 and E18.5 
– WT (+/+), heterozygous (+/-) and homozygous (-/-) mutant animals from the RYR1 and Cav1.1 mouse 
model were examined. Thus, the physiological changes in limb skeletal muscle morphology and gene 
expression during fetal development were compared to those in the absence of RYR1
-/-
 and Cav1.1
-/- 
limb skeletal muscle. The main findings of this part of the results were reported in (Filipova et al., 
2018). 
3.2.1 Gross morphology of WT, RYR1+/-, RYR1-/-, Cav1.1
+/-
 and Cav1.1
-/-
 fetuses 
at E14.5 and E18.5  
First, the gross morphological appearance of entire mouse fetuses was analyzed at embryonic days 
E14.5 and E18.5. For this analysis whole embryos preparations were performed with 3 littermates 
from each genotype, RYR1
+/+
 (WT), RYR1
+/-
 and RYR1
-/-
, as well as Cav1.1
+/+
 (WT), Cav1.1
+/-
 and 
Cav1.1
-/-
 (Fig. 22). At E14.5, no apparent macroscopic differences in the morphology were observed 
between the WT, heterozygous (
+/-
) and homozygous (
-/-
) mutants. At E18.5 the heterozygous 
RYR1
+/-
 and Cav1.1
+/-
 mutants were undistinguishable from their WT littermates which is in 
accordance with previously reports (Pai, 1965a; Takeshima et al., 1994) and the results described in 
the previous Results part. In contrast, homozygous RYR1
-/-
 and Cav1.1
-/-
 mutants exhibited severe 
morphological changes comprising a characteristic spinal curvature, smaller limbs and enlarged 
necks, as well as a smaller body size (Fig. 22). 
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Fig. 22: Gross fetal morphological appearance at E14.5 and E18.5. 
Whole mouse fetuses were photographed at E14.5 and E18.5. Three littermates from each genotype (A) RYR1
+/+
 (WT), 
RYR1
+/-
 and RYR1
-/-
; as well as (B) Cav1.1
+/+
 (WT), Cav1.1
+/-
 and Cav1.1
-/-
 were analyzed. Representative photographs 
are shown. Modified from (Filipova et al., 2018). 
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3.2.2 Histological alterations in RYR1-/-, Cav1.1
+/-
 and Cav1.1
-/-
 fetuses at E14.5 
and E18.5  
In order to examine the structure and composition of the limb skeletal muscle at E14.5 and E18.5 in 
more detail, histological cross sections from the hind limbs of WT, heterozygous (
+/-
), and 
homozygous (
-/-
) RYR1 and Cav1.1 mouse fetuses were analyzed. At E14.5, fascicle formation was 
already initiated in WT muscles (Fig. 23A, B), the predominant cell type was myotubes but some 
primary muscle fibers were detectable. As expected, the RYR1
+/-
 muscle morphology closely 
resembled that of WT fetuses (Fig. 23D, E), whereas the hind limb muscles of homozygous RYR1
-/-
 
mutants were characterized by multiple unorganized myotubes and only few, individual muscle 
fibers with small fiber caliber (Fig. 23G, H). No indication of any organization of muscle fascicles in 
the RYR1
-/-
 muscles was detectable. Similar morphological alterations were found in muscles from 
Cav1.1
-/-
 animals at E14.5 (Fig. 23M, N). However, while the muscles of heterozygous RYR1
+/-
 
animals were morphologically identical to those of the WT fetuses, the muscles of heterozygous 
Cav1.1
+/-
 animals exhibited similar but less severe disorganization of the muscle fascicles as Cav1.1
-/-
 
animals (Fig. 23J, K). Thus, the most severe phenotype was observed in homozygous Cav1.1
-/-
 
fetuses, with skeletal muscles consisting almost exclusively of small caliber myotubes and myoblasts 
while mature muscle fibers were virtually absent (Fig. 23M, N). Additionally, only in Cav1.1
-/-
 
skeletal muscle there was an indication for ongoing apoptosis, revealed by a positive nuclear 
activated caspase-3 staining in a small fraction of myotubes (Fig. 23O, arrows), which was absent in 
the other fetuses. 
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Fig. 23: Histological cross sections of mouse hind limb skeletal muscle at E14.5. 
Cross sections of the lower hind limb of a WT fetus (A-C), a RYR1
+/-
 fetus (D-F), a RYR1
-/-
 fetus (G-I), a Cav1.1
+/-
 fetus 
(J-L), and a Cav1.1
-/-
 fetus (M-O) at E14.5, respectively.  
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At E14.5, the skeletal muscle of the WT fetus (A, B) and RYR1
+/-
 fetus (D, E) already exhibited muscle fascicles 
(surrounded by dotted line) comprised of primary muscle fibers with almost no myoblasts. In contrast, the skeletal muscle 
of the RYR1
-/-
 (G, H), Cav1.1
+/-
 (J, K), and Cav1.1
-/-
 (M, N) fetuses had either disorganized (asterisks) or completely 
lacking muscle fascicles and contained numerous myoblasts. Immunohistochemistry with anti-activated caspase-3 
revealed prominent apoptosis only in nuclei of the myotubes of a Cav1.1
-/-
 fetus (O, arrows).  H&E staining (A, B, D, E, 
G, H, J, K, M, and N); original magnification x100 (A, D, G, J, M) and x200 (B, E, H, K, N). Immunohistochemistry 
(C, F, I, L, O) with rabbit anti-mouse activated caspase-3 (clone C92-605; BD Biosciences) and slight counterstaining 
with hemalum; original magnification x400. Scale bars correspond to 100 µm in all microphotographs. Micrographs were 
taken by PD Dr. Anna Brunn. Modified from (Filipova et al., 2018). 
At E18.5, WT and RYR1
+/-
 muscles exhibited a normal development and consisted almost entirely of 
differentiated muscle fibers organized in fascicles (Fig. 24A-F), whereas the RYR1
-/-
 skeletal muscle 
lacked a distinct fascicle formation and consisted mostly of myotubes and small, disorganized fibers 
(Fig. 24G, H), as shown before (Fig. 14). In contrast to the WT and the unaffected RYR
+/-
 fetuses, the 
skeletal muscles of the heterozygous Cav1.1
+/-
 fetuses displayed a bigger percentage of small fibers 
and myotubes and a higher degree of disorganization as evident from the large spaces devoid of 
fibers within the fascicles (Fig. 24 asterisks in J and K). At E18.5 homozygous Cav1.1
-/-
 skeletal 
muscle still exhibited the greatest signs of immaturity, consisting predominantly of myoblasts and 
myotubes and had virtually no differentiated muscle fibers. (Fig. 24M,N). Moreover, the hind limb of 
the E18.5 Cav1.1
-/-
 fetuses also exhibited a retarded bone maturation, as the bones consisted of a 
hyaline cartilage at a time point when mineralization of bones should be active (Fig. 24; arrows in 
M). The activated caspase-3 stainings revealed no signs of apoptosis in any of the analyzed 
genotypes at E18.5 (Fig. 24C, F, I, L, O). 
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Fig. 24: Histological cross sections of mouse hind limb skeletal muscle at E18.5. 
Cross sections of the lower hind limb of a WT fetus (A-C), a RYR1
+/-
 fetus (D-F), a RYR1
-/-
 fetus (G-I), a Cav1.1
+/-
 fetus 
(J-L), and a Cav1.1
-/-
 fetus (M-O), respectively. At E18.5, the fetal skeletal muscles of a WT fetus (A-C) was mature with 
regularly developed muscle fascicles consisting of differentiated muscle fibers. as well as inconspicuous bone having 
reached a normal state of mineralization. In a RYR1
+/-
 fetus (D-F), skeletal muscle and bone were normally developed, 
thus, being similar to WT mice. In contrast, the skeletal muscle of RYR1
-/-
 (G, H) and Cav1.1
-/-
 (M, N) fetuses, consisted 
predominantly of small, unorganized myotubes with a lack of fascicular organization. In addition, bone of the hind limb 
of a Cav1.1
-/-
 (M-O) fetus was impaired in development as evidenced by persisting hyaline cartilage while mineralization 
had not been initiated (arrows in M). The skeletal muscle of a Cav1.1
+/-
 fetus exhibited milder signs of an incomplete 
development such as partial fiber disorganization within the fascicles (asterisks in J, K). At day E18.5 apoptosis was 
completely absent from all mutant strains as evidenced by the absence of nuclear immunoreaction in 
immunohistochemistry with anti-activated caspase-3. H&E staining (A, B, D, E, G, H, J, K, M, and N); original 
magnification x100 (A, D, G, J, M) and x200 (B, E, H, K, N). Immunohistochemistry with rabbit anti-mouse activated 
caspase-3 (clone C92-605; BD Biosciences) and slight counterstaining with hemalum; original magnification x400. Scale 
bars correspond to 100 µm in all microphotographs. Micrographs were taken by PD Dr. Anna Brunn. Modified from 
(Filipova et al., 2018). 
3.2.3 Global transcriptome analyses of limb skeletal muscle at E14.5 and E18.5 
In order to elucidate the global transcriptomic changes accompanying fetal development and 
secondary myogenesis in mouse limb skeletal muscle from E14.5 – the beginning of fetal 
development and of secondary myogenesis – to E18.5 – the end of prenatal development and 
secondary myogenesis, microarray analyses (MAs) were performed as described in (Filipova et al., 
2018). In particular, at E14.5 and E18.5 the skeletal muscles from the front and hind limbs of 3 
littermates of each of the genotypes RYR1
+/+
 (WT), RYR1
+/-
 and RYR1
-/-
, as well as Cav1.1
+/+
 (WT), 
Cav1.1
+/-
 and Cav1.1
-/-
 were collected separately and used for total RNA extractions (Fig. 25). The 
RNA concentration was measured and the RNA integrity was analyzed on 2% agarose gels (Fig. 26). 
Subsequently, 250 ng of each sample were subjected to microarray analyses. The Affymetrix 
MoGene 2.0 ST array chips were used for the MAs, which provided information about the expression 
levels of 41,345 genomic loci. One advantage of these chips over the previously used Mouse 
Genome 430 2.0 chips (E18.5 RYR1
-/-
 vs. RYR1
+/-
) is, that they span not only the coding regions of 
the mouse transcriptome but also provide information about the expression of non-coding RNAs like 
micro RNAs (miRNAs) or long non-coding RNAs (lncRNAs). 
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Fig. 25: Workflow scheme for the gene expression analysis of limb skeletal muscle at E14.5 and E18.5. 
Six heterozygous RYR1
+/-
 and Cav1.1
+/- 
male and females mice were subjected to timed pairings (always RYR1
+/-
 x 
RYR1
+/-
 and Cav1.1
+/-
 x Cav1.1
+/-
). Three pregnant females were sacrifices at day 14.5 and three – at day 18.5 post 
coitum. From each litter the skeletal muscles from the front and hind limbs of one WT (
+/+
), one heterozygous (
+/-
) and 
one homozygous (
-/-
) fetus were collected and used for RNA extractions. Equal amounts of total RNA from each sample 
were used for individual hybridizations to Affymetrix MoGene 2.0 ST array chips and MAs was performed as described 
in Materials and Methods. Additionally, equal amounts of the total RNAs were used in reverse transcription reactions and 
the resulting cDNAs were used in qRT-PCR analyses. Modified from (Filipova et al., 2018). 
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Fig. 26: RNA quality assessment for MAs. 
RNA agarose electrophoresis. 250 ng or 500 ng total RNA extracted from the skeletal muscles of WT (
+/+
), heterozygous 
(
+/-
) or homozygous (
-/-
) RYR1 and Cav1.1 fetuses were subjected to electrophoresis on 2% agarose gels next to 2 µl 
RiboRuler High Range RNA Ladder as size marker (marked as “M”). Animals from different genotypes belonging to the 
same litter at each time point (E14.5 or E18.5) were marked as 1, 2 and 3, standing for “litter 1”, “litter 2” and “litter 3”. 
Samples marked with “n.” were not subjected to MAs. Modified from (Filipova et al., 2018). 
3.2.3.1 PCA identifies distinct global transcriptomic profiles of RYR1-/- and Cav1.1
-/-
 limb 
skeletal muscle at E18.5 but not E14.5 
Next, the results of the MAs (.CEL files) were subjected to background correction, summarization 
and normalization via a robust Multi-array Analysis (RMA) using the Affymetrix Expression 
Console™ (Affymetrix® / Thermo Fisher). The resulting summarization files (.CHP) were used for 
the construction of a 3D PCA plot representing the variance between the samples on the basis of the 
detected expression levels for the entire transcriptome (Fig. 27). The PCA identified that the factor 
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responsible for the biggest part of the observed variance among the samples (PC1 = 47.2%) was the 
developmental stage – E14.5 or E18.5, as all samples separated along PC1 according to this criteria. 
At E14.5 no genotype-related separation was observed between the samples. In contrast, the samples 
taken at E18.5 segregated into two groups along PC2 (PC2 = 5.3%): in the first group are the RYR1
-/-
 
and Cav1.1
-/-
 samples, which are grouped together and separated from the other group that consists of 
all of the other (WT and heterozygous) genotypes. This is best seen for the Cav1.1.
-/-
 samples (green 
squares in Fig. 27) which are located most distantly from the samples of the WT and heterozygous 
fetuses. Additionally, the E18.5 RYR1
-/-
 and Cav1.1
-/-
 samples appeared slightly closer to the E14.5 
sample group along PC1. This indicates that at E18.5 the RYR1
-/-
 and Cav1.1
-/-
 limb skeletal muscles 
possess similar global transcriptomic profiles, which differ significantly from those of WT and 
heterozygous (RYR1
+/-
 and Cav1.1
+/-
) limb skeletal muscle. 
 
Fig. 27: A 3D PCA plot from the MAs results. 
PCA was performed for all samples with all their genes detected by the MAs via the Expression Analysis Console 3.0 
(Affymetrix® / Thermo Fisher). The shape of each sample corresponds to its embryonic day: E14.5 – circles, and E18.5 – 
squares. The color of each sample corresponds to its genotype. Modified from (Filipova et al., 2018). 
3.2.3.2 DEGs criteria and numbers 
The MAs summarization files (.CHP) were further subjected to one-way ANOVA analyses via the 
Transcriptome Analysis Console 3.0 (Affymetrix® / Thermo Fisher) for detection of differentially 
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regulated genes (DEGs). One major aim of this analysis was to identify and compare DEGs arising 
from E14.5 to E18.5 (E18.5 vs. E14.5 comparisons) within each genotype. In this aspect, a gene was 
considered to be differentially expressed if it had a P-value ≤ 0.05 and a linear FC ≤ -2 or ≥ 2 (Fig. 
28A). Another main purpose of this work was to analyze the differences in gene expression between 
the different genotypes at each developmental point (E14.5 and E18.5). In order to be able to analyze 
less pronounced changes in gene expression, a gene was considered as a DEG if it had a P-value ≤ 
0.05 and a linear FC ≤ -1.5 or ≥ 1.5 (Fig. 28B). Only genes meeting these criteria (Table 15) were 
subjected to further analyses. 
 
Fig. 28: Criteria for DEGs. 
(A) When comparing different developmental stages (E18.5 vs. E14.5), the cut-off criteria for being considered as a DEG 
were a FC ≥ +2 or ≤-2, and a P-value ≤ 0.05 (the example shown is from the comparison WT E18.5 vs. WT E14.5). (B) 
When comparing groups from the same developmental stage, the cut-off criteria were a FC ≥ +1.5 or ≤-1.5, and a P-value 
≤ 0.05 (the example shown is from the comparison Cav1.1-/- E18.5 vs. WT E18.5). Modified from (Filipova et al., 2018). 
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Table 15. Number of DEGs found in various comparisons. 
Test group Comparison 
(Test vs. Control group) 
Total DEGs Downregulated 
DEGs 
Upregulated 
DEGs 
WT E18.5 vs. WT E14.5 1314 541 773 
RYR1
+/-
 E18.5 vs. RYR1
+/-
 E14.5 1426 611 815 
E14.5 vs. WT E14.5 36 27 9 
E18.5 vs. WT E18.5 21 13 8 
RYR1
-/-
 E18.5 vs. RYR1
-/-
 E14.5 812 311 501 
E14.5 vs. WT E14.5 61 32 29 
E18.5 vs. WT E18.5 493 304 189 
Cav1.1
+/-
 E18.5 vs. Cav1.1
+/-
 E14.5 1079 433 646 
E14.5 vs. WT E14.5 8 5 3 
E18.5 vs. WT E18.5 33 10 23 
Cav1.1
-/-
 E18.5 vs. Cav1.1
-/-
 E14.5 900 282 618 
E14.5 vs. WT E14.5 97 66 31 
E18.5 vs. WT E18.5 1047 571 476 
 
As shown by Table 15, the highest numbers of DEGs were detected in the comparisons of the two 
developmental stages, E18.5 vs. E14.5, for WT (1314 DEGs), RYR1
+/-
 (1426 DEGs) and Cav1.1
+/-
 
(1079 DEGs) samples. The homozygous RYR1
-/-
 and Cav1.1
-/-
 mutants exhibited a smaller number of 
DEGs (812 and 900 DEGs, respectively) in this comparison, going in line with the suggestion that 
the secondary myogenesis in these muscles is incomplete and therefore less genes are expected to be 
significantly changed. When comparing the RYR1
+/-
 and Cav1.1
+/-
 mutants to their WT littermates at 
E14.5 and E18.5, both heterozygous mutants revealed only a handful of DEGs, the majority of which 
had a FC between 1.5 and 2 or -1.5 and -2. Therefore, the gene expression changes in the RYR1
+/-
 
and Cav1.1
+/-
 mutants were not further analyzed.  
When comparing the homozygous RYR1
-/-
 or Cav1.1
-/-
 vs. WT samples at E14.5, 61 DEGs were 
identified in the RYR1
-/-
 samples and 97 – in the Cav1.1 samples. At E18.5 these numbers grew by 8 
to 10-fold comparing homozygous E18.5 RYR1
-/-
 (493 DEGs) or Cav1.1
-/-
 (1047) to the WT samples. 
Thus, this dramatic increase in DEGs indicated that the majority of the transcriptomic changes in 
limb skeletal muscle due to the absence of RYR1 or Cav1.1 occur between E14.5 and E18.5. In 
agreement with the slightly more severe phenotype of Cav1.1
-/-
 skeletal muscle (Figs. 23 and 24) two 
times more DEGs were detected in the Cav1.1
-/-
 as in the RYR1
-/-
 vs. WT samples at both E14.5 and 
E18.5. 
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3.2.3.3 qRP-PCRs validation of the MAs  
Next, the gene sets found as differentially regulated in the MAs were validated via qRT-PCRs. This 
required suitable reference genes, having stable expression levels in the two examined developmental 
stages, E14.5 and E18.5, and being not affected by the RYR1 and Cav1.1 deficiency. Many of the 
genes traditionally used as references in qRT-PCR analyses like Gapdh or Actb change their 
expression profiles during development or have been found to be regulated in muscle dystrophies or 
upon exercise (Hildyard & Wells, 2014; Mahoney et al., 2004; Rivers, Simpson, Robertson, Gaskell, 
& Beynon, 2007; Ruiz-Villalba et al., 2017; Seilertuyns, Eldridge, & Paterson, 1984). Since mouse 
development between E14.5 and E18.5 is connected to active growth and protein synthesis 
enhancement, it is to be expected that the majority of the genes alter their expression profiles. In 
order to find the best reference genes that could be utilized as endogenous controls in the qRT-PCRs, 
the expression levels of all detected genes (not only DEGs) in the analyzed mouse genotypes (RYR1 
and Cav1.1: 
+/+
, 
+/-
 and 
-/-
) were compared between the two developmental stages – E18.5 and E14.5. 
Additionally, the expression levels of all heterozygous and homozygous mutants for each time point 
were compared to those of the WTs at the respective time point (i.e. E14.5 or E18.5 
+/-
 vs. 
+/-
 and 
-/-
 
vs. 
+/+
). The comparisons identified two genes, putatively suitable for being used as reference – Cytb, 
encoding cytochrome b, and Uba52, encoding ubiquitin A-52 residue ribosomal protein fusion 
product 1. qRT-PCRs were performed, measuring the expression of Cytb, Uba52, Gapdh, Actb and 
Rplp0, the latter encoding the large ribosomal protein P0. Cytb was used an endogenous control (Fig. 
29). Indeed, the analysis revealed an upregulation of Gapdh and a downregulation of Actb in WT 
samples when comparing E18.5 vs. E14.5.Moreover, Actb was downregulated in RYR1
-/-
 vs. WT 
samples at E14.5 and Gapdh, although not significantly, exhibited a tendency of a downregulation in 
Cav1.1
-/-
 vs. WT samples at E18.5. However, Uba52 and Cytb genes exhibited stable relative 
expression levels and could therefore be suitable for being used as reference (Fig. 29A). For 
consistancy, Cytb was used as an endogenous control in all subsequent qRT-PCRs. 
Results 
90 
 
 
Fig. 29: qRT-PCR analyses of putative endogenous controls. 
The relative expression levels of Gapdh, Actb, Rplp0, Uba52 and CytB (used as endogenous control) were measured via 
qRT-PCRs for WT E18.5 vs. E14.5 samples (A), as well as for RYR1
-/-
 vs. WT (B and C) and for Cav1.1
-/-
 vs. WT (D and 
E) at E14.5 and E18.5. Expression levels of control samples (blue bars) were set to 1. Statistical t-tests were performed 
for each gene, ***represents a P-value ≤ 0.001. Error bars are S.E.M. Modified from (Filipova et al., 2018).  
For validation of the MAs results which compared changes in the expression occurring between 
E14.5 and E18.5 in the WT, RYR1
-/-
 and Cav1.1
-/-
 samples, seven to eight DEGs were randomly 
chosen and subjected to qRT-PCR analysis (Fig. 30A-C). The DEGs spanned both directions of 
regulation (up- and downregulation), as well as the entire analyzed FC spectrum, containing genes 
exhibiting low, medium or high expression changes. Since much fewer DEGs were identified in the 
E14.5 RYR1
-/-
 vs. WT and E14.5 Cav1.1
-/-
 vs. WT analyses (See Table 15), four DEGs were used for 
the validation of these comparisons (Fig. 30D, E). Six DEGs were analyzed via qRT-PCRs in the 
E18.5 RYR1
-/-
 vs. WT and E18.5 Cav1.1
-/-
 vs. WT analyses (Fig. 30F, G). The results showed that all 
analyzed DEGs were regulated in the same direction and with a similar FC as observed in the MAs. 
The most clearly up- or downregulated DEGs tested revealed a much stronger differential regulation 
in the qRT-PCR experiments than in the MAs. This was most likely due to the much higher 
sensitivity of the qRT-PCR technique and its wider dynamic range (Morey, Ryan, & Van Dolah, 
2006). Hence, the MA comparisons could be confirmed via qRT-PCR, suggesting validity of the MA 
analysis also for the genes not additionally tested by qRT-PCR. 
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Fig. 30: Validation of the MAs results via qRT-PCRs. 
DEGs found in the E18.5 vs. E14.5 analyses were validated in (A), WT vs. WT samples, 8 genes, n = 6 biological 
replicates per group (WTs from both the RYR1 and Cav1.1 lines); (B) RYR1
-/-
 vs. RYR1
-/-
, 7 genes, n =3 biological 
replicates per group; (C), Cav1.1
-/-
 vs. Cav1.1
-/-
, 7 genes, n =3 biological replicates per group. At E14.5 four DEGs were 
analyzed for the RYR1
-/-
 vs. WT (D) and for the Cav1.1
-/-
 vs. WT (E) analyses, n=3 biological replicates per group. At 
E18.5 six DEGs were analyzed for the RYR1
-/-
 vs. WT (F) and seven DEGs for the Cav1.1
-/-
 vs. WT (G) analyses, n=3 
biological replicates per group. In all MAs and qRT-PCR analyses the FCs of the control samples were set to 1. The 
relative expression levels obtained by qRT-PCR analysis were normalized to Cytb, which was used as endogenous 
control. Error bars are S.E.M. Modified from (Filipova et al., 2018). 
3.2.3.4 Distinct transcriptomic changes in the RYR1-/- and Cav1.1
-/-
 skeletal muscle at E14.5 
At E14.5 61 DEGs were detected in the samples from RYR1
-/-
 skeletal muscle and 97 DEGS – in the 
samples from Cav1.1
-/-
 skeletal muscle in comparison to samples from WT skeletal muscle (Table 
15). This indicated that initial changes had already occurred in the global transcriptomes at the 
crucial transition phase of end of embryonic development respectively primary myogenesis towards 
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the beginning of fetal development, and respectively secondary myogenesis. GO BP enrichment 
analyses were performed with the detected DEGs in order to analyze which biological processes and 
pathways were affected (Fig. 31A, B). Interestingly, only 2 DEGs were found in both RYR1
-/-
 and 
Cav1.1
-/-
 samples – namely the solute carrier family 44, member 5 (Slc44a5) and Der1-like domain 
family, member 3 (Derl3), suggesting that the absence of RYR1 or Cav1.1 exerts differential effects 
on embryonic skeletal muscle development. The Go BP enrichment analyses indeed found no overlap 
between the most significantly enriched with DEGs in the RYR1
-/-
 and in the Cav1.1
-/-
 samples, and 
specific tendencies were observed in each genotype. In the RYR1
-/-
 limb skeletal muscle the majority 
of the GO BP categories enriched with the highest significance were related to innervation and 
neurogenesis-related processes. “Regulation of neuron differentiation” was the most significantly 
affected process (Fig. 31A). The categories “Microtubule-based transport” and “Cytoskeleton-
dependent intracellular transport” implicated putative changes in the cellular transport regulation. On 
the other hand, in the Cav1.1
-/-
 samples almost all of the top 10 most significantly enriched biological 
processes were related to muscle contraction with the “Muscle contraction” category on position one 
(Fig. 31B). These results correlated with the slightly more severe phenotype and higher muscle 
disorganization observed in Cav1.1
-/-
 skeletal muscle at E14.5 (Fig. 23). 
In order to assess the direction in which these processes were affected, heatmaps were generated 
from the expression values of the genes associated with the two most significantly enriched processes 
(Fig. 31, arrows in A and B). Both heatmaps revealed a systemic downregulation of the genes 
involved in “Regulation of neuron differentiation” (for RYR1-/- vs. WT, Fig. 31C) and in “Muscle 
contraction” (for Cav1.1
-/-
 vs. WT, Fig. 31D). In Cav1.1
-/- 
vs. WT, Myh6, a gene, encoding cardiac 
myosin heavy polypeptide 6, alpha was the only upregulated DEG related to muscle contraction.. 
Thus, a general negative regulation or possibly a missing positive regulation of processes regulating 
innervation responses and muscle contraction was anticipated for the RYR1
-/-
 and Cav1.1
-/-
 limb 
skeletal muscle, respectively. 
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Fig. 31: Biological processes most affected by the RYR1
-/-
 and Cav1.1
-/-
 mutations at E14.5. 
GO BP enrichment analyses were performed using the DEGs identified in the RYR1
-/-
 vs. WT (A) and Cav1.1
-/-
 vs. WT 
(B) samples at E14.5. The ten most significantly enriched categories for each analysis are shown. Arrows indicate 
categories presented as heat maps in (C) and (D). The enrichment analyses was performed via the Enrichr online tool 
(Chen et al., 2013), length of the bars represents the significance (P-value, shown on the x-axes in A,B). Heatmaps were 
generated for the DEGs enriched in the process “Regulation of neuron differentiation” in RYR1-/- samples (C) and for the 
DEGs enriched in the process “Muscle contraction” in Cav1.1
-/-
 samples (D). The heatmaps were generated from the MAs 
intensity levels of each gene via ClustVis (Metsalu & Vilo, 2015). Hierarchical linkage clustering using the average 
Euclidean distance was performed for all rows and columns. Modified from (Filipova et al., 2018). 
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3.2.3.5 Substantial overlap in the transcriptomic changes occurring in RYR1-/- and Cav1.1
-/-
 
skeletal muscle at E18.5 
At E18.5 the numbers of DEGs found in the samples from both mutants were 8- to 10-fold higher 
than at E14.5 (Table 15). Unlike the totally distinct sets of DEGs found in both mutants at E14.5, at 
E18.5 328 DEGs were shared by the RYR1
-/-
 and Cav1.1
-/-
 samples, which correspond to 66.5% of all 
RYR1
-/-
 DEGs and 31.3% of all Cav1.1
-/-
 DEGs, respectively. This suggested that the majority of the 
transcriptomic changes in the mutant limb skeletal muscles occur between E14.5 and E18.5 and that 
the absence of RYR1 or Cav1.1 initially causes divergent transcriptomic changes that converge 
towards E18.5. 
To determine more precisely which biological processes are most influenced by the transcriptome 
changes at E18.5, the DEGs detected in the E18.5 RYR1
-/-
 vs. WT and Cav1.1
-/-
 vs. WT comparisons 
were also subjected to GO BP enrichment analyses (Fig. 32). The enrichment analyses showed that 
the overlap in DEGs found in both mutants corresponds to a substantial overlap in the most affected 
processes in RYR1
-/-
 and Cav1.1
-/-
 samples, since the 3 most significantly enriched processes were 
identical for both mutants and were related to muscle contraction. Further analyses also revealed 
major signaling pathways like the MAPK, PI3K-AKT, Wnt, peroxisome proliferator-activated 
receptor (PPAR), cAMP and cGMP-PKG pathways that were enriched with DEGs in both RYR1
-/-
 
and Cav1.1
-/-
 samples (Suppl. Table 1). Additionally, the GO BP enrichment analyses also identified 
highly significantly enriched processes which were specific for the RYR
-/-
 or for the Cav1.1
-/-
 
samples. In the RYR1
-/-
 samples these processes were connected to the structure and composition of 
the extracellular matrix ECM (Fig. 32A), whereas in the Cav1.1
-/-
 samples these were primarily 
related to lipid metabolism (Fig. 32B).  
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Fig. 32: Biological processes affected by the RYR1
-/-
 and Cav1.1
-/-
 mutations at E18.5. 
GO BP enrichment analyses were performed for the DEGs identified in the RYR1
-/-
 vs. WT (A) and Cav1.1
-/-
 vs. WT (B) 
at E18.5. The ten most significantly enriched categories for each analysis are shown. Arrows indicate categories 
presented as heat maps in Fig. 33A-C. The enrichment analyses was performed via the Enrichr online tool (Chen et al., 
2013), the length of the bars corresponds to the significance (P-value). Modified from (Filipova et al., 2018). 
To evaluate the direction in which the common (found in both mutants) and the specific (found only 
in one of the mutants) processes were regulated, heatmaps were constructed for the DEGs from the 
“Muscle contraction” category – the most significantly enriched biological process in both mutants 
(Fig. 33A). Heatmaps were also generated for the DEGs from “Extracellular matrix organization” in 
RYR1
-/-
 samples (Fig. 33B), and for the DEGs from “Acylglycerol metabolic process” in the Cav1.1
-/-
 
samples (Fig. 33C) – the most significantly affected processes specific for each mutant. 44 out of 49 
DEGs identified under “Muscle contraction” were downregulated either in RYR1-/- or in Cav1.1
-/-
, or 
in both mutants (Fig. 33A). Many of these DEGs, like Myl2, Myl3, Myl6b, Myl9, Myh3, Myh7, 
Csrp3, Tcap, Tpm3, Myom1 and Myom2 encode sarcomeric proteins suggesting significant defects in 
the buildup of the contractile machinery in the mutants. These findings are in line with the observed 
scarcity of myofibrils and the abnormalities in sarcomere arrangement in limb skeletal muscle from 
RYR1
-/-
 and Cav1.1
-/-
 mice at the perinatal stage (Pai, 1965b; Takeshima et al., 1994). 
17 of 27 DEGs found in the “Extracellular matrix organization” in the RYR1-/- samples, were 
downregulated and 10 DEGs were upregulated compared to WT samples, suggesting a shift in the 
ECM structure and composition in RYR1
-/-
 skeletal muscle (Fig. 33B).  
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20 DEGs detected in the E18.5 Cav1.1
-/-
 vs. WT analysis participate in the “Acylglycerol metabolic 
process”. The majority – 17 DEGs – were upregulated in the samples from Cav1.1
-/-
 skeletal muscle 
(Fig. 22C), indicating an increased lipid metabolism in the limb skeletal muscle of these mutants. 
 
Fig. 33: Heatmaps for the most significant common and specific GO BP processes at E18.5. 
Heatmaps were generated for the DEGs enriched in the “Muscle contraction” biological process in RYR1-/- and Cav1.1
-/-
 
samples (A); for the DEGs enriched in “Extracellular matrix organization” biological process in RYR1-/- samples (B); and 
for the DEGs enriched in “Acylglycerol metabolic process” biological process in Cav1.1
-/-
 samples (C). Heatmaps were 
generated from the MAs intensity levels of each included gene via ClustVis (Metsalu & Vilo, 2015). Hierarchical average 
linkage clustering using the Euclidean distance was performed for all rows and columns. Modified from (Filipova et al., 
2018). 
3.2.3.6 Global transcriptomic changes during fetal development in WT, RYR1-/- and Cav1.1
-/-
 
limb skeletal muscle 
One main incentive while comparing the MAs results was to analyze the developmental changes 
occurring in limb skeletal muscle during fetal development and the simultaneous secondary 
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myogenesis. In order to assess the physiological transcriptomic changes accompanying this period in 
skeletal muscle development, the DEGs found in the WT samples from E14.5 to E18.5 (E18.5 vs. 
E14.5) were subjected to GO BP and Wiki Pathways enrichment analyses (Fig. 34A, B). The results 
exhibited a clear predominance of differently expressed genes related to processes associated with 
muscle structure and muscle contraction . Other significantly regulated pathways were related to 
energy metabolism, specifically to glycolysis, gluconeogenesis and fatty acid metabolism; as well as 
pathways related to the cell cycle. Similar results were found when these enrichment analyses were 
performed with the DEGs detected in the E18.5 vs. E14.5 comparisons of the RYR1
-/-
 (Fig. 34C, D) 
and Cav1.1
-/-
 (Fig. 34E, F) samples. However, in both mutants the processes connected to muscle 
contraction are represented by much fewer GO BP and WP categories. Instead, the pathways of fatty 
acid metabolism and beta oxidation seemed to be represented with a higher significance. Additional 
categories related to lipid metabolism and adipogenesis were identified in the mutants, especially in 
the samples from the Cav1.1
-/-
 skeletal muscles. Furthermore, significantly enriched processes with 
the DEGs from the RYR1
-/-
 E18.5 vs. E14.5 comparison were “DNA replication”, “Negative 
regulation of calcium ion transport”, “Cell-cell adhesion via plasma-membrane adhesion molecules”, 
and “Mesenchymal cell differentiation”. Cav1.1
-/-
 samples, on the other hand, showed a specific GO 
BP enrichment in “Lipid storage”, “Carnitine shuttle” and “Glucose homeostasis”. The WP 
enrichment analyses revealed “Striated muscle contraction Mus musculus” as the most significantly 
engaged process in WT and Cav1.1
-/-
 samples, whereas in the RYR1
-/-samples “Fatty acid and beta 
oxidation Mus musculus/Homo sapiens” were more significantly implicated. The “PPAR signaling 
pathway” was identified in the WP enrichment analysis of the RYR1-/- and Cav1.1
-/-
 samples but not 
the WT samples. 
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Fig. 34: Enrichment analysis of all DEGs found in skeletal muscle development from E14.5 to E18.5. 
GO BP (A, C and E) and Wiki Pathways (B, D, F) enrichment analyses of all DEGs found in WT (A, B), RYR1
-/-
 (C, D) 
and Cav1.1
-/-
 (E, F) from E14.5 (control) to E18.5. The ten most significantly enriched categories for each analysis are 
shown. Enrichment analyses (A – F) were performed via the Enrichr online tool (Chen et al., 2013), length of the bars is 
proportional to the significance (P-value). H.s. stands for Homo sapiens, and M.m. stands for Mus musculus. Modified 
from (Filipova et al., 2018). 
3.2.3.7 Common and distinct DEGs during fetal development of WT, RYR1-/- and Cav1.1
-/-
 
skeletal muscle 
To analyze to what degree the observed transcriptomic developmental changes from E14.5 to E18.5 
were specific for each genotype, the DEGs detected in the E18.5 vs. E14.5 analyses in the WT, 
RYR1
-/-
 and Cav1.1
-/-
 skeletal muscles were compared (Fig. 35A). This analysis revealed that 429 
DEGs were shared/observed in all analyzed genotypes from E14.5 to E18.5, 169 DEGs were 
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matching in the development of WT and RYR1
-/-
 skeletal muscle, 164 DEGs – in the development of 
WT and Cav1.1 skeletal muscle, and 100 DEGs – in the development of RYR1
-/-
 and Cav1.1
-/-
 
skeletal muscle. Additionally, 483 DEGs were exclusively found in WT; 91 DEGs – only in RYR1-/-; 
and 171 DEGs – only in Cav1.1
-/-
 skeletal muscle in the comparison of E18.5 vs. E14.5. 
 
Fig. 35: DEGs specific for the E18.5 vs. E14.5 analyses of WT, RYR1
-/-
 or Cav1.1
-/-
 skeletal muscle. 
(A) A Venn diagram, showing the number of DEGs identified in the MA analyses at E18.5 compared to E14.5 in WT, 
RYR1
-/-
 and Cav1.1
-/-
 limb skeletal muscle. Numbers in the overlapping and non-overlapping areas represent the amount 
of shared and not shared DEGs between genotypes, respectively. Wiki Pathways enrichment analyses of the DEGs found 
exclusively in (B) WT (483 DEGs); (C) RYR1
-/-
 (91 DEGs); and (D) Cav1.1
-/-
 (171 DEGs) from E14.5 (control) to E18.5, 
respectively. The ten most significantly enriched categories for each analysis are shown. Enrichment analyses (B – D) 
were performed via the Enrichr online tool (Chen et al., 2013), Modified from (Filipova et al., 2018). 
WP enrichment analyses were performed with the specific DEGs in each genotype (Fig. 35B-D) to 
evaluate which signaling pathways were specifically affected in the development of the skeletal 
muscles of each genotype. The most significant WP pathway identified from the WT-specific DEGs 
was “miRs in muscle cell differentiation” (Fig. 35B). Two other miRNA-related pathways – 
“miR-517 relationship with ARN1 and USP1” and “SRF and miR in smooth muscle differentiation 
and proliferation” – were also among the most significantly regulated WT development-specific 
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pathways. Additionally, pathways related to metabolism, like the “TCA cycle”, as well as to cell 
cycle and signal transduction like “G1 to S cell cycle control”, “DNA replication” were also 
significantly affected WP categories by the WT-specific DEGs. Analyzing the RYR1
-/-
-specific 
DEGs, the WP enrichment analysis identified “Endochondral ossification”, “BMP signaling and 
regulation”, “Focal adhesion” and “Adipogenesis” as very significantly affected pathways (Fig. 35C). 
In Cav1.1
-/-
 pathways related to adipogenesis and lipid metabolism, such as “Adipogenesis”, 
“Triglyceride synthesis” and “Fatty acid and beta oxidation” were most significantly affected. 
In order to analyze in greater detail which biological processes and cellular structures were affected 
differently throughout the E14.5 to E18.5 skeletal muscle development, the genotype-specific DEGs 
found in the E18.5 vs. E14.5 analyses (Fig. 35A) were subjected to GO BP and GO CC enrichment 
analyses (Fig. 36). 
In WT-specific DEGs, the results of the GO BP analyses were similar to those of the WP analyses, 
identifying “Positive regulation of rRNA processing” and several muscle- and cell cycle-related 
processes as highly enriched (Fig. 36A). The RYR1
-/-
-specific DEGs showed a high enrichment for 
“Chondrocyte differentiation”, and several other developmental processes (Fig. 36C). The Cav1.1
-/-
-specific DEGs exhibited a very specific enrichment in “Acylglycerol acyl chain remodeling” and 
other lipid and fatty acid metabolic processes (Fig. 36E).  
The GO CC enrichment analysis indicated specific changes in the “Sarcolemma” and other muscle-
specific structures like “Costamere”, “Sarcomere”, “I-band”, and “Z-disc” in the WT-specific DEGs 
analysis (Fig. 36B). The structures “Postsynaptic membrane”, “Acetylcholine gated channel 
complex” and “Voltage-gated Ca2+ channel complex” were most significantly enriched with the 
RYR1
-/-
-specific DEGs (Fig. 36D). The structures and cellular components most enriched with 
Cav1.1
-/-
-specific DEGs were “Proteinaceous extracellular matrix”, “Integral component of nuclear 
inner membrane” and “Integral component of plasma membrane” (Fig. 36F). 
These results indicate that the RYR1
-/-
 and Cav1.1
-/-
 skeletal muscle only partially recapitulates the 
physiological transcriptomic changes characteristic for the WT fetal development and the secondary 
myogenesis from E14.5 to E18.5. Additionally, both mutants exhibited distinct changes perturbing 
signaling pathways, biological processes and cellular components that were not affected in the 
development of the WT skeletal muscle. Specifically, the RYR1
-/-
 limb skeletal muscle development 
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was characterized by a dysregulation of processes and structures related to the muscle-bone and 
muscle-ECM interaction network.  
 
Fig. 36: GO BP and GO CC enrichment analyses of the E18.5 vs. E14.4 specific DEGs. 
GO BP (A, C, E) and GO CC (B, D, F) enrichment analyses of the DEGs found exclusively in WT (483 DEGs, blue 
charts), RYR1
-/-
 (91 DEGs, yellow charts) and Cav1.1
-/-
 (171 DEGs, red charts) from E14.5 (control) to E18.5, 
respectively (see Fig. 35). The ten most significantly enriched categories for each analysis are shown. Enrichment 
analyses (A–F) were performed via the Enrichr online tool (Chen et al., 2013), length of the bars is proportional to the 
significance (P-value). Modified from (Filipova et al., 2018). 
The development of the Cav1.1
-/-
 limb skeletal muscle was displayed by dysregulation in 
adipogenesis and lipid metabolism. Thus, these data suggest that not only ECC but also additional 
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specific functions exerted by RYR1 and Cav1.1 play distinct roles during limb skeletal muscle 
development. 
3.2.3.8 Differential miRNA expression profiles during limb secondary myogenesis 
The WP enrichment analysis of the WT skeletal muscle development-specific DEGs (Fig. 35B) 
identified several pathways connected to miRNA regulation of different processes, the most 
significant of which was “Mirs in Muscle Cell Differentiation Homo sapiens”. These results implied 
that multiple miRNAs and miRNA-related pathways are impacted by the absence of RYR1 or Cav1.1 
during fetal development and secondary myogenesis. An in-depth analysis of the “Mirs in Muscle 
Cell Differentiation Homo sapiens” WP category revealed that 10 DEGs participating in this pathway 
were identified in WT skeletal muscle development between E14.5 and E18.5 and only three of them 
were found in the development of RYR1
-/-
 or Cav1.1
-/-
 limb skeletal muscle (Fig. 37A). Several of the 
WT-specific DEGs from this pathway encode regulators of the expression and activity of the 
canonical myogenic regulatory factors (MRFs) Pax7, Myf5 and MyoD; as well as the muscle-specific 
miRNAs (MyoMirs) Mir206 and Mir133a-2 implicated in skeletal muscle differentiation and 
development (Chen et al., 2006; Luo et al., 2013).  
miRNAs are potent and versatile regulators of a wide range of processes, including muscle 
development (Luo et al., 2013). In order to better understand and describe the expression changes in 
miRNA genes accompanying secondary myogenesis, the expression levels changes of all miRNAs 
detected in the MAs were analyzed. More precisely, the miRNAs detected as DEGs in the E18.5 vs. 
E14.5 analyses in the WT, RYR1
-/-
 and Cav1.1
-/-
 skeletal muscles were closely examined (Fig. 37B, 
Table 16). From E14.5 to E18.5 61 miRNAs were differentially regulated in the WT samples, 16 of 
which were also found in the Cav1.1
-/-
 samples and only 3 – in the RYR1-/- samples. Additionally, 1 
miRNA was differentially regulated only in the RYR1
-/-
 samples and 4 – only in the Cav1.1
-/-
 
samples. A hierarchical clustering analysis of all samples from the MAs based on their miRNA 
expression profiles revealed that all E18.5 WT samples were clustered together, whereas only a 
partial clustering was observed for the E18.5 RYR1
-/-
 and Cav1.1
-/-
 samples on one side, and for all 
E14.5 samples – on the other. However, one E18.5 RYR1-/- was clustered closer to the E14.5 samples 
than to the other E18.5 samples. Out of the 61 miRNAs detected in the WT E18.5 vs. E14.5 analysis, 
only 5 were downregulated, and the rest were upregulated, indicating a growing importance for the 
miRNA-mediated regulation for the secondary myogenesis. The RYR1
-/-
 and Cav1.1
-/-
 samples 
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exhibited a similar tendency of miRNA expression changes. However, the majority of these changes 
were not found to be significant by the MAs. Six of the canonical MyoMirs, Mir206, Mir133b, 
Mir133a-2, Mir1a-2, Mir133a-1 and Mir1a-1, were found to be upregulated in the WT samples from 
E14.5 to E18.5. Additionally, another 22 miRNAs differentially regulated in the E18.5 vs. E14.5 WT 
samples were related to muscle development or different myopathies (Table 16). ). Interestingly, 32 
(i.e., 52% of all) of the identified miRNAs which were upregulated in E18.5 relative to E14.5 in WT, 
which have been found by others to be downregulated in ageing skeletal muscle [37]. This suggests 
that these miRNAs might have important roles during skeletal muscle development and during 
subsequent adaptation or alteration. Moreover, 26 (43% of all) of the identified miRNAs originate 
from a miRNA cluster located within the imprinted Dlk-Dio3 genomic region on chromosome 12. 
This region might be of eminent importance for skeletal muscle development. 
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Fig. 37: Differentially expressed miRNAs during WT skeletal muscle development. 
 (A) Up (orange) and down (blue) regulated DEGs identified by the MAs for E18.5 vs. E14.5 (control) taking part in the 
Wiki pathway “Mirs in Muscle Cell Differentiation Homo sapiens” (see Fig. 35B). DEGs regulated only in WT samples 
from E14.5 to E18.5 are shown in bold. (B) A heatmap of all miRNAs, found to be differentially regulated at E18.5 
compared to E14.5 in WT samples. Each row represents one biological replicate. miRNAs, found to be differentially 
regulated from E14.5 to E18.5 also in RYR1
-/-
 samples, are underlined in yellow, and in the Cav1.1
-/-
 samples – in red. 
The heatmap was generated from the MAs intensity levels of each of the Mir genes via ClustVis (Metsalu & Vilo, 2015). 
Modified from (Filipova et al., 2018). 
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Table 16. miRNAs differentially regulated from E14.5 to E18.5 in WT, RYR1
-/-
 and Cav1.1
-/-
. 
Description 
Gene 
Symbol 
FC E18.5 vs. E14.5 
Muscle-related 
functions 
Reference 
 
 WT RYR1
-/-
 Cav1.1
-/-
 
 
Downregulated miRNAs 
microRNA 1949 Mir1949 -3.25 - - 
  
insulin-like growth 
factor 2 mRNA 
binding protein 1; 
microRNA 3063 
Igf2bp1 -3.23 -3 -2.43 
  
protein disulfide 
isomerase 
associated 4; 
microRNA 704 
Pdia4 -2.59 - - 
  
microRNA 218-1 Mir218-1 -2.58 - - 
involved in muscle-
bone communication 
and Wnt signaling 
(Qin et al., 
2017) 
RIKEN cDNA 
5730408K05 gene; 
microRNA 5136 
5730408K05
Rik 
-2.1 - - 
  
Upregulated miRNAs 
MyoMirs 
microRNA 206 Mir206 2.08 - - 
promotes myoblast 
entry into terminal 
differentiation 
(Luo et al., 
2013) 
microRNA 133b Mir133b 2.73 - 2.12 
enhances myoblast 
proliferation 
(Chen et al., 
2006) 
microRNA 133a-2 Mir133a-2 3.69 - - 
enhances myoblast 
proliferation 
(Chen et al., 
2006) 
microRNA 1a-2 Mir1a-2 4.01 - - 
positive role in muscle 
development 
(Luo et al., 
2013) 
microRNA 133a-1 Mir133a-1 5.36 - 2.83 
enhances myoblast 
proliferation 
(Chen et al., 
2006) 
microRNA 1a-1 Mir1a-1 6.29 - 2.32 
positive roles in 
muscle development 
(Luo et al., 
2013) 
miRNAs encoded in the Dlk-Dio3 genomic region 
microRNA 323 Mir323 2.22 - - 
  
microRNA 668 Mir668 2.32 - - 
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Description 
Gene 
Symbol 
FC E18.5 vs. E14.5 
Muscle-related 
functions 
Reference 
 
 WT RYR1
-/-
 Cav1.1
-/-
 
 
microRNA 134; 
miRNA 
containing gene 
Mir134 2.35 - - 
possibly targets Pax7 
and Myf5 
(Lamon et 
al., 2017) 
microRNA 485; 
miRNA 
containing gene 
Mir485 2.4 - - 
  
microRNA 494 Mir494 2.42 - - 
  
microRNA 673 Mir673 2.48 - 2.24 
  
microRNA 544 Mir544 2.5 - - 
  
microRNA 382 Mir382 2.53 - - 
increased in Becker 
muscular dystrophy 
(Fiorillo et 
al., 2015) 
microRNA 666 Mir666 2.55 - - 
  
microRNA 539 Mir539 2.58 - - dysregulated in DMD 
dogs 
(Jeanson-
Leh et al., 
2014) 
microRNA 541 Mir541 2.71 - - 
  
microRNA 381 Mir381 2.9 - - 
implicated in muscle 
differentiation 
(Forterre et 
al., 2014) 
microRNA 487b Mir487b 2.98 - - 
delays myogenic 
differentiation in 
C2C12 
(Katase, 
Terada, 
Suzuki, 
Nishimatsu, 
& Nohno, 
2015) 
microRNA 431 Mir431 2.98 - 2 
promotes 
differentiation and 
regeneration of old 
skeletal muscle 
(Wu et al., 
2015) 
miRNA 
containing gene; 
microRNA 410; 
microRNA 412; 
microRNA 369 
Mirg 3 - - 
  
microRNA 409 Mir409 3.17 - - 
upregulated in 
nemaline myopathy 
(Eisenberg 
et al., 2007) 
microRNA 495 Mir495 3.5 
 
2.4 
  
microRNA 496a Mir496a 3.51 - - 
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Description 
Gene 
Symbol 
FC E18.5 vs. E14.5 
Muscle-related 
functions 
Reference 
 
 WT RYR1
-/-
 Cav1.1
-/-
 
 
microRNA 379 Mir379 3.8 - 2.28 
  
microRNA 411 Mir411 3.8 - 2.64 
involved in myogenic 
proliferation in 
FSHD and 
rhabdomyosarcoma 
(Harafuji, 
Schneiderat
, Walter, & 
Chen, 2013; 
Sun et al., 
2015) 
microRNA 341 Mir341 2.15 - - 
  
microRNA 380 Mir380 2.57 - - 
  
microRNA 654 Mir654 2.85 - - 
  
microRNA 154 Mir154 3.2 - - 
downregulated by 
TNF-α in skeletal 
muscle differentiation 
(Meyer et 
al., 2015) 
microRNA 376c Mir376c 3.35 - 3.34 
  
microRNA 376b Mir376b 3.69 - - 
a role in 
cardioprotection 
(Pan et al., 
2012) 
Other miRNAs implicated in skeletal muscle development 
RIKEN cDNA 
6430411K18 gen; 
microRNA 127; 
microRNA 433 
6430411K18
Rik 
2.78 - - 
enhances myogenic 
cell differentiation 
(Zhai, Wu, 
Han, 
Zhang, & 
Zhu, 2017) 
microRNA 376a Mir376a 2.81 - - 
involved in skeletal 
muscle development 
(McDaneld 
et al., 2009) 
microRNA 665 Mir665 2.92 
 
2.04 
associated in 
secondary 
myogenesis in pigs 
(Verardo et 
al., 2013) 
microRNA 136 Mir136 3.41 - - 
downregulated in 
mouse skeletal 
muscle after birth 
(Lamon et 
al., 2017) 
microRNA 434 Mir434 3.55 - - 
influences AChR 
expression in rat 
hind limb 
(Shang et 
al., 2016) 
microRNA 540 Mir540 3.56 - 2.05 induces hypertrophy 
in C2C12 
(Hitachi & 
Tsuchida, 
2017) 
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Description 
Gene 
Symbol 
FC E18.5 vs. E14.5 
Muscle-related 
functions 
Reference 
 
 WT RYR1
-/-
 Cav1.1
-/-
 
 
microRNA 432 Mir432 2.04 - - 
regulates myoblast 
proliferation and 
differentiation 
(Ren, Liu, 
Zhao, & 
Cao, 2016) 
microRNA 365-2 Mir365-2 2.04 - - 
putative inhibition of 
myogenic 
differentiation in 
C2C12 
(Sun et al., 
2011) 
microRNA 145a Mir145a 2.1 - - 
promotes myoblast 
differentiation 
(Du et al., 
2016) 
microRNA 22; 
Mir22 host gene 
(non-protein 
coding); TLC 
domain containing 
2 
Mir22 2.24 - - 
up-regulated during 
myocyte 
differentiation 
(Huang et 
al., 2013) 
microRNA 5123 Mir5123 2.29 - - 
upregulated in ageing 
muscle 
(Soriano-
Arroquia, 
House, 
Tregilgas, 
Canty-Laird, 
& Goljanek-
Whysall, 
2016) 
miRNAs not yet described in skeletal muscle development 
microRNA 1193 Mir1193 2.01 - - 
  
microRNA 329 Mir329 2.15 - - 
  
microRNA 1188 Mir1188 2.16 - - 
  
microRNA 543 Mir543 2.43 - - 
 
 
retrotransposon-
like 1; microRNA 
3071 
Rtl1 3.54 - - 
  
microRNA 337 Mir337 5.61 - 3.06 
  
microRNA 882 Mir882 2.01 - - 
  
microRNA 3070b Mir3070b 2.81 - 2.01 
  
microRNA 3070a Mir3070a 2.83 - - 
  
microRNA 370 Mir370 3.02 - - 
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Description 
Gene 
Symbol 
FC E18.5 vs. E14.5 
Muscle-related 
functions 
Reference 
 
 WT RYR1
-/-
 Cav1.1
-/-
 
 
microRNA 493 Mir493 3.76 - 2.52 
  
microRNA 568; 
zinc finger and 
BTB domain 
containing 20 
Mir568 4.41 2.65 - 
  
phosphodiesterase 
4D interacting 
protein 
(myomegalin); 
microRNA 7225 
Pde4dip 4.49 4.1 3.79 
  
miRNAs found exclusively in RYR1
-/-
 skeletal muscle development (E18.5 vs. E14.5) 
microRNA 125b-1 Mir125b-1 - -2.11 - 
represses myocyte 
differentiation 
(Ge, Sun, & 
Chen, 2011) 
miRNAs found exclusively in Cav1.1
-/-
 skeletal muscle development (E18.5 vs. E14.5) 
microRNA 205; 
RIKEN cDNA 
4631405K08 gene 
Mir205 - - -2.38 
  
microRNA 669d Mir669d - - -2.07 
  
glutamate-
ammonia ligase 
(glutamine 
synthetase); 
microRNA 8114 
Glul - - 2.14 
  
microRNA 130a Mir130a - - 2.28 
  
miRNAs reported as downregulated in ageing skeletal muscle are written in bold text (Lee et al., 2015b). The FCs of 
miRNAs not detected as differentially regulated in some of the conditions are marked as “-”. Modified from (Filipova et 
al., 2018). 
3.2.4 Minor MRFs expression changes in RYR1-/- and Cav1.1
-/-
 at E14.5 and 
E18.5. 
Next, putative changes in the expression levels of the canonical MRFs – genes Six1, Six4, Pax3, 
Pax7, Myf5, MyoD, MyoG and Mrf4 – in the samples from RYR1-/- and Cav1.1
-/-
 skeletal muscle at 
E14.5 and E18.5 were examined via qRT-PCRs and compared to WT (Fig. 38). At E14.5 a slight 
decrease in the expression of Six1 (0.7-fold of WT) was observed in the RYR1
-/-
 samples and of Mrf4 
(0.33-fold of WT) – in the Cav1.1
-/-
 samples. Pax3 exhibited a tendency towards downregulation in 
the RYR1
-/-
 samples, which was insignificant at E14.5 and gained significance at E18.5. The 
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expression levels of none of the other MRFs were changed in both mutants at both E14.5 and E18.5. 
These discrepancies with the previous results showing an upregulation in almost all MRFs in E18.5 
RYR1
-/-
 vs. WT (Fig. 21B) might be caused by the different endogenous controls used for both 
analyses – Gapdh and CytB. Since the CytB gene was found to have a more stable expression across 
the examined genotypes and developmental stages (Fig. 29) the present data probably reflects more 
accurately the changes observed in the MRFs expression. 
 
Fig. 38: MRFs expression in limb skeletal muscle from WT, RYR1
-/-
 and Cav1.1
-/-
 mice at E14.5 and at E18.5. 
Relative expression levels of Six1, Six4, Pax3, Pax7, Myf5, MyoD, MyoG and Mrf4 in WT, RYR1
-/-
 and Cav1.1
-/-
 samples 
(each n = 6) at E14.5 (upper part) and E18.5 (lower part) were obtained by qRT-PCR analyses using Cytb as endogenous 
control. Expression levels of WT samples were set to 1. One-way ANOVA with Bonferroni’s Multiple Comparison tests 
were performed for each gene, *represents a P-value ≤ 0.05. Error bars are S.E.M. Modified from (Filipova et al., 2018). 
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3.2.5 Attenuated Cav1.1 isoform-switch at E14.5 and lower Cav1.1 mRNA levels 
at E18.5 in RYR1
-/-
 limb skeletal muscle 
It has been previously shown that a Cav1.1 splice variant missing exon 29 (Cav1.1 Δ29) is highly 
expressed during embryonic skeletal muscle development and that its expression is gradually 
attenuated with the myogenic progression, being only weakly expressed at birth and ultimately lost 
until the third week of postnatal development (Flucher & Tuluc, 2011; Tuluc et al., 2009). Unlike the 
full length Cav1.1 that has poor Ca
2+
 conducting properties and predominates in fully differentiated 
skeletal muscles, the Δ29 Cav1.1 conducts strong Ca
2+
 currents and has putative roles in the 
development of the neuromuscular junctions (Flucher & Tuluc, 2011). Thus, changes in the ratio 
between Δ29 and full length Cav1.1 might be a factor affecting skeletal muscle development. 
To analyze whether this ratio is changed in the samples from RYR1
-/-
 skeletal muscle the region 
between exons e28 and e32 of the Cav1.1 mRNA was analyzed via PCRs (Fig. 39A-C). Total mRNA 
from the limb skeletal muscle of 6 WT and 6 RYR1
-/-
 fetuses at E14.5 and E18.5 was subjected to 
reverse transcription and the resulting cDNA was used as template in the PCR reactions. The 
amplification products of the full length Cav1.1 and the Cav1.1 Δ29 mRNAs were 343 bp and 286 bp, 
respectively. The PCR products were visualized on 2% agarose gels, the intensities of the bands in 
each sample were measured and used for calculation of the relative amount of each splice variant as a 
percentage of the total Cav1.1 transcript (Fig. 39C). At E14.5, each splice variant (full length and 
Δ29) accounted for approximately 50% of the total Cav1.1 mRNA in WT samples. However, in 
RYR1
-/-
 samples the amount of the Cav1.1 Δ29 (70% of the total Cav1.1) was significantly higher that 
this of the full length Cav1.1 (30% of the total Cav1.1). At E18.5 both WT and RYR1
-/-
 sample 
groups exhibited higher transcript levels for the full length Cav1.1 (77% in WT and 69% in RYR1
-/-
). 
The relative Cav1.1 expression levels were examined in the RYR1
-/-
 vs. WT samples at E14.5 and 
E18.5 via qRT-PCRs (Fig. 39D). While at E14.5 there was no significant differences in the 
expression of Cav1.1 in the WT and RYR1
-/-
 samples, at E18.5 the RYR1
-/-
 samples exhibited 
approximately 2-fold lower Cav1.1 transcript levels than in WT. These results are in agreement with 
previous studies demonstrating a 2-fold reduced Cav1.1 protein expression, as well as a strong 
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decrease of L-type Ca
2+
 current density and charge movements in skeletal muscle from RYR1
-/-
 
neonates (Avila, O'Connell, Groom, & Dirksen, 2001; Buck et al., 1997; Nakai et al., 1996). 
Thus, the increased Cav1.1 Δ29 to full length Cav1.1 at E14.5 and the decreased total Cav1.1 
expression in the RYR1
-/-
 samples may be indicative of an impaired skeletal muscle development. 
These results also infer possible defects in proper neuromuscular junction formation that might have 
various downstream effects on the myogenic program. 
 
 
Fig. 39: Cav1.1 splice variants in WT and RYR1
-/-
 skeletal muscle. 
 (A) Graphical representation of the genomic exon 29 vicinity of murine full length and Δ29 Cav1.1 (NCBI Reference 
Sequence: NM_001081023.1) splice variants. Arrows indicate the primer binding positions used for amplification of 
exons 28-32. (B) PCR products of the full length (343 bp) and Δ29 (286 bp) Cav1.1 splice variants from 6 WT and 6 
RYR1
-/-
 at each time point (E14.5 and E18.5, n = 6). (C) Full length (343 bp) and Δ29 (286 bp) splice variants as 
percentage of total Cav1.1 mRNA in limb skeletal muscle from WT and RYR1
-/-
 animals at E14.5 and E18.5. (D) Relative 
expression of total Cav1.1 mRNA measured via qRT-PCR in RYR1
-/-
 vs. WT skeletal muscle at E14.5 and E18.5, using 
Cytb as endogenous control. T-tests were performed for comparison of Δ29 vs. full length splice variants (C) and for WT 
vs. RYR1
-/-
 (D) in each group; * indicates P-values ˂ 0.05 and *** P-values ˂  0.001; error bars are S.E.M. Modified from 
(Filipova et al., 2018). 
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4 Discussion 
In the present work I examined how the absence of each of the two Ca
2+
 channels necessary for 
muscle contraction, RYR1 and Cav1.1, will affect structure and gene expression of developing limb 
skeletal muscle on a global scale. In situ, the term skeletal muscle comprises diverse tissues and cell 
types, the majority of which is devoted to the muscle lineage at different stages of differentiation. 
Even though myofibers make up most of the mass of the skeletal muscle organ, it also contains 
fibroblasts, neurons, blood vessels and connective tissue. All of these contribute to muscle organ 
development, structure and functions. Therefore, it is not only unavoidable, but also desirable to have 
their transcriptomic impact integrated in the present analysis. This analysis yielded valuable in-depth 
information about biological processes, signaling pathways and cellular structures that dependent on 
the presence or on the proper functioning of the two critical components of the ECC machinery, 
RYR1 and Cav1.1, throughout skeletal muscle development. 
The first part of this work demonstrated that loss of the type 1 ryanodine receptor (RYR1) – the SR 
Ca
2+
 release unit in ECC – has detrimental effects on skeletal muscle structure at the end of fetal 
development and of secondary myogenesis – at E18.5 (Filipova et al., 2016). Moreover, RYR1’s 
absence altered the global transcriptomic profile of E18.5 limb skeletal muscle, resulting in over 300 
differentially expressed genes (DEGs) identified in a microarray (MA) analysis. Enrichment analysis 
of these DEGs pointed to their involvement in skeletal muscle’s structure and central signaling 
pathways. Furthermore, the expression of six major myogenic regulatory factors (MRFs) – Six1, 
Six4, Pax7, MyoD, MyoG and Mrf4 – was upregulated, although these results were not reproduced in 
my succeeding study, using Cytb as a reference gene. Thus, RYR1-deficient skeletal muscle is 
characterized by a distinct transcriptomic signature at E18.5. 
The second part of this work compared the structural and transcriptomic alterations caused either by 
the loss of RYR1 or that of its upstream activator during ECC – Cav1.1 (Filipova et al., 2018). An 
analysis of WT (
+/+
), heterozygous (
+/-
) and homozygous (
-/-
) RYR1 and Cav1.1 fetuses at E14.5 
revealed that their absence of either Ca
2+
 channel leads to structural and transcriptomic changes 
already at the end of primary and the beginning of secondary myogenesis. Interestingly, at E14.5 
around twice as many DEGs were found in Cav1.1
-/-
 compared to RYR1
-/-
 samples and completely 
different sets of genes and biological processes were dysregulated in the two mutants (Table 15, Fig. 
31). Much more pronounced structural alterations were observed in the RYR1
-/-
 and Cav1.1
-/-
 skeletal 
Discussion 
114 
 
muscles at E18.5. At this stage an 8- to 10-fold increase in the total number of DEGs for both 
mutants was observed, while the number of DEGs remained 2 times higher in Cav1.1
-/-
 than in 
RYR1
-/-
 muscles (Table 15). Moreover, a significant overlap of the differentially regulated gene sets 
and processes was observed for both mutants (Fig. 32), although some genotype-specific patterns of 
regulation were still detected (Fig. 33). Furthermore, the overall transcriptome dynamics between the 
beginning (E14.5) and the end (E18.5) of secondary myogenesis significantly differed in RYR1
-/-
 and 
Cav1.1
-/-
 in comparison to WT skeletal muscle (Fig. 35). This analysis showed that both mutants 
failed to regulate multiple genes connected to muscle differentiation, structure and signaling. 
Enrichment analyses of the respective DEGs hinted at altered metabolism, focal adhesion and 
formation of the musculoskeletal system. Moreover, expression changes of a large set of microRNAs 
(miRNAs) were observed from E14.5 to E18.5 only in WT, but neither in RYR1
-/-
, nor in Cav1.1
-/-
 
skeletal muscle. Finally, this thesis demonstrates that these two Ca
2+
 channels exert modulatory 
effects on one another showing that the absence of RYR1 alters the ratio of Cav1.1 mRNA splice 
variants at E14.5, and their total content at E18.5 (Fig. 39). Taken together, these results reveal that 
RYR1 and Cav1.1 play complex and in part also divergent roles during secondary skeletal 
myogenesis.  
The impact of RYR1 and Cav1.1 absence on different aspects of skeletal muscle development are 
discussed in detail below. Full lists of all DEGs from both gene profiling experiments are available as 
a “Supplementary Table 1” in the respective publications (Filipova et al., 2016) and (Filipova et al., 
2018). 
4.1 Divergent effects of the absence of RYR1 and Cav1.1 in the 
beginning of secondary myogenesis 
At E14.5 – the stage of transition from embryonic to fetal development, as well as from primary to 
secondary myogenesis, the limb skeletal muscle of RYR1
-/-
 and Cav1.1
-/-
 mice already displayed 
initial structural abnormalities (Fig. 23). Specifically, both mutants exhibited an impaired fascicle 
organization, as well as smaller, unaligned fibers. Interestingly, active apoptosis at this stage was 
detected only in the Cav1.1
-/-
 skeletal muscle (Fig. 23O). These findings are contrary to earlier 
observations that necrosis and not apoptosis was responsible for the cell death of extraocular muscles 
of Cav1.1
-/-
 mice at E16.5 (Heimann, Kuschel, & Jockusch, 2004). However, the authors of this study 
did not report any cell death at E14.5, which might be due to differences in the experimental design 
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or between extraocular and limb muscles (Sekulic-Jablanovic, Palmowski-Wolfe, Zorzato, & Treves, 
2015). Histology of developmentally paralyzed muscle suggests a high degree of fiber degeneration 
(Gonzalez de Aguilar et al., 2008). Apoptosis is a common, stringently controlled event during 
normal skeletal muscle development but it also occurs in response to a large variety of factors such as 
muscle loading or disuse, denervation and ER stress (Nakanishi, Sudo, & Morishima, 2005; 
Schwartz, 2008). Therefore, the signaling alterations caused by the ablation of ECC-mediated Ca
2+
 
release at the onset of muscle contraction, E14.5, probably affect the apoptosis rate in Cav1.1
-/-
 
skeletal muscle, thus introducing changes in the equilibrium between cellular differentiation, 
degeneration and regeneration. The observed apoptosis in the present work might be caused by 
altered signaling due to the lack of Ca
2+
 entry through Cav1.1 that is not necessary for ECC but which 
has been implicated in CamKII activation and downstream signaling pathways like MAPK and 
PI3K/Akt/mTOR (Lee et al., 2015a). This notion is supported by a report that the downregulation of 
Cav1.1 from regions on the sarcolemma, different than the T-tubules, that does not impair ECC, leads 
to skeletal muscle atrophy (Pietri-Rouxel et al., 2010). In addition, at rest Cav1.1 seems to have a 
stabilizing effect on RYR1, preventing or minimizing passive Ca
2+
 leak from the SR: Eltit et al. 
reported higher basal intracellular Ca
2+
 concentrations, [Ca
2+
]i, in Cav1.1
-/-
 cultured myotubes as 
compared to WT myotubes (Eltit et al., 2011). Hence, a higher [Ca
2+
]i could be a contributing factor 
to the apoptosis observed in Cav1.1
-/-
 skeletal muscle. 
At E14.5 less than 100 DEGs were detected in the RYR1
-/-
 and Cav1.1
-/-
 skeletal muscles compared 
to WT littermates (Table 15). The modesty of these transcriptomic changes was confirmed by a 
principal component analysis (PCA), which did not display a significant variance between the global 
transcriptomic profiles of WTs, homozygous and heterozygous mutants at this stage. Nevertheless, 
the identified DEGs indicate that RYR1 and Cav1.1 have important developmental functions already 
at the beginning of secondary myogenesis. Interestingly, only two DEGs were found both in RYR1
-/-
 
and Cav1.1
-/-
 vs. WT, suggesting that the absence of each Ca
2+
 channel has distinct effects during 
early myogenesis at the mRNA level, although the changes in muscle structure observed in both 
mutants were not very different at this stage. These findings were reflected by the completely 
different sets of biological processes, identified as significantly affected by the DEGs in each mutant 
by the Gene Ontology (GO) enrichment analyses (Fig. 31). E14.5 is the stage at which the first limb 
muscle contractions take place (Kodama & Sekiguchi, 1984). Thus, although the primary roles of 
RYR1 and Cav1.1 are related to ECC, the different transcriptomic changes in both mutants at this 
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early stage imply additional, non-contractile functions of each channel during the myogenic process. 
The absence of RYR1 seems to negatively regulate multiple processes connected to neurogenesis 
(Fig. 31A, C). This indicates a possible impairment of proper muscle innervation and of the 
communication between nerves and skeletal muscle. In Cav1.1
-/-
 samples from the same 
developmental stage, however, a clear downregulation of processes related to muscle contraction had 
already started (Fig. 31B, D). A possible explanation for these differences between RYR1
-/-
 and 
Cav1.1
-/-
 samples might be that the absence of Cav1.1 alters Ca
2+
 release from the SR not only 
through RYR1, but also through the inositol 1,4,5-triphosphate receptor (IP3R). IP3Rs are relatively 
abundant in non-differentiated muscle fibers (see below), co-reside with RYR1s on the SR membrane 
and, unlike the fast Ca
2+
 release kinetics of RYR1 in ECC, mediate a so called “slow” Ca2+ release, 
generating cytosolic Ca
2+
 transients that can last tens of seconds but do not trigger muscle contraction 
(Powell et al., 2001). Rather, the IP3R-mediated slow Ca
2+
 release has been implicated in regulation 
of gene expression and different signaling pathways related to myogenesis (Carrasco et al., 2003; 
Juretic et al., 2007). Cav1.1 is expressed prior to RYR1 in cell culture (Kyselovic, Leddy, Ray, 
Wigle, & Tuana, 1994) and can activate phospholipase C (PLC), which triggers Ca
2+
 release from the 
SR via IP3Rs (Eltit et al., 2006). Furthermore, IP3R is highly expressed in mice during early 
embryonic development and its expression is reduced towards the late myogenic stages, whereas 
RYR1 expression roughly follows the opposite pattern (Rosemblit et al., 1999). Thus, some of the 
transcriptomic changes observed in Cav1.1
-/-
 muscle could probably be linked to changes in IP3R 
expression and/or activity.  
Another possible reason for the distinct transcriptomic changes in RYR1
-/-
 vs. Cav1.1
-/-
 mutants at 
E14.5 may be ascribed to an altered Ca
2+
 influx from the extracellular space through the embryonic 
Cav1.1 Δ29 splice variant. Cav1.1 Δ29 is highly expressed in early fetal stages and its expression 
dwindles with the progressing muscle development. It has been implicated in acetylcholine receptor 
(AChR) pre-patterning of developing skeletal muscle (Flucher & Tuluc, 2011). At E14.5 a higher 
ratio of Δ29 to full length Cav1.1 mRNA was observed in RYR1
-/- 
compared to WT skeletal muscle, 
which might increase the Cav1.1-mediated Ca
2+
 influx into these muscles upon spontaneous or motor 
neuron-caused depolarization. In contrast, no Cav1.1-mediated Ca
2+
 influx can occur in Cav1.1
-/-
 
muscle, which might also be a reason for the observed genotype-specific expression changes. 
Nevertheless, a recent study of a mouse model expressing exclusively a non-conducting Cav1.1 has 
found no phenotypical, developmental or contractile changes in the skeletal muscle of these animals 
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(Dayal et al., 2017). Thus, the extent to which changes in the Cav1.1-mediated Ca
2+
 influx contribute 
to the transcriptomic changes of RYR1
-/-
 or Cav1.1
-/-
 muscles remains unclear. 
Surprisingly, structural alterations similar to these in Cav1.1
-/-
 and RYR1
-/-
 mice were also observed 
in heterozygous Cav1.1
+/-
 mice (but not in heterozygous RYR1
+/-
 mice) at E14.5 (Fig. 23J, K). This 
was unexpected since these mice have long been regarded to have no phenotype and have been used 
as “normal” controls alongside WTs in many studies (Bannister, Papadopoulos, Haarmann, & Beam, 
2009; Chaudhari & Beam, 1989; Flucher et al., 1993; Herring & Lakars, 1982). These defects partly 
persist at E18.5, observed as an incomplete fascicular organization and higher fiber caliber variability 
in Cav1.1
+/-
 skeletal muscle (Fig. 24J, K). Nevertheless, at E18.5 these muscles are far better 
developed than the ones of homozygous RYR1
-/-
 and Cav1.1
-/-
 mutants and an insignificant number 
of DEGs was detected in Cav1.1
+/-
 vs. WT samples at both E14.5 and E18.5. Postnatally Cav1.1
+/-
 
mice develop normally and do not seem to be impacted by the presence of only a single functional 
copy of the Cacna1s gene (encoding Cav1.1) with regard to activity, fertility or lifespan. One study, 
however, describes an impairment of mandible development in Cav1.1
+/-
 mice (Atchley, Herring, 
Riska, & Plummer, 1984). This, together with the severe bone phenotype observed in Cav1.1
-/-
 mice 
at E18.5, suggests that besides triggering ECC, Cav1.1 might also be implicated in bone 
development. Thus, it seems that the correct gene dosage of Cacna1s could play a wider role during 
early fetal development. It is possible that reduced levels of the embryonic splice variant Cav1.1 Δ29 
in Cav1.1
+/-
 mice could be a factor in the formation of this phenotype. 
4.2 The effects of the absence of RYR1 and Cav1.1 converge towards 
the end of secondary myogenesis 
In accordance with the original characterization of RYR1
-/-
 and Cav1.1
-/-
 neonates (Buck et al., 1997; 
Pai, 1965a), this study also reports severe morphological aberrations in both mutants at E18.5, a stage 
marking the end of fetal development, shortly prior to birth (E19 – E20.5) (Figs. 13 and R22). 
Histological analysis of the hind limb reveal a terminal prenatal muscle differentiation in WT and 
RYR1
+/-
 mice (and partially also in Cav1.1
+/-
 mice, as discussed above), exhibiting a predominance of 
differentiated myofibers, organized into fascicles (Figs. 14A and 24A,B,D,E). In contrast, limb 
skeletal muscle of RYR1
-/-
 and Cav1.1
-/-
 mice are represented with features of degeneration and / or 
impaired development – mainly myotubes were detected and only a few small, unorganized fibers 
could be seen (Figs. 14B and 24G, H, M, N). Furthermore, fascicle formation was almost completely 
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absent in both mutants, with the larger volume of extracellular space that might be indicative of 
fibrosis. At E18.5 no activated caspase-3 was present in any of the analyzed mouse muscles 
(Fig. 24C, F, I, L, O). This suggests that the higher apoptosis levels detected in Cav1.1
-/-
 muscles at 
E14.5 had declined until E18.5, probably due to the death of all affected cells at an earlier stage.  
The severe structural abnormalities of RYR1
-/-
 and Cav1.1
-/-
 limb skeletal muscle at E18.5 are 
accompanied by a remarkable increase in the numbers of detected DEGs in both mutants vs. their 
WT littermates (Table 15). This indicates that the majority of changes caused by the absence of each 
of the Ca
2+
 channels occurs during fetal development and thus influences secondary myogenesis. 
Furthermore, unlike the DEGs detected at E14.5, those detected at E18.5 display a significant overlap 
in the two mutants – 66.5% of all RYR1-/- DEGs were equal to 31.3% of all Cav1.1
-/-
 DEGs. These 
similarities are recapitulated in the GO enrichment analyses performed for the affected biological 
processes (BPs) in both mutants, showing that the most significantly affected BPs at the 
transcriptomic level are the same in RYR1
-/-
 and Cav1.1
-/-
 muscle (Fig. 32). Specifically, these are 
processes mainly related to muscle contraction. In addition, global changes are found in diverse 
signaling pathways like MAPK, PI3K/Akt/mTOR, Wnt and peroxisome proliferator-activated 
receptor (PPAR) pathways, as well as cAMP and cGMP-PKG signaling (Suppl. Table 1). The 
observed similarities are probably due to the absence of mechanotransduction signaling, triggered by 
muscle contraction in WT mice, as well as to associated Ca
2+
 signaling changes (discussed below). 
This notion is supported by the fact that spontaneous intrauterine movements in mice begin around 
E14.5 (Kodama & Sekiguchi, 1984). These results demonstrate that the distinct transcriptomic 
changes in E14.5 mouse skeletal muscle lacking RYR1 or Cav1.1 converge at E18.5 (Filipova et al., 
2018). Still, some mutant-specific changes were also observed (Figs. 32 and 33). Furthermore, more 
than twice as many DEGs were found in Cav1.1
-/-
 than in RYR1
-/-
 vs. WT samples (Table 15), 
probably due to an additional impairment of the slow Ca
2+
 release through IP3Rs (as mentioned 
above, 4.1). The most prominent transcriptomic changes at E18.5 in each of the RYR1
-/-
 and Cav1.1
-/-
 
mutants or in both, are discussed below. 
4.2.1 Severe alterations in the structure of E18.5 skeletal muscle in the absence of 
RYR1 and Cav1.1 
The absence of RYR1 and Cav1.1 at E18.5 changes the expression of numerous genes encoding 
intracellular and extracellular structural proteins that participate in the buildup and composition of 
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the skeletal muscle organ. As stated above, the most explicit transcriptomic changes found in both 
mutants affect the muscle’s contractile apparatus. Previous analyses indicated that RYR1-/- skeletal 
muscle expresses major elements of the triadic junction (Buck et al., 1997; Takeshima et al., 1994). 
However, both MA analyses performed on RYR1
-/-
 skeletal muscle at E18.5 reveal 34 DEGs 
involved in the formation, organization, structure and function of the muscle contractile machinery 
(Fig. 33A). Almost all of the 34 genes displayed a lower expression, with the exception of Ednrb, 
Chrna1, Chrng, Mb and Tnnt2. Most of these genes were also differentially expressed in the samples 
from Cav1.1
-/-
 skeletal muscle, displaying a total of 41 downregulated and 3 upregulated (Chrna1, 
Scn7a, Ednrb) contraction-related DEGs (Fig. 33A). Functionally these DEGs encode thick (Myl2, 
Myh13, Myl9, Myh7, Myl6b) and thin (Tpm3, Cnn1, Tnnt2) filament proteins, M-line proteins 
(Myom1, Myom2), Z-disc proteins (Csrp3, Rcsd1, Actn2, Tcap), as well as proteins taking part in the 
structure of costameres (Myof, Ankrd1, Ankrd2, Dmd, Sgca, Myot) and ion channels (Cacna1h, 
Kcne1l, Kcnma1, Ryr1, P2rx6, Cacna1s, Cacng1, Kcnq1, Clcn1 ). Interestingly, the expression of 
some of these genes is already changed at E14.5 in Cav1.1
-/-
 but not in RYR1
-/-
 samples, indicating 
the earlier onset of pathological changes in the muscles of Cav1.1
-/- 
mutants, as discussed above.  
Some of the products of the detected DEGs in RYR1
-/-
 and Cav1.1
-/-
 samples at E18.5 have dual 
functions, like the gene encoding myosin light chain 2 (Myl2), which is an essential component of the 
contraction machinery, as well as a regeneration marker (Sifringer et al., 2004). Regulators of muscle 
contraction like smoothelin-like 1 (Smtnl1), a calmodulin-binding modulator of smooth and skeletal 
muscle contractility (Ulke-Lemee et al., 2014) and calponin 1 (Cnn1), a thin filament-associated 
protein of muscle contraction that binds tropomyosin and calmodulin and inhibits myosin cross-
bridge cycling (Winder et al., 1993), are also downregulated in both RYR1
-/-
 and Ca1.1
-/-
 samples. 
These results exemplify the perturbed synthesis of contractile proteins in the absence of the ECC-
mediating Ca
2+
 channels in limb skeletal muscle. Notably, many of the negatively regulated DEGs 
encode proteins that localize to the Z-discs of sarcomeres or participate in the formation of 
costameres, connecting the sarcomeres to the sarcolemma. In addition to their important function 
related to contraction, these proteins are critical elements of cellular mechanosensing, transmitting 
the signals induced by mechanical loading between the ECM, the sarcolemma and the myofibrils 
(Danowski, Imanaka-Yoshida, Sanger, & Sanger, 1992; Frank et al., 2006). They are also connected 
to signaling cascades contributing to muscle development and hypertrophy like calcineurin/NFAT 
(nuclear factor of activated T cells), MAPK, PI3K/AKT/mTOR and GPCR-mediated signaling 
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(Gehlert et al., 2015; Knoll et al., 2011; Tidball, 2005; Yamada, Verlengia, & Bueno Junior, 2012). 
Moreover, these proteins interact with each other and with the products of other DEGs identified by 
the MAs, such as the a basic helix-loop-helix transcription factor CLOCK (upregulated in RYR1
-/-
), a 
key factor in the circadian regulation of gene expression (Schroder & Esser, 2013) and the histone 
deacetylase HDAC4 (upregulated in RYR1
-/-
 and Cav1.1
-/-
), which modulates the Ca
2+ 
sensitivity of 
certain Z-disc proteins, as well as negatively regulates the myogenic program (Knoll et al., 2011; 
Miska et al., 2001). Thus, the absence of RYR1 and Cav1.1 also strongly impacts on different 
hierarchical levels of muscle cell function, structure and organization.  
The changes in the RYR1
-/-
 and Cav1.1
-/-
 skeletal muscle transcriptomes do not spare the extracellular 
matrix. ECM structure and composition is crucial for proper muscle formation and differentiation 
(Fry, Kirby, Kosmac, McCarthy, & Peterson, 2017; Gillies & Lieber, 2011; Hinds, Bian, Dennis, & 
Bursac, 2011; Yeung et al., 2015; Yi et al., 2017). Both mutants exhibit a dysregulation of multiple 
ECM protein-coding genes. However, the GO BP enrichment analyses identified more significant 
ECM organization-related changes in the RYR1
-/-
 samples (Figs. 32 and 33). In them, the 
downregulation of the Mfap5, Tnxb, Tnc, Fn1, Adamtsl4 and Fbn1 genes, encoding ECM proteins 
involved in microfibrillar assembly and matrix structuring (Bayle et al., 2008; Gabriel et al., 2012; 
Sabatier et al., 2009; Zweers et al., 2004), suggests an impaired elastic fiber formation. This concept 
is supported by the repression of Loxl2 in RYR1
-/-
 muscle, a gene encoding a member of the lysyl 
oxidases family, proteins which bind and crosslink elastin monomers into an insoluble amorphous 
tissue (Xiao & Ge, 2012). Conversely, the expression levels of four collagen species (Col6a5, 
Col19a1, Col20a1, and Col25a1) are upregulated in samples from RYR1
-/-
 and Cav1.1
-/-
 mice. These 
changes may indicate a shift in the ECM composition towards collagen fibers at the expense of 
elastic fibers. However, two other collagen-coding DEGs in RYR1
-/-
 samples, Col2a1 and Col12a1, 
were downregulated. The organization and turnover rate of ECM in skeletal muscle is highly 
regulated by mechanical loading (Kjaer, 2004). Thus, the paralysis of RYR1
-/-
 and Cav1.1
-/-
 skeletal 
muscle is certainly an important factor in the above-mentioned changes and might contribute to the 
observed tissue disorganization (Figs. 14 and 24). Nevertheless, it seems that the absence of RYR1 
induces additional downstream changes influencing the ECM. It is possible that due to its numerous 
interactions with other proteins and molecules, RYR1 represents a hub for communication between 
different signaling pathways, influencing the ECM composition.  
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Interestingly, the development of the skeleton was also challenged in Cav1.1
-/-
 mice. At E18.5 the 
bones of the hind limbs of these mice consisted of hyaline cartilage with no signs of mineralization 
(Fig. 24M, N). Previous studies argue that the absence of contraction in Cav1.1
-/-
 mice affects tendon, 
bone and joint development (Blitz et al., 2009; Huang et al., 2015; Kahn et al., 2009). However, since 
both RYR1
-/-
 and Cav1.1
-/-
 mutants are paralyzed, the defects in Cav1.1
-/-
 bones cannot be caused by 
the mere absence of mechanical loading. One possible explanation could be that the absence of 
Cav1.1 has downstream effects on the expression, activity or targeting of morphogens and signaling 
molecules in skeletal muscle that aid ossification and bone mineralization. This hypothesis is partly 
supported by a study showing that E18.5 Cav1.1
-/-
 mice have an incomplete bone ridge formation due 
to a block of bone morphogenic protein (Bmp4) signaling (Blitz et al., 2009). Indeed, the MAs 
identified Bmp4 as being 1.9-fold downregulated in Cav1.1
-/-
 at E18.5 (S1 Table in (Filipova et al., 
2018)). However, the authors argue that BMP4 (the product of Bmp4) necessary for bone ridge 
development originates from the tendons (Blitz et al., 2009), the signal from which can also 
contribute to the observed Bmp4 downregulation in the MAs. This implies that either Cav1.1 is 
normally also expressed and has functions in the tendons and/or skeleton; or that its absence in 
skeletal muscle triggers a more intricate downstream cascade of events, resulting in a lower Bmp4 
expression in the tendons. 
4.2.2 Absence of RYR1 or Cav1.1 at E18.5 alters the transcriptomic signature of 
skeletal muscle metabolism 
The high energy demand during muscle contraction is met via the particularly high metabolic 
capacity of the skeletal muscle organ. As one of the organs with highest plasticity capabilities, 
skeletal muscle adapts its volume, composition and versatile metabolic pathways according to the 
levels of contractile activity (Hood, Irrcher, Ljubicic, & Joseph, 2006). Thus, it is not surprising that 
at E18.5 the muscle paralysis caused by the absence of RYR1 or Cav1.1 changes the expression 
levels of many genes related to different metabolic processes. In particular, the results of the MAs 
indicate that both RYR1
-/-
 and Cav1.1
-/-
 skeletal muscles undergo metabolic adaptations related to 
fatty acids metabolism and β-oxidation (Fig. 34). A particular upregulation of key constituents of 
these processes was observed in the Cav1.1
-/-
 skeletal muscle at E18.5, as exemplified by DEGs from 
the “Acylglycerol metabolic process” category (Fig. 33C). Among the upregulated DEGs are typical 
modulators of lipid metabolism like the gene for lipoprotein lipase (Lpl) and apolipoprotein E (Apoe) 
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(Huang & Mahley, 2014; Olivecrona, 2016). Furthermore, multiple genes from the peroxisome 
proliferator-activated receptor (PPAR) signaling pathway are also specifically upregulated only in the 
Cav1.1
-/-
 skeletal muscle at E18.5 (Suppl. Table 1). PPARs are a family of lipid-activated nuclear 
receptors that regulate the expression and activity of multiple proteins participating in fatty acid 
metabolism (Desvergne & Wahli, 1999). Pathologic alterations in the PPAR signaling cause changes 
in skeletal muscle glucose uptake and are associated with insulin resistance and obesity-related 
diabetes (Finck et al., 2005; Leonardini, Laviola, Perrini, Natalicchio, & Giorgino, 2009). Therefore, 
the upregulation of the PPAR signaling pathway in the Cav1.1
-/-
 mice may induce expression changes 
related to an increased accumulation of adipose tissue in these muscles. Accordingly, differences in 
[Ca
2+
]i have been implicated in the commitment of progenitor cells either towards the myogenic or to 
the adipogenic lineage (Sun et al., 2017). Thus, the altered basal [Ca
2+
]i resulting from the absence of 
RYR1 or Cav1.1 may be directing the metabolism of RYR1
-/-
 and Cav1.1
-/-
 skeletal muscle towards 
an adipogenic fate. The more pronounced effects on metabolic gene regulation in Cav1.1
-/-
 skeletal 
muscles might, once again, be related to the additional inhibition of the IP3R-mediated Ca
2+
 release 
in these animals. 
The DEGs indicating global metabolic alterations in the RYR1
-/-
 and especially in the Cav1.1
-/-
 
skeletal muscles also suggest changes in mitochondrial biogenesis, content and stability in these 
muscles. This is not surprising if one considers the important role of Ca
2+
 for mitochondrial 
(patho)physiology in skeletal muscle (Elustondo, Nichols, Robertson, & Pavlov, 2016; Lundby & 
Jacobs, 2016). Moreover, mitochondria are important regulators of Ca
2+
 signaling (Rizzuto, De 
Stefani, Raffaello, & Mammucari, 2012). Furthermore, mitochondria are associated with the ECC 
Ca
2+
 release units (CRUs) in skeletal muscle in an age- and exercise-dependent manner (Protasi, 
2015). In the C2C12 myocyte cell culture, mitochondrial genetic and metabolic stress induces the 
expression of RYR1 and Ca
2+
-responsive factors (Biswas et al., 1999). Thus, absence of ECC-
mediated Ca
2+
 release in RYR1
-/-
 and Cav1.1
-/-
 muscle may cause mitochondrial stress and impair the 
mitochondrial regulation of myogenesis (Wagatsuma & Sakuma, 2013). Surprisingly, no changes in 
the mRNA levels were detected for any mitochondrially-encoded proteins in either mutant. This 
suggests that putative mitochondrial alterations are caused by expression changes in the nuclear-
encoded genes or are the result of post-transcriptional modifications. 
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4.2.3 Changes in global signaling networks: the role of Ca
2+
  
As discussed above, upon membrane depolarization Cav1.1 triggers a “fast” and a “slow” Ca
2+
 
release from RYR1 and IP3R, respectively. Experimental evidence suggests that in myotubes, both 
the IP3R and RYR1 are involved in Ca
2+
 signaling not immediately related to contraction (Arias-
Calderon et al., 2016; Juretic et al., 2007; Witherspoon & Meilleur, 2016). However, it is not clear to 
what extent the Ca
2+
 signaling functions of the two channels are interwoven: Upon depolarization, 
primarily IP3R-mediated Ca
2+
 release from the SR of C2C12 myotubes caused long lasting elevation 
in nuclear [Ca
2+
], leading to extracellular signal–regulated kinases 1 and 2 (ERK1/2) activation and 
phosphorylation of the cAMP response element-binding protein (CREB) (Powell et al., 2001). 
Depolarization of primary myotubes, on the other hand, resulted in reactive oxygen species (ROS) 
generation, increased ERK1/2 and CREB phosphorylation, as well as increase in mRNA for c-Fos 
and c-Jun, and these effects could specifically be blocked by RYR1 inhibition (Espinosa et al., 2006). 
In this respect, changes in the interplay between the RYR1- and IP3R-mediated Ca
2+
 release could 
account for the observed downregulation of c-Fos and c-Jun in specific, and in MAPK-related genes 
in general, in RYR1
-/-
 skeletal muscle. 
[Ca
2+
]i in skeletal muscle is characterized by ~100nM resting levels and by its ~100-fold rise upon 
activation of RYR1 (Berchtold, Brinkmeier, & Muntener, 2000). Increased [Ca
2+
]i levels will 
increase Ca
2+
 binding by calmodulin (CaM), leading to activation of calcineurin and calmodulin 
kinases II (CAMKII) and IV (CAMKIV), with various effects on downstream signaling (Gehlert et 
al., 2015). Interestingly, unlike Cav1.1
-/-
 primary muscle cells, where the resting [Ca
2+
]i is elevated 
relative to WT, it is ~2-fold lower in RYR1
-/-
 compared to WT myotubes (Eltit et al., 2011; Eltit et 
al., 2010). Thus, the absence of RYR1 vs. Cav1.1 is likely to differentially affect the resting-state 
[Ca
2+
]i availability, and thus, to differently change various resting-state Ca
2+
 signaling mechanisms. 
For instance, the 2.2-fold downregulation of the gene encoding CAMKIIβ, Camk2b, in Cav1.1
-/-
 but 
not in RYR1
-/-
 samples at E18.5 could somehow be related to the differences in resting Ca
2+ 
(Suppl. 
Table 1). Since numerous signaling molecules are regulated by phosphorylation (Cardenas et al., 
2004; Enslen, Tokumitsu, & Soderling, 1995; Kramer & Goodyear, 2007), changes in CAMKII and 
CAMKIV activity, resulting in an altered cAMP, cGMP and protein kinases A, C or G (PKA, PKC, 
PKG) signaling, could contribute to the distinct expression profile of genes in RYR1
-/-
 and Cav1.1
-/-
 
skeletal muscle. Yet, multiple DEGs participating in all these signaling cascades have been identified 
in both mutants (Suppl. Table 1). Significant differences in the identified DEGs were observed in 
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some pathways like mitogen-activated protein kinase (MAPK) pathway. A consistent downregulation 
of c-Fos, c-Jun, Jund and Nfatc2, encoding phosphorylation targets of ERK1/2, JNK and p38 was 
observed in RYR1
-/-
 samples, but c-Jun, Jund were not detected as DEGs in Cav1.1
-/-
 samples at 
E18.5, implying more pronounced MAPK signaling changes in RYR1
-/-
 skeletal muscle. 
Interestingly, Jund was downregulated in Cav1.1
-/-
 samples at E14.5. The products of c-Fos, c-Jun 
and Jund take part in the composition of the AP-1 complex, a major transcription factor that can exert 
either positive or negative functions on muscle development and differentiation, depending on its 
composition (Andreucci et al., 2002). Thus, some of the differences between the DEGs found in the 
RYR1
-/-
 and Cav1.1
-/-
 samples at E18.5 can be caused by putative changes in the composition of 
AP-1. At E18.5 multiple DEGs identified only in Cav1.1
-/-
 samples encode membrane proteins and 
ion channels acting upstream of the MAPK cascades. These findings could imply a disturbed 
regulation of the three central MAPK branches, ERK1/2, JNK and p38, which are activated in a 
Ca
2+
-dependent manner (Chuderland & Seger, 2008; Enslen, Tokumitsu, Stork, Davis, & Soderling, 
1996). Moreover, all of these are also activated via mechanical stress like cell stretching and play a 
crucial role in myogenesis (Benavides Damm & Egli, 2014). Furthermore, DEGs identified in both 
RYR1
-/-
 and Cav1.1
-/-
 samples have been shown to be under the influence of p38γ in the context of 
exercise-induced metabolic adaptation (Pogozelski et al., 2009). Alterations in the activity of p38y in 
both mutant models are likely to have an impact on mitochondrial biogenesis and oxidative 
metabolism. In this line of thought, some of the downregulated DEGs in both mutants encode 
proteins participating in oxidative reactions, like the gene encoding methionine sulfoxide reductase 
B3 (Msrb3), or genes regulated by oxidative stress, like the gene encoding thrombospondin 4 
(Thbs4). Moreover, the expression of c-Jun and c-Fos is positively regulated by oxidative stress in a 
RYR1-dependent manner (Espinosa et al., 2006), further indicating that the absence of RYR1 or 
RYR1 activation via Cav1.1 may influence various ROS-sensitive signaling cascades. ROS-mediated 
signaling furthermore influences the expression and modifications of many contractile proteins, 
including multiple thick, thin and titin filament proteins (Beckendorf & Linke, 2014), detected as 
downregulated DEGs in both mutant models at E18.5. Interestingly, the gene encoding myoglobin 
(Mb), a classical oxidative stress response protein, is highly upregulated in RYR1
-/-
 skeletal muscle. 
This is unexpected in view of the missing mechanical loading in RYR1
-/-
 samples and the observed 
downregulation of Nfatc2, a major activator of Mb expression (Wittenberg, 2009). However, an 
increase of Mb expression has been observed in immobilized rat muscles (Lee et al., 2013).  
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Other signaling pathways, enriched with DEGs in RYR1
-/-
 and Cav1.1
-/-
 skeletal muscles, like the 
Wnt and the PI3K/AKT/mTOR pathways (Suppl. Table 1), are also influenced by Ca
2+
 (Drenning et 
al., 2009; Kohn & Moon, 2005). Factors promoting the Wnt signaling (Wnt2, Cd44, Fzd10, Tgfb1i1) 
were downregulated in RYR1
-/-
 samples at E18.5 (Table 12), whereas Sfrp1, an inhibitor of Wnt 
signaling, was upregulated, suggesting an overall repression of Wnt signaling in RYR1
-/-
 skeletal 
muscle. Furthermore, in RYR1
-/-
 samples an overexpression was observed for Nkd1 (Table 12), 
encoding an intracellular switch which suppresses the canonical and promotes the non-canonical Wnt 
pathway (Ekici et al., 2010). This may indicate a shift towards the non-canonical pathway in E18.5 
RYR1
-/-
 muscle. The downregulation of the non-transforming Wnt ligand gene Wnt2, associated with 
the activation of the non-canonical pathway, is another indication of a dysregulation between the 
canonical and non-canonical Wnt pathway. A repression of the canonical Wnt pathway suggests 
inhibition of the Wnt myogenic activity which is mediated mainly through the β-catenin pathway 
(Yann Fedon, 2012). The Wnt pathway seems to be affected also by the absence of Cav1.1 (Suppl. 
Table 1). In E18.5 Cav1.1
-/-
 samples, the gene Dkk2, encoding a member of the dickkopf family – 
potent inhibitors of the canonical Wnt signaling, was 1.6-fold upregulated. Furthermore, Dkk2 is a 
target of different miRNAs and has been shown to regulate the cell cycle and apoptosis (Sun et al., 
2016) (Lou, Liu, Zhan, Wang, & Fan, 2016; Mu et al., 2017). The observed Wnt regulation, 
combined with follistatin (Fst) overexpression, might reflect an attempt to prevent negative 
regulation of muscle mass by myostatin in RYR1
-/-
 and Cav1.1
-/-
 muscles. A putative shift towards 
the non-canonical Wnt/calcium pathway in the RYR1
-/-
 muscle might also be a compensatory effect 
to raise the intracellular Ca
2+ 
concentrations via activation of IP3Rs.  
The Wnt non-canonical pathway, together with G protein signaling, have been implicated in the 
activation of the PI3K/Akt/mTOR pathway, involved in increased anabolic activity and in 
hypertrophy of skeletal muscle (von Maltzahn, Bentzinger, & Rudnicki, 2012). Accordingly, an 
upregulation of DEGs taking part in the central (Pik3r1, Akt2) and late (Cdkn1a) stages of this 
pathway was observed in RYR1
-/-
 samples at E18.5 (Table 12). The PI3K/Akt/mTOR pathway was 
represented by many more DEGs in the Cav1.1
-/-
 E18.5 samples (Suppl. Table 1). This observation is 
probably related to the more prominent metabolic changes (as indicated by the number of the 
respective DEGs) in muscle samples from Cav1.1
-/-
 mice.  
The Notch and BMP signaling pathways, also involved in the regulation of myogenesis, are 
represented among the DEGs of RYR1
-/-
 and Cav1.1
-/-
 at E18.5 to a lesser extent. The upregulation of 
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Megf10 and Hes6, positive regulators of Notch signaling, both of which have been shown to suppress 
myogenic differentiation (Cossins, Vernon, Zhang, Philpott, & Jones, 2002; Holterman, Le Grand, 
Kuang, Seale, & Rudnicki, 2007), indicates an impaired terminal differentiation of RYR1
-/-
 skeletal 
muscle (Table 12).  
These findings demonstrate that the crosstalk between many intracellular global signaling pathways 
is significantly altered in skeletal muscles of RYR1
-/-
 and Cav1.1
-/-
 mice. These substantial alterations 
in signaling are very likely to be causative for the myogenic impairment observed in limb skeletal 
muscle of these animals. 
4.2.4 The effects of paralysis – comparison to other models 
As a consequence of EC uncoupling, the RYR1
-/-
 and Cav1.1
-/-
 mice are characterized by both a lack 
of ECC-mediated Ca
2+
signaling and, consequently, a lack of mechanical movement. The two deficits 
may have far-reaching consequences, an obvious one being the complete skeletal muscle paralysis of 
the embryo. Paralysis itself, in turn, impairs the embryonic development of cartilage and bones 
(Nowlan, Sharpe, Roddy, Prendergast, & Murphy, 2010). The latter leads to neuromuscular 
degeneration due to the absence of mechanotransduction-associated signaling, which significantly 
alters global gene expression in skeletal muscle (Rodriguez, Garcia-Alix, Palacios, & Paniagua, 
1988; Rolfe et al., 2014). Concomitantly, Ca
2+
 itself is a crucial second messenger in diverse 
signaling pathways, as discussed above. Thus, the observed phenotype of the RYR1
-/-
 and Cav1.1
-/-
 
muscle, especially at E18.5, could be a direct effect of missing ECC-dependent Ca
2+ 
signaling, a 
secondary effect due to the lack of mechanotransduction, or most likely – a combination of both. This 
leads to a dilemma of cause or consequence. To address this problem, the present results are 
compared to other studies involving models that share the characteristics of paralysis, like 
denervation, amyotrophic lateral sclerosis (ALS), or toxin-paralyzed models. Although the adult 
models for neuromuscular degeneration recapitulate many aspects of prenatal paralysis, one should 
be aware that the (predominantly reactive) processes in differentiated, adult muscle models are not 
necessarily all homologous to the ones taking place in fetal skeletal muscle. Furthermore, the effects 
of species-specific differences (e.g. patient-derived samples vs. mouse models) should also be 
considered. 
Multiple typical denervation markers, consisting of genes of the post-synaptic end-plate, are 
upregulated in the RYR1
-/-
 and Cav1
-/-
 mutants at E18.5. Such are the acetylcholine receptor subunit 
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AChRα (Chrna1), upregulated in both RYR1-/- and Cav1.1
-/-
 samples; the fetal subunit AChRγ 
(Chrng), upregulated in RYR1
-/-
 samples; and receptor-associated protein of the synapse (Rapsn), 
which is clustered with the nAChR complex and is also upregulated in RYR1
-/-
 samples (Ohno, 
Sadeh, Blatt, Brengman, & Engel, 2003). In further analogy to paralysis models, the ECM genes, 
which are responsive to muscle loading and training, tenascin C (Tnc) and microfibrillar associated 
protein 5 (Mfap5), were down-regulated in RYR1
-/-
 and Cav1.1
-/-
 mice at E18.5 (Irintchev, Salvini, 
Faissner, & Wernig, 1993; Llano-Diez et al., 2011). Conversely, another ECM gene, coding for 
collagen type XIXα1 (Col19a1), which plays a role in muscle organ development, is up-regulated in 
both RYR1
-/-
 and Cav1.1
-/-
 muscle at E18.5, and is also found to be elevated in ALS and other 
denervation models (Shtilbans et al., 2011). Shtilbans et al. (2011) further reported an upregulation of 
the myostatin antagonist follistatin (Fst) – also upregulated in both mutants – which is linked to 
muscle regeneration after injury, mediating myoblast recruitment and subsequent fusion into 
myotubes (Shtilbans et al., 2011). The upregulation of these genes in RYR1
-/-
 and Cav1.1
-/-
 skeletal 
muscle might result from compensatory mechanisms attempting to counteract the processes leading 
to the observed muscle degeneration in the mutants. 
The transcription factor-coding gene Runx1 is upregulated in both RYR1
-/-
 and Cav1.1
-/-
 skeletal 
muscle at E18.5 (Table 11; S1 Table in (Filipova et al., 2018)). Runx1 regulation in the same 
direction was also observed in skeletal muscle of ALS and other denervation models (Gonzalez de 
Aguilar et al., 2008). In the context of muscle disuse, Runx1 upregulation may occur in differentiated 
muscle fibers and could compensate to a certain extent the lack of muscle movement, preventing 
muscle wasting, autophagy and myofibrillar disorganization (Wang et al., 2005). 
Similar changes were observed in the expression of one cytoskeletal and three contraction-related 
DEGs, comprising Tppp (downregulated in RYR1
-/-
 and Cav1.1
-/-
 at E18.5), Tnnt2 (upregulated in 
RYR1
-/-
 at E18.5), Fhl1 and Myl3 (both downregulated in RYR1
-/-
 at E18.5 and in Cav1.1
-/-
 at E14.5 
and E18.5) (Loughna, Mason, Bayol, & Brownson, 2000; Petrie, Suneja, Faidley, & Shields, 2014; 
Saggin, Gorza, Ausoni, & Schiaffino, 1990; Toivonen et al., 2014). The downregulation of Fhl1 and 
Myl3 in Cav1.1
-/-
 but not RYR1
-/-
 samples at the early (E14.5) stage implies that their regulation is not 
exclusively dictated by muscle paralysis. Furthermore, this can indicate that gene expression changes 
caused by absence of Cav1.1
-/-
 occur earlier than those caused by the absence of RYR1
-/-
.  
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Other DEGs implicated in paralysis and signaling include Hdac4, Mylk2, Actn3, Mybpc2, Fmod (in 
RYR1
-/-
 and Cav1.1
-/-
 ); Cd44, Cdkn1a, Lphn3, Trib1 and Sfrp1 (only in RYR1
-/-
); Eno3, Pgam2, 
Asb2, Klhl38, Fbp2, Tcea3 (only in Cav1.1) (Cohen et al., 2007; de Oliveira et al., 2014; Gonzalez de 
Aguilar et al., 2008; Qin, Pan, Bauman, & Cardozo, 2010; Shtilbans et al., 2011; Svensson, Norrby, 
Libelius, & Tagerud, 2008; Uyan et al., 2013). In addition, the expression of Prr32 gene, encoding a 
protein named proline rich 32, is increased in muscles from ALS patients and decreased in muscles 
from multifocal motor neuropathy patients, is also downregulated in Cav1.1
-/-
 at E18.5 (Shtilbans et 
al., 2011). These similarities imply that the missing contraction and respectively, 
mechanotransduction causes many of the observed transcriptomic changes in the RYR1
-/-
 and 
Cav1.1
-/- 
mutants. 
However, some DEGs in the RYR1
-/-
 and Cav1.1
-/-
 samples at E18.5 are regulated in the opposite 
direction compared to the above mentioned models for paralysis and denervation. Such a DEGs is 
Ankrd1, the product of which – ankyrin repeat domain protein 1 – is a member of the titin-N2A 
mechanosensory complex of the Z-disc (Miller et al., 2003). It participates in the mechanical 
response to stress and stretching, influencing muscle morphogenesis and remodeling and can also 
translocate to the nucleus and regulate gene expression (Jeyaseelan et al., 1997). Thus, Ankrd1 
represents a downstream target gene for multiple myogenic regulators like MyoD, MyoG and MEF2 
(Blais et al., 2005). Furthermore, it was shown to be a p53 target, as well as an interaction partner of 
p53 for regulation of downstream expression (Kojic et al., 2010). In different studies, an upregulation 
of Ankrd1 was observed in ALS muscle and after denervation (Gonzalez de Aguilar et al., 2008; 
Shtilbans et al., 2011), whereas a strong downregulation of this gene is found in Cav1.1
-/-
 at E14.5 
and in both RYR1
-/-
 and Cav1.1
-/-
 skeletal muscle at E18.5. However, one study also reported a strong 
down-regulation of mouse Ankrd1, but only 35 days post denervation (Qin et al., 2010).  
The Tnfrsf12a transcript, coding for the TWEAK receptor, is upregulated upon denervation (Mittal et 
al., 2010) but, like Ankrd1, is downregulated in RYR1
-/-
 and Cav1.1
-/-
 skeletal muscle at E18.5. Both, 
TWEAK and Ankrd1 are Bcl-3 targets and are repressed by the MAPK p38γ (Pogozelski et al., 
2009). Thus, alterations in p38 signaling in the mutants, might be causing the observed expression 
changes of Ankrd1 and Tnfrsf12a in RYR1
-/-
 and Cav1.1
-/-
 mice. 
The Anxa1 gene encodes annexin A1 – a protein binding biological membranes in a Ca2+-dependent 
manner, that has been implicated in muscle differentiation and regeneration (Bizzarro, Petrella, & 
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Parente, 2012). While the expression of Anxa1 was increased in ALS, it is decreased in RYR1
-/-
 
skeletal muscle at E18.5. 
Deletion or mutations of the gene for prolyl endopeptidase-like, Prepl, have been linked to 
myasthenic disorders at birth, possibly affecting the ACh presynaptic vesicles (Regal et al., 2014), 
and Prepl KO mice exhibit growth impairment and neonatal hypotonia (Lone et al., 2014). Prepl was 
overexpressed in the skeletal muscle of ALS patients (Shtilbans et al., 2011) but interestingly, it is 
downregulated in Cav1.1
-/-
 muscles at E14.5 and in both RYR1
-/-
 and Cav1.1
-/-
 muscles at E18.5. 
Thus, lower levels of Prepl mRNA may be involved in the formation of the RYR1
-/-
 and Cav1.1
-/-
 
phenotype, characterized by smaller body size and reduced skeletal muscle content. Furthermore, the 
detection of Prepl downregulation already at E14.5 in Cav1.1
-/-
 samples, substantiates the assumption 
of an earlier onset of pathological muscle alterations in Cav1.1
-/-
 than in RYR1
-/-
 muscles.  
The inhibitor of DNA binding 2 protein (Id2) was downregulated in gastrocnemius muscle of a 40-
day old presymptomatic ALS mouse model (de Oliveira et al., 2014), but was upregulated both in 
RYR1
-/-
 and Cav1.1
-/-
 samples at E18.5 (S1 Table in (Filipova et al., 2018)). Id2 encodes a myogenic 
repressor and its upregulation may be responsible for some of the developmental abnormalities 
observed in the RYR1
-/-
 and Cav1.1
-/-
 skeletal muscle. 
The multiple similarities between gene expression changes in muscles of paralysis models and 
RYR1
-/-
 and Cav1.1
-/-
 muscles highlight the great importance of ECC-triggered mechanotransduction 
for the developing skeletal muscle. As in RYR1
-/-
 and Cav1.1
-/-
 mice, the skeletal muscles of many of 
the models above display pathological alteration of muscle structure, myofibrillar disorganization and 
muscle atrophy. Thus, the DEGs common for both mutants and the paralysis models, might be 
directly connected to the observed phenotype of RYR1
-/-
 and Cav1.1
-/-
 skeletal muscles at E18.5. 
Interestingly, some paralysis-associated DEGs, were found only in one of the mutants. Since both 
mutants are paralyzed, this would suggest that additional levels govern the expression of these DEGs. 
However, some differences, especially for the DEGs with low FCs, might also be caused by the 
technical handling and the dynamic range of the MAs. In addition, the paralysis-related DEGs that 
were detected in the RYR1
-/-
 or Cav1.1
-/-
 samples at E14.5, the time point of the first movements in 
mouse fetuses, might be involved in the early steps of the mechanotransduction-induced signaling 
and hence, have downstream effects at later developmental stages like E18.5. 
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4.3 Changes in the developmental transcriptome of RYR1
-/-
 and 
Cav1.1
-/-
 mice: effects on secondary myogenesis 
The proper spatio-temporal coordination of intra- and extracellular signaling networks is essential for 
embryonic and fetal development. Hence, the plethora of signaling-related DEGs, detected in 
RYR1
-/-
 and Cav1.1
-/-
 limb skeletal muscles, strongly indicates that the observed pathological 
structural alterations in these muscles are caused by a failure in myogenesis. Accordingly, the first 
part of this work detected a differential expression of various genes involved in the regulation of 
satellite cells motility, proliferation and differentiation (Six1, Six4, Pax7, Sfrp4, Dusp10, Nes, Rgs5, 
Cav2, Megf10, Hgf, Ptpz1, Aif1, Cnr1); myoblast differentiation and fusion (Mfap5, Nov, Dpysl3, 
Wnt2, Cd44, Nfatc2, Cdkn1a, Hes6, Akt2, Adamtsl2, Hdac4, Fst, Sfrp1, Bai3, Marveld2) and terminal 
muscle differentiation (MyoD, MyoG, Mrf4, Hes6, Csrp3,Bcl6, Fgf6, Nfatc2) in the limb skeletal 
muscles of RYR1
-/-
 mice at E18.5 (Supplementary Table1 in (Filipova et al., 2016)). Furthermore, an 
upregulation was observed for the canonical myogenic regulatory factors (MRFs) Six1, Six4, Pax7, 
MyoD, MyoG and Mrf4 (Fig. 21), the expression of which (except for Mrf4) is attenuated in 
terminally differentiated skeletal muscle (Bentzinger et al., 2012), pointing to a delay in myogenic 
development. However, this upregulation could not be reproduced in the second part of this work, 
analyzing the MRFs expression relative to Cytb (Fig. 38). This is probably caused by slight 
difference in the expression levels of the used endogenous controls – Gapdh vs. Cytb, the first of 
which is also developmentally regulated and may be therefore unsuitable for the analysis of 
developmentally-challenged mutants (Hildyard & Wells, 2014). However, at E18.5, the end of 
secondary myogenesis, the observed morphological and transcriptomic changes in RYR1
-/-
 and 
Cav1.1
-/-
 mice might also be the result of skeletal muscle degeneration in the late stages of fetal 
development.  
In order to examine the putative changes in transcriptome dynamics from the beginning to the end of 
secondary myogenesis, the global transcriptomic changes occurring between E14.5 and E18.5 
(E18.5, test vs. E14.5, control) were analyzed for WT, RYR1
-/-
 and Cav1.1
-/-
 limb skeletal muscles. 
These comparisons revealed a higher number of DEGs for WT than for either mutant (Table 15). 
Thus, a considerable fraction of the DEGs found in the mutants vs. WT at E18.5, might emerge from 
a failure in the two mutants to activate the normal developmental expression program. Supporting 
this notion are the processes associated with the DEGs emerging from the E18.5 vs. E14.5 
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enrichment analyses (Figs. 34, 35, 36). A general analysis of all DEGs in the E18.5 vs. E14.5 
comparisons suggests that in all three genotypes – WT, RYR1-/- and Cav1.1
-/-
 an induction of 
differential regulation connected to muscle contraction takes place (Fig. 34). However, the same 
analysis also indicates that myogenic and contractile processes like “Muscle organ development” and 
“Myofibril assembly”, as well as processes related to DNA replication and the cell cycle, were 
preferentially regulated in the WTs, but not in the mutants, indicated an incomplete developmental 
progression in the mutants. On the other hand, more significant changes related to fatty acids 
metabolism and β-oxidation were observed in both mutants, and especially in the Cav1.1
-/-
 (Fig. 34), 
which is in line with the observed metabolic changes in Cav1.1
-/-
 muscles at E18.5. These differences 
clearly stand out in the analyses of the WT, RYR1
-/-
 and Cav1.1
-/-
 specific DEGs in the E18.5 vs. 
E14.5 analyses (Figs. 35 and 36). Specifically, multiple genes involved in the cell cycle control 
(Prim2, Ccnd2, Mcm7, Cdk4, Mcm2, Plk1, Mad2l1) were downregulated only in WT samples – a 
typical sign for terminal differentiation. The failure of RYR1
-/-
 and Cav1.1
-/-
 skeletal muscles to 
downregulate these genes is an indication of a disturbed terminal muscle differentiation. 
Furthermore, many cellular compartments (CCs) related to the buildup of the contractile machinery 
like the sarcolemma, costameres, sarcomeres and I-band are differentially regulated only in the WTs 
from E14.5 to E18.5 (Fig. 36). These findings are supported by the detection of contraction-related 
DEGs upregulated from E14.5 to E18.5 exclusively in the WTs samples; or to be upregulated with a 
much smaller FC in the mutants like Mybpc2, Ckmt2, Myh2, Myh4 and Mylk2 (S1 Table in (Filipova 
et al., 2018)). These observations strongly imply that the secondary myogenesis, normally involving 
an increased level and organization of contractile structures, and accompanied by the exit from the 
cell cycle during fetal development, is impaired in RYR1
-/-
 and Cav1.1
-/-
 limb skeletal muscle.  
Various differentiation-related processes were affected by the RYR1
-/-
 specific DEGs in the E18.5 vs. 
E14.5 analyses (Figs. 35 and 36), further suggesting that the absence of RYR1 leads to changes in the 
global developmental program. Most of the affected cellular processes and structures were related to 
bone, cartilage and neuron differentiation, focal adhesion and ion channels. Interestingly, several 
processes related to ossification, were detected as significantly enriched with RYR1
-/-
- and not with 
Cav1.1
-/-
-specific DEGs (Figs. 35 and 36). A possible reason for this might be compensatory 
paralysis-triggered processes that could not be set in action in the Cav1.1
-/-
 skeletal muscles.  
The DEGs specific for the fetal development of Cav1.1
-/-
 muscles these were predominantly 
associated with processes linked to adipogenesis and lipid metabolism (Figs. 35 and 36). Thus, the 
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elevation of the expression levels of lipid-metabolism in Cav1.1
-/-
 vs. WT muscles at E18.5 (Fig. 
33C) seems to be a result of an active developmental upregulation of these genes in the Cav1.1
-/-
 
mutants. The higher [Ca
2+
]i in Cav1.1
-/-
 compared to WT and RYR1
-/-
 myotubes due to a higher rate 
of RYR1-mediated passive Ca
2+
 leak from the SR (Eltit et al., 2011; Eltit et al., 2010) may be the 
cause of some of these Cav1.1
-/-
 specific expression changes during secondary myogenesis. These 
changes suggest significant alterations in the mitochondrial Ca
2+
 content, and hence also in their 
functions, volume or stability in the muscles of these animals. Accordingly, the increased 
mitochondrial Ca
2+
 and decreased SR Ca
2+
 content have been implicated in mitochondrial myopathy, 
arguing that higher mitochondrial Ca
2+
 concentrations can stimulate metabolic events but in the same 
time can trigger cell damage (Aydin et al., 2009). Thus, a mitochondrial Ca
2+
 overload might be the 
cause of the observed apoptosis in the skeletal muscle of Cav1.1
-/-
 mice at E14.5, and lipotoxicity 
might also be a contributing factor (Akhmedov & Berdeaux, 2013). Furthermore, an upregulation of 
the paralysis hallmarks Musk, Chrnd and Chrng, is detected only during development of RYR1
-/-
 
skeletal muscle. Reduced [Ca
2+
]i in RYR1
-/-
 and increased [Ca
2+
]i in Cav1.1
-/-
 muscles can explain 
this observation, as these genes are negatively regulated by increased [Ca
2+
]i and in turn regulate 
proper neuromuscular synaptic pre-patterning (Chen et al., 2011). 
At least 61 miRNAs are differentially expressed in WT limb skeletal muscle from E14.5 to E18.5 
(Fig. 37, Table 16). Only 3 of these miRNAs undergo a parallel regulation in RYR1
-/-
 and 16 
miRNAs – in Cav1.1
-/-
 skeletal muscle from E14.5 to E18.5 (Table 16). In addition, one miRNA 
(Mir125b-1, downregulated) was found exclusively in RYR1
-/-
 and four (Mir205, Mir669d, Glul and 
Mir130a) – in Cav1.1
-/-
 muscles in the course of secondary myogenesis. Mir125b-1 is a negative 
regulator of myoblast differentiation and its levels decline with progression of the myogenic program 
(Ge et al., 2011). Classically, miRNAs function as potent regulators of gene expression in general 
and of muscle differentiation, in particular (Goljanek-Whysall, Sweetman, & Munsterberg, 2012). 
Therefore, the altered miRNA developmental patterns in RYR1
-/-
 and Cav1.1
-/-
 limb skeletal muscle 
are likely to have contributed to the observed transcriptomic changes. The vast majority of 
differentially expressed miRNAs identified in the WT showed an upregulation at E18.5 vs. E14.5. 
Among the upregulated miRNAs are six of the MyoMirs (Mir206, Mir133b, Mir133a-1, Mir133a-2, 
Mir1a-1 and Mir1a-2), named after their pivotal role in muscle development and differentiation (Luo 
et al., 2013). The expression of all of them is regulated by the late MRFs MyoD and myogenin, as 
well as by other myogenic TFs like the myocyte enhancer factor 2 (MEF-2) (Luo et al., 2013). None 
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of the MyoMirs were significantly upregulated in the development of RYR1
-/-
 skeletal muscle from 
E14.5 to E18.5. In Cav1.1
-/-
 only Mir133b, Mir133a-1 and Mir1a-1 were developmentally 
upregulated, all of which exhibit a lower FC than in WT. Furthermore, both Mir133b and Mir133a-1 
suppress differentiation and promote myoblast proliferation (Chen et al., 2006; Luo et al., 2013). The 
MyoMirs of the Mir1 and Mir206 families have opposing actions, promoting terminal muscle 
differentiation by targeting HDAC4, an inhibitor of MEF2 expression, as well as of muscle 
differentiation and growth (Luo et al., 2013). However, these two miRNAs do not show functional 
redundancy, as they cannot replace each other (Luo et al., 2013). Although Mir1a-1 is 2.3-fold 
upregulated in Cav1.1
-/-
 samples from E14.5 to E18.5, it is 6.3-fold upregulated in WT samples in the 
same period. Accordingly, Mir1a-1 is 3.3-fold downregulated in Cav1.1
-/-
 vs. WT samples at E18.5. 
Insufficient action of Mir1 and Mir206 is also suggested by the upregulation of Hdac4 in both 
RYR1
-/-
 and Cav1.1
-/-
 skeletal muscle at E18.5. Additionally, multiple other miRNAs that were 
implicated in the regulation of muscle development and differentiation were only upregulated in WT 
skeletal muscle during secondary myogenesis (Table 16). Thus, a global failure of the RYR1
-/-
 and 
Cav1.1
-/-
 skeletal muscle to induce a physiological upregulation of this multitude of miRNAs is very 
probably causing many of the transcriptional changes observed in these muscles at E18.5.  
Interestingly, more than half of the miRNAs upregulated in the WT E18.5 vs. E14.5 comparison are 
also downregulated in ageing skeletal muscle (Table 16) (Lee et al., 2015b), suggesting important 
and dynamic roles for these miRNAs in myogenesis and in skeletal muscle maintenance. In this 
respect, the Dlk-Dio3 genomic region – a miRNA megacluster encoding more than 50 miRNAs – 
appears to be of eminent importance (Glazov, McWilliam, Barris, & Dalrymple, 2008): 26 of the 
developmentally upregulated miRNAs found in WT skeletal muscle originate from this region (Table 
16). Reduced expression of miRNAs from the Dlk-Dio3 cluster has been implicated in the ageing 
process in gastrocnemius muscles (Kim et al., 2014), and myostatin deficiency has been shown to 
lead to a transcriptional activation of this locus (Hitachi & Tsuchida, 2017). Only 6 of the miRNAs 
from the Dlk-Dio3 genomic locus upregulated in WT (E18.5 vs. E14.5) are also upregulated in 
Cav1.1
-/-
 muscle, and none in RYR1
-/-
 muscle (Table 16). These findings suggest that the increased 
expression level of multiple miRNAs from the Dlk-Dio3 genomic region is a significant contributor 
to secondary myogenesis and that muscle contraction and ECC-mediated Ca
2+
 release probably 
drives their expression. All of these results highlight novel important roles for RYR1 and Cav1.1 in 
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the regulation of gene expression via an intricate network of signaling cascades during secondary 
myogenesis. 
4.4 Putative similarities to RYR1- and Cav1.1-linked diseases 
As main components of the ECC apparatus in skeletal muscle, multiple mutations in the genes of 
RYR1 and Cav1.1 have been associated with a range of diseases and neuromuscular disorders, often 
described as channelopathies, including malignant hyperthermia (MH) and hypokalemic periodic 
paralysis type 1 (HPP-1) (Cannon, 2015; Robinson, Carpenter, Shaw, Halsall, & Hopkins, 2006; 
Striessnig et al., 2010). Furthermore, a wide range of Ryr1 (the gene encoding RYR1) mutations 
cause different congenital myopathies, the majority of which have an early onset – at birth, during 
infancy or childhood (Jungbluth et al., 2018). Autosomal dominant Ryr1 mutations are associated 
with diverse core myopathies – a class of congenital myopathies, characterized by the presence of 
“cores” of reduced oxidative activity in skeletal muscle fibers (Snoeck et al., 2015). In addition, 
sarcomere disorganization and mitochondrial depletion are often observed in muscles from these 
patients. Two of the more prominent core myopathies caused by Ryr1 mutations are central core 
disease (CCD) and multiminicore disease (MmD), commonly associated with malignant 
hyperthermia (MH) susceptibility (Robinson et al., 2006; Snoeck et al., 2015). Recently, mutations in 
Cacna1s (the gene encoding Cav1.1) have been linked to similar pathological alterations in patients 
with a so-called CACNA1S congenital myopathy (Schartner et al., 2017). 
The complete absence of Cav1.1 or RYR1 in the homozygous mutant (
-/-
) mice leads to EC 
uncoupling and perinatal lethality accompanied by abnormal alterations in muscle phenotype 
indicative of muscle degeneration (Figs. 13, 14, 23 and 24). Similarly, severe mutations leading to 
the functional abolishment of RYR1 have been linked to lethal multiple pterygium syndrome – a 
disease characterized by fetal akinesia and death in utero (Kariminejad et al., 2016; McKie et al., 
2014). Ultrastructure studies of these skeletal muscles have revealed a myofibrillar disarray, loss of 
fibers and fibrosis, similar to the phenotype observed in RYR1
-/-
 and Cav1.1
-/-
 skeletal muscle at 
E18.5 (McKie et al., 2014). Hence, the transcriptomic changes in the muscle of RYR1
-/-
 and Cav1.1
-/-
 
mice may be reconstituted to a different degree in patients carrying various mutations in the Ryr1 and 
Cacna1s genes. If this is the case, the present analysis might aid future development of 
pharmaceuticals and therapies aiming to alleviate the symptoms of the respective RYR1- and Cav1.1-
linked channelopathies. 
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4.5 Conclusions and outlook 
In conclusion, this work provides the first extensive analysis of the global transcriptomic changes 
occurring in developing murine limb skeletal muscle in the absence of RYR1 or Cav1.1. As essential 
ECC components these two channels act as a team – Cav1.1 senses membrane depolarization and 
transmits this signal to RYR1 that in turn releases Ca
2+
 from the SR into the cytosol, resulting in 
muscle contraction. However, the present work suggests discrete roles of each channel for skeletal 
muscle gene expression and development, as observed by the consequences of their complete 
absence. 
The loss of RYR1 or Cav1.1 causes morphological alterations in skeletal muscle already at E14.5 – 
the period of transition from primary to secondary myogenesis. These changes are accompanied by 
elevated levels of apoptosis in the Cav1.1
-/-
 but not in the RYR1
-/-
 limb skeletal muscle. Furthermore, 
at E14.5 the RYR1- and Cav1.1-deficient skeletal muscles are characterized by distinct transcriptomic 
changes, affecting neuronal development and innervation in RYR1
-/-
 muscles, and muscle contraction 
– in Cav1.1
-/-
 muscles. The ability of RYR1 and Cav1.1 to modulate each other’s functions is 
demonstrated by the change of the Δ29 to full length Cav1.1 ratio in RYR1
-/-
 muscle at E14.5 and by 
the 2-fold downregulation of total Cav1.1 mRNA in these samples at E18.5. 
At E18.5, the end of secondary myogenesis and prenatal development in mice, the absence of RYR1 
and Cav1.1 causes severe morphological abnormalities of skeletal muscle, as well as of the gross 
body appearance of RYR1
-/-
 and Cav1.1
-/-
 fetuses. The limb skeletal muscle of these animals is 
characterized by an impaired fascicle formation, a predominance of small, unaligned fibers, and an 
overall degeneration. Additionally, the bone development is disturbed in Cav1.1
-/-
 fetuses. Microarray 
analyses identified an 8- to 10-fold increase in the number of DEGs in limb skeletal muscles of both 
mutants at E18.5. Moreover, at this stage the global transcriptomic changes in RYR1
-/-
 and Cav1.1
-/-
 
skeletal muscle partially converge while still presenting with characteristic transcriptomic signatures, 
differing from those of WT muscles. Multiple genes involved in skeletal muscle contraction and in 
the buildup of the contractile machinery are downregulated while global signaling pathways like the 
MAPK, Wnt and PI3K/Akt/mTOR are markedly represented among the DEGs in both mutants. 
Mutant-specific transcriptomic changes suggest a shift of the ECM composition in RYR1
-/-
 and an 
upregulation of fatty acid metabolism and adipogenesis in Cav1.1
-/-
 skeletal muscle. Interestingly, a 
mild phenotype was observed in the morphological but not in the transcriptomic analysis of 
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heterozygous Cav1.1
+/-
 skeletal muscle at both E14.5 and E18.5. This would suggest that the precise 
Cacna1s gene dosage may also be important for skeletal muscle development. 
The RYR1 and Cav1.1 absence induces significant changes in the transcriptomic dynamics of skeletal 
muscle from the beginning (E14.5) to the end (E18.5) of secondary myogenesis. The transcriptomic 
development of RYR1
-/-
 and Cav1.1
-/-
 muscles in this period suggests that both mutants fail to exit the 
cell cycle and to appropriately upregulate the synthesis of components for the contractile machinery. 
Impaired Ca
2+
 signaling and lack of mechanotransduction are probably responsible for the majority 
of the observed transcriptomic changes. A profound differential regulation of miRNAs in WT but not 
in RYR1
-/-
 and Cav1.1
-/-
 muscles between E14.5 and E18.5 suggests that changes in the miRNA-
mediated gene regulation are involved in the formation of the RYR1
-/-
 and Cav1.1
-/-
 transcriptomic 
signature. 
Taken together, these results reveal that RYR1 and Cav1.1 play complex and partially discrete roles 
throughout secondary myogenesis in limb skeletal muscle. Future research should analyze the extent 
to which the observed transcriptomic changes are recapitulated on a proteomic level. A targeted 
analysis of the individual signaling pathways affected in both mutants will aid the elucidation of the 
precise molecular mechanisms behind the RYR1- and Cav1.1-mediated regulation of muscle organ 
development. Finally, a more in-depth analysis of the differentially regulated genes and processes, 
occurring during secondary myogenesis in WT skeletal muscle, will provide a valuable reference for 
the studies of the developmental changes caused by various treatments, mutations or diseases of the 
skeletal muscle organ.  
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Suppl. Table 1. DEGs at E18.5 involved in signaling cascades 
Transcript 
Cluster ID 
Description Gene Symbol Fold Change 
E18.5 
RYR1
-/-
 vs. WT 
E18.5 
Cav1.1
-/-
 vs. WT 
MAPK signaling pathway 
17498041 dual specificity phosphatase 8 Dusp8 -2.06 -2.29 
17277387 FBJ osteosarcoma oncogene Fos -2.05 -1.55 
17463332 fibroblast growth factor 6 Fgf6 -2.01 -1.72 
17345465 serum response factor Srf -1.76 -1.87 
17342642 dual specificity phosphatase 1 Dusp1 -1.73 -1.66 
17220475 dual specificity phosphatase 10; 
predicted gene, 39725 
Dusp10 -1.7 -1.65 
17480420 p21 protein (Cdc42/Rac)-activated 
kinase 1 
Pak1 -1.69 -2.27 
17336824 heat shock protein 1-like Hspa1l -1.68 -2.08 
17342249 calcium channel, voltage-dependent, T 
type, alpha 1H subunit 
Cacna1h -1.56 -1.6 
17212185 interleukin 1 receptor, type I Il1r1 1.52 1.63 
17502001 jun D proto-oncogene Jund -1.93 NA 
17427312 jun proto-oncogene Jun -1.76 NA 
17332974 ribosomal protein S6 kinase, 
polypeptide 2 
Rps6ka2 -1.62 NA 
17271168 protein kinase C, alpha Prkca -1.5 NA 
17339772 RAS, guanyl releasing protein 3 Rasgrp3 -1.5 NA 
17283270 ribosomal protein S6 kinase, 
polypeptide 5 
Rps6ka5 1.52 NA 
17413915 transforming growth factor, beta 
receptor I 
Tgfbr1 1.56 NA 
17443342 heat shock protein 1 Hspb1 NA -2.86 
17217678 calcium channel, voltage-dependent, L 
type, alpha 1S subunit 
Cacna1s NA -2.67 
17271143 calcium channel, voltage-dependent, 
gamma subunit 1 
Cacng1 NA -1.92 
17264960 fibroblast growth factor 11 Fgf11 NA -1.77 
17439517 fibroblast growth factor 5 Fgf5 NA -1.72 
17320307 mitogen-activated protein kinase 12 Mapk12 NA -1.71 
17473166 calcium channel, voltage-dependent, 
gamma subunit 6 
Cacng6 NA -1.7 
17390079 phospholipase A2, group IVE Pla2g4e NA -1.69 
17456627 filamin C, gamma Flnc NA -1.6 
17235511 growth arrest and DNA-damage-
inducible 45 beta 
Gadd45b NA -1.59 
17406031 Rap guanine nucleotide exchange 
factor (GEF) 2 
Rapgef2 NA -1.56 
17371912 sterile alpha motif and leucine zipper 
containing kinase AZK 
Zak NA -1.5 
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Transcript 
Cluster ID 
Description Gene Symbol Fold Change 
E18.5 
RYR1
-/-
 vs. WT 
E18.5 
Cav1.1
-/-
 vs. WT 
17290111 fibroblast growth factor 10 Fgf10 NA 1.5 
17252013 arrestin, beta 2 Arrb2 NA 1.51 
17482766 protein kinase C, beta Prkcb NA 1.55 
17500535 dual specificity phosphatase 4 Dusp4 NA 1.79 
PI3K/Akt/mTOR signaling pathway 
17321094 collagen, type II, alpha 1 Col2a1 -5.57 -3.25 
17336681 tenascin XB Tnxb -2.81 -2.32 
17399347 thrombospondin 3 Thbs3 -2.61 -2.02 
17426365 tenascin C Tnc -2.35 -2.58 
17294934 thrombospondin 4 Thbs4 -2.31 -2.8 
17463332 fibroblast growth factor 6 Fgf6 -2.01 -1.72 
17458682 cAMP responsive element binding 
protein 5 
Creb5 -1.61 -1.83 
17322369 integrin alpha 5 (fibronectin receptor 
alpha) 
Itga5 -1.6 -1.5 
17530159 protein phosphatase 2, regulatory 
subunit B, alpha 
Ppp2r3a -1.51 -1.69 
17434933 hepatocyte growth factor Hgf 1.58 1.97 
17295796 phosphatidylinositol 3-kinase, 
regulatory subunit, polypeptide 1 (p85 
alpha) 
Pik3r1 1.63 1.84 
17381717 integrin alpha 8 Itga8 1.64 1.52 
17530540 collagen, type VI, alpha 5 Col6a5 2.23 2.41 
17224071 fibronectin 1 Fn1 -1.74 NA 
17271168 protein kinase C, alpha Prkca -1.5 NA 
17501919 cartilage oligomeric matrix protein Comp NA -3.48 
17255227 chondroadherin Chad NA -3.31 
17211458 collagen, type IX, alpha 1 Col9a1 NA -3.13 
17228712 tenascin N Tnn NA -1.79 
17264960 fibroblast growth factor 11 Fgf11 NA -1.77 
17439517 fibroblast growth factor 5 Fgf5 NA -1.72 
17427746 protein kinase, AMP-activated, alpha 
2 catalytic subunit 
Prkaa2 NA -1.72 
17385654 integrin beta 6 Itgb6 NA -1.58 
17226043 B cell leukemia/lymphoma 2 Bcl2 NA -1.57 
17290111 fibroblast growth factor 10 Fgf10 NA 1.5 
17507799 angiopoietin 2 Angpt2 NA 1.53 
17211043 serum/glucocorticoid regulated kinase 
3 
Sgk3 NA 1.57 
17316780 angiopoietin 1 Angpt1 NA 1.65 
17301886 lysophosphatidic acid receptor 6 Lpar6 NA 1.69 
17457310 cholinergic receptor, muscarinic 2, 
cardiac 
Chrm2 NA 1.71 
17310259 prolactin receptor Prlr NA 1.75 
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Transcript 
Cluster ID 
Description Gene Symbol Fold Change 
E18.5 
RYR1
-/-
 vs. WT 
E18.5 
Cav1.1
-/-
 vs. WT 
17351053 colony stimulating factor 1 receptor Csf1r NA 1.93 
17284839 integrin beta 8 Itgb8 NA 2.26 
17380222 phosphoenolpyruvate carboxykinase 
1, cytosolic 
Pck1 NA 3.12 
Wnt signaling pathway 
17285546 secreted frizzled-related protein 4 Sfrp4 -2.11 -2.12 
17237701 Wnt inhibitory factor 1 Wif1 -1.7 -2.45 
17394806 nuclear factor of activated T cells, 
cytoplasmic, calcineurin dependent 2 
Nfatc2 -1.56 -1.57 
17427312 jun proto-oncogene Jun -1.76 NA 
17271168 protein kinase C, alpha Prkca -1.5 NA 
17500068 secreted frizzled-related protein 1 Sfrp1 1.78 NA 
17260261 calcium/calmodulin-dependent protein 
kinase II, beta 
Camk2b NA -2.23 
17420154 wingless-type MMTV integration site 
family, member 4 
Wnt4 NA -1.53 
17482766 protein kinase C, beta Prkcb NA 1.55 
17402698 dickkopf homolog 2 (Xenopus laevis) Dkk2 NA 1.65 
17307738 frizzled homolog 3 (Drosophila) Fzd3 NA 1.81 
PPAR signaling pathway 
17501633 lipoprotein lipase Lpl 1.63 2.33 
17529398 
malic enzyme 1, NADP(+)-dependent, 
cytosolic Me1 2 2.28 
17233384 fatty acid binding protein 7, brain Fabp7 2.43 2.13 
17404091 fatty acid binding protein 4, adipocyte Fabp4 NA 1.74 
17400862 
3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2 Hmgcs2 NA 1.74 
17427994 sterol carrier protein 2, liver Scp2 NA 1.97 
17500996 
acyl-CoA synthetase long-chain 
family member 1 Acsl1 NA 2.72 
17461942 
peroxisome proliferator activated 
receptor gamma Pparg NA 2.97 
17380222 
phosphoenolpyruvate carboxykinase 
1, cytosolic Pck1 NA 3.12 
17492406 perilipin 1 Plin1 NA 4.02 
17324404 
adiponectin, C1Q and collagen 
domain containing Adipoq NA 4.12 
17502899 
uncoupling protein 1 (mitochondrial, 
proton carrier) Ucp1 NA 21.17 
cAMP signaling pathway 
17277387 FBJ osteosarcoma oncogene Fos -2.05 -1.55 
17378663 myosin, light polypeptide 9, 
regulatory 
Myl9 -1.76 -2.23 
17480420 p21 protein (Cdc42/Rac)-activated 
kinase 1 
Pak1 -1.69 -2.27 
17458682 cAMP responsive element binding 
protein 5 
Creb5 -1.61 -1.83 
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Transcript 
Cluster ID 
Description Gene Symbol Fold Change 
E18.5 
RYR1
-/-
 vs. WT 
E18.5 
Cav1.1
-/-
 vs. WT 
17534337 ATPase, (Na+)/K+ transporting, beta 
4 polypeptide 
Atp1b4 -1.61 -1.97 
17359160 phospholipase C, epsilon 1 Plce1 -1.6 -1.77 
17295796 phosphatidylinositol 3-kinase, 
regulatory subunit, polypeptide 1 (p85 
alpha) 
Pik3r1 1.63 1.84 
17510772 Hedgehog-interacting protein Hhip 1.89 2.07 
17427312 jun proto-oncogene Jun -1.76 NA 
17217678 calcium channel, voltage-dependent, L 
type, alpha 1S subunit 
Cacna1s NA -2.67 
17260261 calcium/calmodulin-dependent protein 
kinase II, beta 
Camk2b NA -2.23 
17264792 ATPase, Na+/K+ transporting, beta 2 
polypeptide 
Atp1b2 NA -1.87 
17535572 ATPase, Ca++ transporting, plasma 
membrane 3 
Atp2b3 NA -1.72 
17229178 ATPase, Na+/K+ transporting, beta 1 
polypeptide 
Atp1b1 NA -1.68 
17489420 FXYD domain-containing ion 
transport regulator 1 
Fxyd1 NA -1.6 
17331918 T cell lymphoma invasion and 
metastasis 1 
Tiam1 NA 1.54 
17403866 prostaglandin E receptor 3 (subtype 
EP3) 
Ptger3 NA 1.56 
17325206 adenylate cyclase 5 Adcy5 NA 1.58 
17245874 GLI-Kruppel family member GLI1 Gli1 NA 1.63 
17406145 glutamate receptor, ionotropic, 
AMPA2 (alpha 2) 
Gria2 NA 1.7 
17457310 cholinergic receptor, muscarinic 2, 
cardiac 
Chrm2 NA 1.71 
17482021 phosphodiesterase 3B, cGMP-
inhibited 
Pde3b NA 1.77 
17355264 melanocortin 2 receptor Mc2r NA 1.97 
17452709 hydrocarboxylic acid receptor 1 Hcar1 NA 2.5 
cGMP-PKG signaling pathway 
17377816 myosin, light polypeptide kinase 2, 
skeletal muscle 
Mylk2 -2.4 -2.82 
17306577 myosin, heavy polypeptide 7, cardiac 
muscle, beta 
Myh7 -1.79 -1.72 
17345465 serum response factor Srf -1.76 -1.87 
17378663 myosin, light polypeptide 9, 
regulatory 
Myl9 -1.76 -2.23 
17458682 cAMP responsive element binding 
protein 5 
Creb5 -1.61 -1.83 
17534337 ATPase, (Na+)/K+ transporting, beta 
4 polypeptide 
Atp1b4 -1.61 -1.97 
17394806 nuclear factor of activated T cells, 
cytoplasmic, calcineurin dependent 2 
Nfatc2 -1.56 -1.57 
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Transcript 
Cluster ID 
Description Gene Symbol Fold Change 
E18.5 
RYR1
-/-
 vs. WT 
E18.5 
Cav1.1
-/-
 vs. WT 
17304012 potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1 
Kcnma1 -1.53 -1.78 
17295796 phosphatidylinositol 3-kinase, 
regulatory subunit, polypeptide 1 (p85 
alpha) 
Pik3r1 1.63 1.84 
17309268 endothelin receptor type B Ednrb 1.66 2.18 
17217678 calcium channel, voltage-dependent, L 
type, alpha 1S subunit 
Cacna1s NA -2.67 
17264792 ATPase, Na+/K+ transporting, beta 2 
polypeptide 
Atp1b2 NA -1.87 
17535572 ATPase, Ca++ transporting, plasma 
membrane 3 
Atp2b3 NA -1.72 
17229178 ATPase, Na+/K+ transporting, beta 1 
polypeptide 
Atp1b1 NA -1.68 
17282309 solute carrier family 8 
(sodium/calcium exchanger), member 
3 
Slc8a3 NA -1.62 
17363903 protein kinase, cGMP-dependent, type 
I 
Prkg1 NA -1.6 
17496211 ATPase, Ca++ transporting, cardiac 
muscle, fast twitch 1 
Atp2a1 NA -1.58 
17304010 potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1; RIKEN cDNA 
A830039N20 gene 
Kcnma1 NA -1.5 
17325206 adenylate cyclase 5 Adcy5 NA 1.58 
17482021 phosphodiesterase 3B, cGMP-
inhibited 
Pde3b NA 1.77 
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